



**CD4+ cell count  $\geq$ 200 cells/mm<sup>3</sup> and Moderate Alcohol Consumption: Evidence of Protection against Coronary and other Arterial Disease Events in an 11-year Cohort of HIV-infected Patients on Antiretroviral Therapy**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001155
Article Type:	Research
Date Submitted by the Author:	19-Mar-2012
Complete List of Authors:	Carrieri, Maria Patrizia Protopopescu, Camelia; INSERM, U912 (SESSTIM), Aix Marseille Univ, IRD, UMR-S912, ORS PACA, Observatoire Régional de la Santé Provence Alpes Côte d'Azur Le Moing, Vincent Reboud, Philippe Raffi, François Mahy, Sophie Roux, Perrine Cuzin, Lise Spire, Bruno Leport, Catherine
<b>Primary Subject Heading</b>:	Infectious diseases
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Myocardial infarction < CARDIOLOGY, Coronary heart disease < CARDIOLOGY

1  
2  
3 **CD4+ cell count  $\geq 200$  cells/mm<sup>3</sup> and Moderate Alcohol Consumption: Evidence of**  
4 **Protection against Coronary and other Arterial Disease Events in an 11-year Cohort of**  
5 **HIV-infected Patients on Antiretroviral Therapy**  
6  
7  
8

9  
10  
11  
12  
13 **Maria Patrizia Carrieri<sup>1,2,3\*</sup>, Camelia Protopopescu<sup>1,2,3\*§</sup>, Vincent Le Moing<sup>4</sup>, Philippe**  
14 **Reboud<sup>5</sup>, François Raffi<sup>6</sup>, Sophie Mahy<sup>7</sup>, Perrine Roux<sup>1,8</sup>, Lise Cuzin<sup>9</sup>, Bruno Spire<sup>1,2,3</sup>,**  
15 **Catherine Leport<sup>10,11</sup> and the ANRS CO8 APROCO-COPILOTE Study Group**  
16  
17  
18

19  
20  
21 \* Equal contribution  
22  
23  
24  
25  
26

27 <sup>1</sup> *INSERM, U912 (SESSTIM), Marseille, France*  
28

29 <sup>2</sup> *Aix Marseille Univ, IRD, UMR-S912, Marseille, France*  
30

31 <sup>3</sup> *ORS PACA, Observatoire Régional de la Santé Provence Alpes Côte d'Azur, Marseille,*  
32 *France*  
33

34 <sup>4</sup> *Service de Maladies Infectieuses et Tropicales, CHU de Montpellier, UMI 233 TransVIHMI,*  
35 *IRD, Université Montpellier 1, Montpellier, France*  
36  
37

38 <sup>5</sup> *INSERM, U897; Université Bordeaux Segalen, ISPED, Bordeaux, France*  
39

40 <sup>6</sup> *CHU Hôtel-Dieu, Nantes, France*  
41

42 <sup>7</sup> *CHU de Dijon, Université de Bourgogne, Dijon, France*  
43  
44

45 <sup>8</sup> *Substance Use Research Center, NYSPI, Columbia University, New York, USA*  
46  
47

48 <sup>9</sup> *Service de Maladies Infectieuses et Tropicales, CHU Purpan, Toulouse, France*  
49

50 <sup>10</sup> *Université Paris Diderot, Sorbonne Paris Cité, UMR 738, Paris, France*  
51

52 <sup>11</sup> *INSERM, UMR 738, Paris, France*  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 § Corresponding author address: INSERM U912 – ORS PACA, 23 rue Stanislas Torrents,  
4  
5 13006 Marseille, France

6  
7 📞: +33 4 96 10 28 80    📠: + 33 4 96 10 28 99    @: camelia.protopopescu@inserm.fr  
8  
9

10  
11  
12 *Abstract word count: 276 words*

13  
14  
15 *Text word count: 3264 words*  
16  
17  
18  
19

20  
21 **Funding sources:** The ANRS CO8 (APROCO/COPILOTE) cohort is funded by ANRS  
22 (Agence Nationale de Recherches sur le Sida et les hépatites virales) and CMIT (Collège des  
23 Universitaires de Maladies Infectieuses et Tropicales), which received research grants from  
24 Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences,  
25 Pfizer and Roche.  
26  
27

28  
29  
30 The funders were responsible for initiating, managing and financing the cohort, but did not  
31  
32 interfere with data analysis and interpretation and dissemination of the scientific results.  
33  
34  
35  
36  
37

38  
39 **Competing interests:** All authors have completed the Unified Competing Interest form at  
40 [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) <[http://www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf)> (available on  
41 request from the corresponding author) and declare that (1) they have no support from any  
42 company for the submitted work; (2) they have no relationships with any company that might  
43 have an interest in the submitted work in the previous 3 years; (3) their spouses, partners, or  
44 children have no financial relationships that may be relevant to the submitted work; and (4)  
45 they have no non-financial interests that may be relevant to the submitted work.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Exclusive licence:** The Corresponding Author has the right to grant on behalf of all authors  
4 and does grant on behalf of all authors, an exclusive licence (or non exclusive for government  
5 employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to  
6 permit this article (if accepted) to be published in BMJ editions and any other BMJ PGL  
7 products and sublicences to exploit all subsidiary rights, as set out in our licence  
8 (<http://resources.bmj.com/bmj/authors/checklists-forms/licence-for-publication>).  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

19 **Data sharing:** There is no additional data available.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **Summary**

### **Article Focus**

- Major coronary or other arterial disease events (CADE) are frequent in HIV-infected individuals receiving antiretroviral therapy.
- While some antiretroviral classes can increase the risk of CADE, it is still controversial to what extent immune reconstitution and other factors like moderate alcohol consumption can reduce the risk of CADE in this population.

### **Key Messages**

- Moderate alcohol consumption and CD4+ cell count  $\geq 200$  cells/mm<sup>3</sup> can be beneficial to reduce the risk of CADE in HIV-infected patients.
- Reduced immunological response to ART over a long follow-up may have a more important impact on CADE than exposure to a specific antiretroviral drug.

### **Strengths and Limitations**

- This paper suggests the importance of combined risk reduction interventions including adherence counselling for assuring long term immunological response and decrease the risk of CADE.

## **Short title**

**CD4+, Moderate Alcohol Consumption and Coronary Events in HIV-infected patients**

**Abstract**

**Objective:** To investigate the relationship between response to antiretroviral treatment (ART), alcohol use and occurrence of a major coronary or other arterial disease event (CADE) in HIV-infected individuals.

**Design:** Cohort study. A Cox model was used to identify correlates of a first occurrence of a major CADE.

**Setting:** The French ANRS CO8 APROCO-COPILOTE cohort was set up in 1997 to study clinical progression and patient-reported outcomes (PRO) after initiating protease inhibitor-containing ART. Clinical data were retrieved from medical records. Self-administered questionnaires collected data on PRO and behaviours, including alcohol use.

**Participants:** Metabolic data were only available for a subgroup (n=675) of the study group (n=1154).

**Main outcomes measures:** Major coronary or other arterial disease first event.

**Results:** Over the 11-year follow-up, 49 major CADE were observed, with an incidence rate [95%CI]=0.75[0.57 to 0.99] per 100 person-years. CD4+ cell count  $\geq 200$  cells/mm<sup>3</sup> was associated with a reduced risk of CADE (adjusted hazard ratio AHR[95% CI]=0.40[0.18 to 0.86]) after adjustment for female gender (0.25[0.08 to 0.83]), age (1.07[1.04 to 1.10]) and smoking>20 cigarettes/day (4.19[2.17 to 8.11]). Moreover, individuals with moderate alcohol consumption ( $\leq 3$  AU/day) had a lower risk of CADE (0.38[0.20 to 0.71]) than alcohol abstainers, while the risk for those drinking>3 AU/day was not significantly different from this latter group. These associations remained valid after adjustment for metabolic disorders. No significant association with exposure to any specific antiretroviral was detected.

1  
2  
3 **Conclusions:** In the long term, CD4+ cell count  $\geq 200$  cells/mm<sup>3</sup> and moderate alcohol  
4  
5 consumption remain the principal factors associated with a lower risk of CADE. Combined  
6  
7 interventions to reduce CADE risk-related behaviours and sustain ART adherence in HIV-  
8  
9 infected individuals are now a clinical and public health priority.  
10

11  
12  
13  
14  
15 **Key words:** Coronary and other arterial disease events, Alcohol, CD4+ cell count, HIV,  
16  
17 ARV.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Cardiovascular disease risk factors (including for example hypertension and tobacco use), as well as immunological status[1] are major predictors of atherosclerosis in HIV-infected women and men. Although antiretroviral (ARV) therapy agents[2-5] have consistently been found to be associated with coronary and other arterial disease events (CADE) in these patients, more recently Butt and colleagues put into evidence the negative effect of HIV viral replication on heart failure[6]. In one study, patients having experienced myocardial infarction (MI) presented lower baseline and proximal CD4+ cell counts than those who did not, while no association was found with specific antiretroviral agents[7]. Moreover, known factors associated with the risk of CADE[8] such as hyperlipidemia and insulin resistance[9-11] are becoming an increasingly major clinical concern in ART-treated individuals.

Though excessive alcohol use may be frequent in HIV-infected individuals, its impact on the occurrence of CADE in this population has been less investigated. Excessive alcohol consumption also plays a major role in HIV risk-taking behaviours, particularly in men who have sex with men and drug users[12, 13]. In HIV-infected individuals, excessive alcohol use is known to compromise patients' response to antiretroviral therapy (ART) through reduced adherence[14-17] and to predict HIV progression and increased mortality[18-21], mostly from liver diseases[22-25]. Some recent cross-sectional analyses in HIV-infected and uninfected men have found that heavy alcohol consumption is associated with a higher risk of CADE[26, 27]. On the other hand, in uninfected adults, moderate alcohol consumption has been found to be associated with a reduced risk[28], improved lipid profiles, increased insulin sensitivity and reduced risk of MI[29]. However, this association has not yet been studied in longitudinal studies involving HIV-infected populations including women. Moreover, there are as yet no consistent results in the literature regarding the role that alcohol use plays in exacerbating the risk of CADE in ART-treated patients and to what extent it can confound or



1  
2  
3 boost the effect of immuno-virological response to ART, ART-associated dyslipidemia and  
4  
5 insulin resistance on the risk of CADE.  
6  
7

8 We used data from the 11-year follow-up of the APROCO-COPILOTE cohort of patients  
9  
10 receiving ART since 1997 to investigate the relationship between undetectable viral load,  
11  
12 CD4+ cell count, alcohol consumption and the first occurrence of a CADE, after adjustment  
13  
14 for known risk factors including metabolic disorders.  
15  
16  
17  
18  
19

## 20 **Methods**

21  
22  
23 The French APROCO-COPILOTE cohort (ANRS CO8) was designed to study the clinical,  
24  
25 immunological, virological, and socio-behavioural course of HIV disease in HIV-1 positive  
26  
27 individuals who started the first generation of potent ART (treatment regimens including  
28  
29 protease inhibitors (PI)). The study was approved by the Ethics Committee of Cochin  
30  
31 Hospital (Paris) and informed consent was obtained from all participants.  
32  
33  
34

### 35 *Setting*

36  
37  
38 Patients were enrolled in the cohort at their first PI-based ART prescription between May  
39  
40 1997 and June 1999 (n=1281) in 47 French centres, and clinically followed-up every 4  
41  
42 months thereafter, up to month 132 (M132).  
43  
44

### 45 *Patients*

46  
47  
48 In the present study were included all patients who had either two alcohol assessment or one  
49  
50 alcohol assessment just preceding the CADE over the whole follow-up (n=1154).  
51  
52

### 53 *Medical questionnaire*

1  
2  
3 The medical questionnaire at enrolment (M0) collected retrospective data about patient's HIV  
4 history including HIV transmission category, time since HIV diagnosis, previous exposure to  
5 antiretroviral treatment before enrolment, co-infection with hepatitis C virus (HCV). This  
6 information was complemented by another medical questionnaire, completed by the HIV  
7 physician at each follow-up visit, which collected clinical and laboratory data (plasma HIV  
8 RNA level, CD4+ cell count, HIV clinical stage) as well as data on the antiretroviral regimen  
9 prescribed. A third form, based on updated medical records, detailed all clinical severe events,  
10 including CADE, occurring during the study period. Information on metabolic disorders was  
11 available at M12 for a subset of cohorts' patients, who participated in a parallel cross-  
12 sectional survey, designed to study clinical and laboratory metabolic complications[30].  
13 These "metabolic" data included height, weight, hypertriglyceridemia, hypercholesterolemia,  
14 personal history of coronary heart disease (CHD) and hypertension, and finally any family  
15 history of CHD.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32 At each follow-up visit, CD4+ cell count was measured by standardized flow cytometry, and  
33 plasma HIV RNA levels were measured using the assay routinely available in each  
34 participating centre. HIV clinical stage was defined using the 1993 Centres for Disease  
35 Control and Prevention (CDC) clinical classification system[31].  
36  
37  
38  
39  
40  
41

42 Serum triglyceride and total cholesterol levels were measured after a 12-hour overnight fast.  
43 Hypertriglyceridemia was defined as a triglyceride level  $\geq 2.2$  mmol/l, while  
44 hypercholesterolemia was defined as a total cholesterol level  $\geq 5.5$  mmol/l.  
45  
46  
47  
48

#### 49 *Outcome*

50  
51  
52 The clinical severe events occurring during follow-up, including CADE, were initially  
53 recovered from medical records and validated by a validation committee[30]. The  
54 classification of clinical severe events was based on the 10th Revision of the International  
55  
56  
57  
58  
59  
60

1  
2  
3 Statistical Classification of Diseases and Related Health Problems (ICD-10)<sup>i</sup>. The major  
4  
5 CADE selected for this study were MI, stroke, coronary heart disease, peripheral arterial  
6  
7 disease and cardiovascular surgery for coronary disease.  
8  
9

### 10 *Self-administered questionnaire*

11  
12  
13 A self-administered questionnaire collected - at M0, M4, M12 and every 8 months thereafter  
14  
15 during the first 5 years of follow-up, then yearly thereafter – data on socio-demographic  
16  
17 characteristics including age, gender and educational level. Among other psycho-social and  
18  
19 behavioural information, it also collected details on depressive symptoms, tobacco use,  
20  
21 alcohol consumption, self-reported ART-related symptoms and adherence to ART.  
22  
23

24  
25 Depression was measured using the validated French version of the Centre for Epidemiologic  
26  
27 Studies Depression Scale (CES-D), which is a 20-item scale commonly used in studies  
28  
29 involving HIV-infected patients[32].  
30  
31

32  
33 Tobacco and alcohol consumption were evaluated during the previous 4 weeks. Alcohol  
34  
35 consumption was assessed using two questions about frequency of consumption and quantity  
36  
37 consumed daily, if applicable.  
38  
39

40  
41 A 13-item scale comprising the French version of the symptom index validated by Justice *et*  
42  
43 *al*[33] and described elsewhere[34] collected information about self-reported symptoms. Five  
44  
45 other questions gathered information about adherence to ART, according to the methodology  
46  
47 established by the AIDS Clinical Trial Group[35].  
48  
49

### 50 *Statistical analysis*

51  
52  
53 As the results of the analysis on the whole dataset (n=1154) could be affected by the lack of  
54  
55 important predictors of CADE like hypertriglyceridemia or hypercholesterolemia, we  
56  
57

58  
59 <sup>i</sup> <http://www.who.int/classifications/icd/en/>  
60

1  
2  
3 conducted a secondary analysis on a subset of patients who had additional metabolic disorders  
4  
5 data. Precisely, two analyses on two different study populations were performed to study  
6  
7 predictors of major CADE:  
8  
9

10 1) First analysis: the study population included all patients who had either two alcohol  
11  
12 assessment or one alcohol assessment just preceding the event over the whole follow-up  
13  
14 (n=1154). The follow-up period was M0-M132.  
15  
16

17 2) Second analysis: the study population was restricted to the subset of patients with available  
18  
19 data on metabolic disorders, measured at M12 (n=675). Consequently, only events occurring  
20  
21 after M12 were considered in this second analysis.  
22  
23  
24

25 The WHO body mass index (BMI) categories were used in the analysis: underweight and  
26  
27 overweight/obese patients were defined respectively as having a BMI lower than 18.5 and  
28  
29 greater than 25.  
30  
31

32 A cumulative measure of time exposure to specific ARV medications (abacavir, efavirenz,  
33  
34 nevirapine, lopinavir and protease inhibitor) was computed from cohort enrolment to the date  
35  
36 of each follow-up visit.  
37  
38  
39

40 Tobacco consumption was dichotomized in two categories: more than 20 cigarettes/day vs  
41  
42 other[36]. The average number of alcohol units (AU) consumed per day[37] was computed  
43  
44 using the two questions on alcohol consumption.  
45  
46  
47

48 Patients were classified as non-adherent if they reported taking less than 100% of prescribed  
49  
50 medications during the previous 4 weeks, using a validated algorithm[38]. A patient with a  
51  
52 CES-D score value above 17 (men) or 23 (women) was considered as presenting depressive  
53  
54 symptoms[39].  
55  
56  
57  
58  
59  
60

1  
2  
3 Incidence rate of major CADE was computed as the number of cases divided by the number  
4  
5 of person-years of follow-up. Follow-up duration was calculated as the difference in days  
6  
7 from enrolment to the date of the CADE, death or last visit, whichever occurred first. Follow-  
8  
9 up of patients experiencing major CADE was censored after the date of the first CADE. We  
10  
11 used a Cox proportional hazards model to identify characteristics associated with the first  
12  
13 occurrence of a major CADE. Psychosocial characteristics - depressive symptoms, tobacco  
14  
15 and alcohol consumption, self-reported symptoms, CD4+ cell count and viral load - were  
16  
17 evaluated at each visit and used as time-varying covariates in the statistical analysis. All the  
18  
19 other covariates were used as fixed variables (measured at M0, M1 or M12). For time-varying  
20  
21 factors, the last known value was carried forward in the case of missing data at a scheduled  
22  
23 visit. In the case of an event occurring between two consecutive follow-up visits, the values  
24  
25 for the time-varying variables measured at the visit preceding the event were used. Covariates  
26  
27 with a p-value<0.25 in univariate Cox analyses were considered eligible for the multivariate  
28  
29 Cox model, which was built using a backward selection procedure based on the Wald test  
30  
31 (p<0.05). The proportional-hazards assumption was verified globally for the multivariate  
32  
33 models and separately with respect to each covariate, using both Kaplan-Meier estimates and  
34  
35 tests based on Schoenfeld residuals[40]. A residual analysis for outliers' detection was  
36  
37 performed and the sensitivity of the model to influential outliers was tested. All analyses were  
38  
39 performed using Stata Intercooled software, version 10.1.  
40  
41  
42  
43  
44  
45  
46  
47  
48

## 49 **Results**

50  
51  
52 A total of 1154 patients were included in the present study, accounting for 9401 person-visits.  
53  
54 When comparing the study patients (n=1154) with those included in the cohort, but excluded  
55  
56 from the study due to missing alcohol data (n=127), no significant difference was found for  
57  
58  
59  
60

1  
2  
3 gender, age at enrolment, antiretroviral naivety, CDC clinical stage, baseline CD4+ cell  
4  
5 counts and HIV viral load at M0 (data not shown).  
6  
7

8 Median [interquartile range (IQR)] duration of follow-up of the selected patients, from their  
9  
10 first visit after the ART prescription (M1) until M132, was 5.9 [1.8-9.4] years.  
11  
12

13 Over the 11-year follow-up of the cohort, a total of 85 CADE were observed. These included  
14  
15 49 major CADE as follows: myocardial infarction (n=30), coronary heart disease (n=4),  
16  
17 stroke (n=7), peripheral arterial disease (n=7) and cardiovascular surgery (n=1). The  
18  
19 distribution of the other thirty six CADE was as follows: phlebitis/pulmonary embolism  
20  
21 (n=22), cardiomyopathy/congestive heart failure (n=5), cardiac dysrhythmia (n=6), cerebral  
22  
23 haemorrhage (n=2) and aortic aneurysm (n=1).  
24  
25  
26

27 The incidence rate [95% CI] of all CADE was 1.3 [1.0 to 1.6] per 100 person-years, while for  
28  
29 major CADE the incidence rate was 0.75 [0.57 to 0.99] per 100 person-years. Of the 49 major  
30  
31 CADE, 40 occurred after M12. Furthermore, the major CADE incidence over the period  
32  
33 M12-M132 was 0.89 [0.66 to 1.22] per 100 person-years.  
34  
35  
36

37 The distribution of factors associated with major CADE, as well as the results of univariate  
38  
39 and multivariate Cox models, are reported in Table 1 for the entire study population (n=1154).  
40  
41 Table 2 focuses instead on the subset of patients with available data on metabolic disorders  
42  
43 (n=675).  
44  
45  
46

47 In the subsample of patients with available metabolic data (Table 2), the majority (73%) had a  
48  
49 normal BMI, 17% were classified in the overweight category and a minority was classified in  
50  
51 each of the two more extreme categories (6% underweight and 3% obese). About 8% of the  
52  
53 patients had hypertriglyceridemia and 6% had hypercholesterolemia at M12. One year after  
54  
55 the enrolment in the cohort, 6% of the patients reported a personal history of hypertension.  
56  
57 Only 1% and 28% respectively had a personal and family history of CHD.  
58  
59  
60

1  
2  
3 In the entire study group (n=1154), the following factors were found to be independent  
4 predictors of major CADE: older age at baseline (Adjusted Hazard Ratio (AHR)[95%  
5 CI]=1.07[1.04 to 1.10]), tobacco consumption>20 cigarettes/day (4.19[2.17 to 8.11]) and  
6 CD4+ cell count  $\geq 200$  cells/mm<sup>3</sup> (0.40[0.18 to 0.86]) (see Table 1). In addition, a negative  
7 association was found between female gender and major CADE (0.25[0.08 to 0.83]). After  
8 accounting for the effect of age, gender, tobacco consumption and CD4+ cell count  $\geq 200$   
9 cells/mm<sup>3</sup> in the multivariate Cox model, individuals with moderate alcohol consumption ( $\leq 3$   
10 AU/day) were at lower risk of major CADE (0.38[0.20 to 0.71]), than alcohol abstainers,  
11 while those drinking more than 3 AU/day were not significantly different from abstainers  
12 (p=0.229).  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

26 These results remained valid even when the analysis was restricted to the subgroup of patients  
27 with available metabolic data and the follow-up period M12-M132. After adjusting for age,  
28 tobacco consumption, hypertriglyceridemia and a family history of CHD, we consistently  
29 found a negative association between moderate alcohol use (0.23[0.11-0.49]), CD4+ cell  
30 count  $\geq 200$  cells/mm<sup>3</sup> (0.25[0.09-0.69]) and major CADE one year after enrolment (Table 2).  
31  
32  
33  
34  
35  
36  
37

38 No significant association was found between time of exposure to different ARV drugs and  
39 major CADE, the only exceptions being efavirenz and nevirapine, for which a slight negative  
40 association was found in univariate analysis only. No significant interaction was found  
41 between smoking habits and hypertriglyceridemia or personal history of CHD. Furthermore,  
42 detectable viral load was not associated with major CADE in univariate or multivariate  
43 analyses.  
44  
45  
46  
47  
48  
49  
50

51 For the Cox models fitted in this study, proportional-hazards assumption remained valid,  
52 either globally and with respect to each covariate. The residual analysis did not alter the  
53 results of the multivariate model.  
54  
55  
56  
57  
58  
59  
60

## Discussion

This longitudinal study clearly confirms that in ART-treated individuals, proximal CD4+ cell count higher than 200 cells/mm<sup>3</sup> remains a major risk factor negatively associated with major coronary and other arterial disease events. This result remains valid even after adjustment for metabolic disorders such as hypertriglyceridemia and family history of CHD, the strength of the association remaining unchanged.

The relationship between CADE and CD4+ cell count, in addition to the lack of association between CADE and specific ARV classes, confirms previous results[7] where the association between exposure to certain ARV and CADE was no longer evident after controlling for traditional risk factors and HIV disease markers. Indeed, the association between specific ARV drugs and major CADE, like myocardial infarctus, has been shown in very powerful studies[5], where adjustment for nadir CD4+ lymphocyte count or peak HIV-1 RNA level did not modify the results. However, in the study cited, no adjustment for proximal CD4+ cell count was performed, and the association with the class of ARV became weaker after adjustment for serum lipid levels[5]. Indeed, although ART may modify lipid levels and increase the risk of CADE, it may also reduce this risk because of CD4+ reconstitution following long-term suppression of HIV replication or HIV-associated inflammation. The lack of association with exposure to specific ARV classes in the present study, something usually associated with an increased risk of CADE[41], suggests that reduced immunological response to ART over a long follow-up, as well as known CADE risk factors may have a more important impact than exposure to a specific antiretroviral drug.

It is also possible that patients with altered lipid profiles were switched to other classes of antiretroviral drugs during the follow-up. As a consequence, in the long term, CD4+ cell



1  
2  
3 count  $\geq 200$  cells/mm<sup>3</sup> remain the main correlate of a decreased risk of CADE, whatever the  
4  
5 antiretroviral received.  
6

7  
8 In our study, individuals reporting elevated alcohol consumption exhibited the same risk of  
9  
10 CADE as alcohol abstainers. In contrast, those reporting moderate alcohol consumptions had  
11  
12 a lower risk. This result was confirmed after adjustment for additional risk factors including  
13  
14 tobacco use, age, gender and CD4+ cell count. This relationship between alcohol  
15  
16 consumption and CADE remained significant and J-shaped, even after adjustment for data on  
17  
18 metabolic risk factors- such as having a history of CHD and hypertriglyceridemia -which was  
19  
20 available for a subset of patients. As highlighted in previous observations of the general  
21  
22 population[28, 42-45] and certain populations affected by other diseases[46], these results  
23  
24 confirmed that the increased risk of CADE in HIV-infected patients receiving ART is not  
25  
26 attributable to elevated alcohol use. Furthermore, we highlighted the apparent protective  
27  
28 effect of moderate alcohol consumption in ART treated HIV-infected patients.  
29  
30  
31

32  
33 It is important to note that after the introduction of ART in 1996, the sudden decrease  
34  
35 observed in HIV-related mortality was nonetheless accompanied by an increase in non-HIV  
36  
37 based mortality[47], cardiovascular diseases becoming increasingly important. This increase  
38  
39 can be explained firstly by a reduction in the competing role of HIV-related mortality, which  
40  
41 in the long term was much more detrimental to health than other causes of deaths. Secondly,  
42  
43 the high prevalence in this population of other risk factors like tobacco use, together with  
44  
45 ART-related morbidity including altered lipid profiles and triglycerides, may contribute to an  
46  
47 increased risk of CADE.  
48  
49

50  
51 The association found between moderate alcohol use and reduced CADE risk is not consistent  
52  
53 with all previous research in HIV-infected patients. Freiberg *et al*[26] pointed out that among  
54  
55 HIV-infected men in the US, hazardous drinking and both alcohol abuse and dependence  
56  
57  
58  
59  
60

1  
2  
3 were associated with a higher prevalence of CADE compared with infrequent and moderate  
4 drinking, even after adjusting for traditional risk factors, antiretroviral therapy and CD4+ cell  
5 count. This difference in the results may be due to the different design of the two studies  
6  
7 (longitudinal for ours *vs* cross-sectional for Freidberg's), but probably also to the different  
8  
9 types of alcohol mainly consumed in the two populations, red wine consumption being more  
10  
11 widespread in France than in the US. This difference in the pattern of alcohol use has already  
12  
13 been highlighted in a comparative study on CADE in non HIV-infected Irish and French  
14  
15 males, showing an increased protective effect of drinking red wine in the latter  
16  
17 population[48]. Increased wine consumption probably brings about an increase in high-  
18  
19 density lipoprotein cholesterol levels, which helps protect against CADE. On the other hand,  
20  
21 beer and spirits consumption are linked to increased triglyceride levels[49]. We do not know  
22  
23 to what extent moderate alcohol users are representative of a population with better health  
24  
25 status as alcohol use in France is extremely frequent in the general population and this fact  
26  
27 may increase the strength of the association found.  
28  
29  
30  
31  
32  
33

34  
35 While one hypothesis is that excessive alcohol consumption can increase inflammatory  
36  
37 markers' levels, which in turn probably leads to a higher risk of CADE and premature aging  
38  
39 in HIV patients, this hypothesis was not demonstrated in a study conducted in older adults  
40  
41 without cardiovascular disease, where alcohol intake was found to be associated with lower  
42  
43 levels of inflammatory markers[50]. In the meantime it is important to remember that  
44  
45 individuals with immune suppression are at a greater risk of cancer, a disease whose pattern  
46  
47 of risk factors also include alcohol use, even when moderate[51].  
48  
49  
50

51 Tobacco smoking has consistently been found to be a major risk factor for CADE[52].

52  
53 Smoking prevalence and dependence in HIV-infected patients is higher than in the general  
54  
55 population[53]. Effective interventions for reducing and quitting smoking[54], especially for  
56  
57 patients with several risk factors, are strongly recommended especially considering the  
58  
59  
60

1  
2  
3 increased CADE risk which exists in HIV-infected smokers receiving ART[55]. However,  
4  
5 results from studies reporting on the effectiveness of interventions for quitting smoking in  
6  
7 HIV-infected individuals are inconsistent[56].  
8  
9

10 Some limitations of this study need to be acknowledged. First, our definition of CADE  
11  
12 includes different types of events which might not share the same pattern of risk factors.  
13  
14 However, an additional analysis performed on a restricted dataset and which adjusted for  
15  
16 other potential risk factors (such as hypertriglyceridemia) confirmed the pattern found in the  
17  
18 main analysis. Second, information on alcohol use was mainly based on self-reports and these  
19  
20 may tend to underestimate alcohol consumption. However, it has been reported that HIV-  
21  
22 HCV co-infected patients tend to underreport alcohol use more to their hepatologist than to  
23  
24 other physicians[57]. As our patients were all followed-up by HIV physicians, it is likely that  
25  
26 the degree of underreporting did not greatly affect hazard ratios' estimates.  
27  
28  
29  
30

31 This cohort is representative of the first generation of patients receiving potent ART. As  
32  
33 cardiovascular disease is a rising issue in all HIV-infected populations receiving ART, these  
34  
35 results can give important information about the pattern of risk and protective factors in all  
36  
37 treated HIV-infected populations.  
38  
39

40  
41 In conclusion, in the long term, CD4+ cell count  $\geq 200$  cells/mm<sup>3</sup> and moderate alcohol  
42  
43 consumption remain the principal factors negatively associated with the risk of major CADE.  
44  
45 Combined interventions to reduce CADE-risk-related behaviours and assure sustained  
46  
47 adherence and response to ART in HIV-infected individuals are now a clinical and public  
48  
49 health priority.  
50  
51

#### 52 53 54 **Acknowledgments**

55  
56 The authors would like to thank all participating patients, nurses and physicians in clinical  
57  
58 sites.  
59  
60

1  
2  
3 We would also like to thank Jude Sweeney for the English revision and editing of the  
4 manuscript.  
5  
6

7  
8 **Authors' contribution:**  
9

10 Maria Patrizia Carrieri planned the data analyses and wrote the manuscript; Camelia  
11 Protopopescu analyzed the data and wrote the manuscript; Vincent Le Moing contributed to  
12 patients' recruitment and investigation and revised the manuscript; Philippe  
13 Reboud contributed to patients' evaluation; François Raffi was responsible for cohort  
14 initiation, contributed to patients' recruitment and investigation and revised the manuscript;  
15 Sophie Mahy contributed to patients' recruitment and investigation; Perrine Roux contributed  
16 to patients' evaluation and revised the manuscript; Lise Cuzin contributed to patients'  
17 recruitment and investigation; Bruno Spire contributed to data analyses and revised the  
18 manuscript; Catherine Leport was responsible for cohort initiation, contributed to patients'  
19 recruitment and investigation and revised the manuscript. All authors approved the final  
20 version of the manuscript.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

37 **Authors' work position and postal address:**  
38

39 Maria Patrizia Carrieri (PhD) is Senior Public Health Researcher in the "Environments,  
40 Health Systems and Transmitted Diseases (ESSEM)" Team, National Institute of Health  
41 (INSERM), U912 (SESSTIM), 23 rue Stanislas Torrents, 13006 Marseilles, France; Camelia  
42 Protopopescu (PhD) is Senior Biostatistician in the "Environments, Health Systems and  
43 Transmitted Diseases (ESSEM)" Team, National Institute of Health (INSERM), U912  
44 (SESSTIM), 23 rue Stanislas Torrents, 13006 Marseilles, France; Pr Vincent Le Moing (MD,  
45 PhD) is Professor of Infectious Diseases, Department of Infectious and Tropical Diseases,  
46 University Hospital Montpellier, 80 avenue Augustin Fliche, 34295 Montpellier cedex 5,  
47 France; Dr Philippe Reboud (MD) is Project Manager, National Institute of Health  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

(INSERM), U897, University Victor Segalen Bordeaux 2, 146, rue Léo Saignat – case 11, 33076 Bordeaux cedex, France; Pr François Raffi (MD, PhD) is Professor of Infectious Diseases, Department of Infectious and Tropical Diseases, University Hospital Nantes – Hôtel Dieu, Place Alexis Ricordeau, 44093 Nantes cedex 1, France; Dr Sophie Mahy (MD) is Associate specialist, Department of Infectious and Tropical Diseases, University Hospital Dijon, boulevard Maréchal-de-Lattre-de-Tassigny, 21000 Dijon, France; Perrine Roux (PhD) is Senior Public Health Researcher in the “Environments, Health Systems and Transmitted Diseases (ESSEM)” Team, National Institute of Health (INSERM), U912 (SESSTIM) and Substance Use Research Center, NYSPI, Columbia University, New York, USA; Dr Lise Cuzin (MD) is Associate specialist, Department of Infectious and Tropical Diseases, University Hospital Purpan - COREVIH – Bat TURIAF - TSA 40031, 31059 Toulouse Cedex, France; Dr Bruno Spire (MD, PhD) is Senior Public Health Researcher and leader of the “Environments, Health Systems and Transmitted Diseases (ESSEM)” Team, National Institute of Health (INSERM), U912 (SESSTIM), 23 rue Stanislas Torrents, 13006 Marseilles, France; Pr Catherine Leport (MD, PhD) is Professor of Infectious Diseases, LRPI-UMR 738, UFR Médecine site Bichat, 16 rue Henri Huchard, 75018 Paris, France.

**The ANRS CO8 APROCO-COPILOTE Study Group is composed of the following:**

**Scientific Committee:**

• Steering Committee:

Principal investigators: C. Leport, F. Raffi

Methodology: G. Chêne, R. Salamon

Social sciences: JP. Moatti, J. Pierret, B. Spire

Virology: F. Brun-Vézinet, H. Fleury, B. Masquelier

Pharmacology: G. Peytavin, R. Garraffo

- 1  
2  
3 • Other members: D. Costagliola, P. Dellamonica, C. Katlama, L. Meyer, D. Salmon, A.  
4 Sobel.  
5

6  
7 **Events Validation Committee:** L. Cuzin, M. Dupon, X. Duval, V. Le Moing, B. Marchou,  
8 T. May, P. Morlat, C. Rabaud, A. Waldner-Combernoux.  
9

10 **Project coordination:** P. Reboud.  
11

12 **ANRS representatives:** Sandrine Couffin-Cadiergues, Lucie Marchand.  
13

14 **Data monitoring and statistical analysis:** V. Bouteloup, AD. Bouhnik, C. Brunet-François,  
15 V. Caron, MP. Carrieri, M. Courcoul, F. Couturier, L. Hardel, L. Iordache. P. Kurkdji, S.  
16 Martiren, M. Préau, C. Protopopescu, J. Surzyn, A. Taieb, V. Villes.  
17  
18

19 **Promotion:** Agence Nationale de Recherches sur le Sida et les hépatites virales (ANRS,  
20 Action Coordonnée n°7).  
21

22 **Other support:** Collège des Universitaires de Maladies Infectieuses et Tropicales (CMIT ex  
23 APPIT), Sidaction Ensemble contre le Sida and associated pharmaceutical companies:  
24 Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences,  
25 Pfizer and Roche.  
26

27 **Clinical Centres (investigators):** Amiens (Pr JL. Schmit), Angers (Dr JM. Chennebault),  
28 Belfort (Dr JP. Faller), Besançon (Pr N. Mgy-Bertrand, Pr B. Hoen, Dr Drobachef), Bobigny  
29 (Pr O. Bouchaud), Bordeaux (Pr M. Dupon, Pr Longy-Boursier, Pr P. Morlat, Pr JM.  
30 Ragnaud), Bourg-en-Bresse (Dr P. Granier), Brest (Pr M. Garré), Caen (Pr R. Verdon),  
31 Compiègne (Dr D. Merrien), Corbeil Essonnes (Dr A. Devidas), Créteil (Pr A. Sobel), Dijon  
32 (Pr L. Piroth), Garches (Pr C. Perronne), Lagny (Dr E. Froguel), Libourne (Dr J. Ceccaldi),  
33 Lyon (Pr D. Peyramond), Meaux (Dr C. Allard), Montpellier (Pr J. Reynes), Nancy (Pr T.  
34 May), Nantes (Pr F. Raffi), Nice (Pr JG Fuzibet, Pr P. Dellamonica), Orléans (Dr P. Arsac),  
35 Paris (Pr E. Bouvet, Pr F. Bricaire, Pr P. Bergmann, Pr J. Cabane, Dr J. Monsonego, Pr PM.  
36 Girard, Pr L. Guillevin, Pr S. Herson, Pr C. Leport, Pr MC. Meyohas, Pr JM. Molina, Pr G.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Pialoux, Pr D. Salmon), Poitiers (Pr P. Roblot), Reims (Pr R. Jaussaud), Rennes (Pr C.  
4  
5 Michelet), Saint-Etienne (Pr F. Lucht), Saint-Mandé (Pr T. Debord), Strasbourg (Dr D. Rey),  
6  
7 Toulon (Dr JP. De Jaureguiberry), Toulouse (Pr B. Marchou), Tours (Pr L. Bernard).  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



## References

1. Kaplan RC, Kingsley LA, Gange SJ *et al.* Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. *Aids* 2008, **22**(13):1615-1624.
2. Henry K, Melroe H, Huebsch J *et al.* Severe premature coronary artery disease with protease inhibitors. *Lancet* 1998, **351**(9112):1328.
3. Lai S, Fishman EK, Lai H *et al.* Long-Term Cocaine Use and Antiretroviral Therapy Are Associated with Silent Coronary Artery Disease in African Americans with HIV Infection Who Have No Cardiovascular Symptoms. *Clin Infect Dis* 2008, **46**:600-610.
4. Mary-Krause M, Cotte L, Simon A *et al.* Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. *Aids* 2003, **17**(17):2479-2486.
5. Friis-Moller N, Reiss P, Sabin CA *et al.* Class of antiretroviral drugs and the risk of myocardial infarction. *N Engl J Med* 2007, **356**(17):1723-1735.
6. Butt AA, Chang CC, Kuller L *et al.* Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. *Arch Intern Med* 2011, **171**(8):737-743.
7. Lichtenstein KA, Armon C, Buchacz K *et al.* Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. *Clin Infect Dis* 2010, **51**(4):435-447.
8. Mondy KE, de las Fuentes L, Waggoner A *et al.* Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy. *Aids* 2008, **22**(7):849-856.
9. Sax PE. Strategies for management and treatment of dyslipidemia in HIV/AIDS. *AIDS Care* 2006, **18**(2):149-157.
10. Smith CJ, Levy I, Sabin CA *et al.* Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population. *HIV Med* 2004, **5**(2):88-92.
11. Guaraldi G, Squillace N, Stentarelli C *et al.* Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. *Clin Infect Dis* 2008, **47**(2):250-257.
12. Michel L, Carrieri MP, Fugon L *et al.* Harmful alcohol consumption and patterns of substance use in HIV-infected patients receiving antiretrovirals (ANRS-EN12-VESPA Study): relevance for clinical management and intervention. *AIDS Care* 2010, **22**(9):1136-1145.
13. Stein M, Herman DS, Trisvan E *et al.* Alcohol use and sexual risk behavior among human immunodeficiency virus-positive persons. *Alcohol Clin Exp Res* 2005, **29**(5):837-843.
14. Braithwaite RS, Conigliaro J, McGinnis KA *et al.* Adjusting alcohol quantity for mean consumption and intoxication threshold improves prediction of nonadherence in HIV patients and HIV-negative controls. *Alcohol Clin Exp Res* 2008, **32**(9):1645-1651.
15. Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. *J Acquir Immune Defic Syndr* 2006, **43**(4):411-417.
16. Spire B, Duran S, Souville M *et al.* Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. *Soc Sci Med* 2002, **54**(10):1481-1496.
17. Conen A, Fehr J, Glass TR *et al.* Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. *Antivir Ther* 2009, **14**(3):349-357.
18. Braithwaite RS, Conigliaro J, Roberts MS *et al.* Estimating the impact of alcohol consumption on survival for HIV+ individuals. *AIDS Care* 2007, **19**(4):459-466.
19. Galai N, Vlahov D, Baretta JC *et al.* Prognostic factors for survival differ according to CD4+ cell count among HIV-infected injection drug users: pre-HAART and HAART eras. *J Acquir Immune Defic Syndr* 2005, **38**(1):74-81.
20. Hooshyar D, Hanson DL, Wolfe M *et al.* Trends in perimortal conditions and mortality rates among HIV-infected patients. *Aids* 2007, **21**(15):2093-2100.



- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
21. Samet JH, Cheng DM, Libman H *et al*. Alcohol consumption and HIV disease progression. *J Acquir Immune Defic Syndr* 2007, **46**(2):194-199.
22. Salmon-Ceron D, Lewden C, Morlat P *et al*. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. *J Hepatol* 2005, **42**(6):799-805.
23. Di Martino V, Rufat P, Boyer N *et al*. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. *Hepatology* 2001, **34**(6):1193-1199.
24. Puoti M, Spinetti A, Ghezzi A *et al*. Mortality for liver disease in patients with HIV infection: a cohort study. *J Acquir Immune Defic Syndr* 2000, **24**(3):211-217.
25. Rosenthal E, Pialoux G, Bernard N *et al*. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). *J Viral Hepat* 2007, **14**(3):183-188.
26. Freiberg MS, McGinnis KA, Kraemer K *et al*. The association between alcohol consumption and prevalent cardiovascular diseases among HIV-infected and HIV-uninfected men. *J Acquir Immune Defic Syndr* 2010, **53**(2):247-253.
27. Freiberg MS, Cheng DM, Kraemer KL *et al*. The association between hepatitis C infection and prevalent cardiovascular disease among HIV-infected individuals. *Aids* 2007, **21**(2):193-197.
28. Mukamal KJ, Chen CM, Rao SR *et al*. Alcohol consumption and cardiovascular mortality among U.S. adults, 1987 to 2002. *J Am Coll Cardiol* 2010, **55**(13):1328-1335.
29. Mukamal KJ, Conigrave KM, Mittleman MA *et al*. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. *N Engl J Med* 2003, **348**(2):109-118.
30. Saves M, Chene G, Ducimetiere P *et al*. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. *Clin Infect Dis* 2003, **37**(2):292-298.
31. CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *MMWR Recomm Rep*. 1992 Dec 18;41(RR-17):1-19.
32. Radloff L. The CES-D scale: a self-report depression scale for research in the general population. *Applied Psychology Measurement* 1977, **3**:385-491.
33. Justice AC, Holmes W, Gifford AL *et al*. Development and validation of a self-completed HIV symptom index. *J Clin Epidemiol* 2001, **54 Suppl 1**:S77-90.
34. Carrieri MP, Villes V, Raffi F *et al*. Self-reported side-effects of anti-retroviral treatment among IDUs: a 7-year longitudinal study (APROCO-COPILOTE COHORT ANRS CO-8). *Int J Drug Policy* 2007, **18**(4):288-295.
35. Chesney MA, Ickovics JR, Chambers DB *et al*. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). *AIDS Care* 2000, **12**(3):255-266.
36. Ueshima H, Choudhury SR, Okayama A *et al*. Cigarette smoking as a risk factor for stroke death in Japan: NIPPON DATA80. *Stroke* 2004, **35**(8):1836-1841.
37. Bissell D, Paton A, Ritson B. ABC of alcohol. Help: referral. *Br Med J (Clin Res Ed)* 1982, **284**(6314):495-497.
38. Carrieri P, Cailleton V, Le Moing V *et al*. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. *J Acquir Immune Defic Syndr* 2001, **28**(3):232-239.
39. Fuhrer R, Rouillon F. La version française de l'échelle CES-D. Description and translation of the autoevaluation scale (*in French*). *Psychiatrie et Psychobiologie* 1989, **4**:163-166.
40. Therneau TM, Grambsch PM: *Modeling Survival Data: Extending the Cox Model* Springer; 2000.

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
41. Friis-Moller N, Thiebaut R, Reiss P *et al*. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. *Eur J Cardiovasc Prev Rehabil* 2010, **17**(5):491-501.
42. Mukamal KJ, Chung H, Jenny NS *et al*. Alcohol use and risk of ischemic stroke among older adults: the cardiovascular health study. *Stroke* 2005, **36**(9):1830-1834.
43. Waskiewicz A, Sygnowska E, Drygas W. Relationship between alcohol consumption and cardiovascular mortality--the Warsaw Pol-MONICA Project. *Kardiol Pol* 2004, **60**(6):552-562; discussion 563.
44. Burger M, Mensink G, Bronstrup A *et al*. Alcohol consumption and its relation to cardiovascular risk factors in Germany. *Eur J Clin Nutr* 2004, **58**(4):605-614.
45. Murray RP, Connett JE, Tyas SL *et al*. Alcohol volume, drinking pattern, and cardiovascular disease morbidity and mortality: is there a U-shaped function? *Am J Epidemiol* 2002, **155**(3):242-248.
46. Beulens JW, Algra A, Soedamah-Muthu SS *et al*. Alcohol consumption and risk of recurrent cardiovascular events and mortality in patients with clinically manifest vascular disease and diabetes mellitus: the Second Manifestations of ARterial (SMART) disease study. *Atherosclerosis* 2010, **212**(1):281-286.
47. Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. *HIV Med* 2005, **6**(2):99-106.
48. Marques-Vidal P, Montaye M, Arveiler D *et al*. Alcohol consumption and cardiovascular disease: differential effects in France and Northern Ireland. The PRIME study. *Eur J Cardiovasc Prev Rehabil* 2004, **11**(4):336-343.
49. Foerster M, Marques-Vidal P, Gmel G *et al*. Alcohol drinking and cardiovascular risk in a population with high mean alcohol consumption. *Am J Cardiol* 2009, **103**(3):361-368.
50. Mukamal KJ, Cushman M, Mittleman MA *et al*. Alcohol consumption and inflammatory markers in older adults: the Cardiovascular Health Study. *Atherosclerosis* 2004, **173**(1):79-87.
51. Grulich AE, Jin F, Poynten IM *et al*. HIV, cancer, and aging. *Sex Health* 2011, **8**(4):521-525.
52. Palella FJ, Jr., Phair JP. Cardiovascular disease in HIV infection. *Curr Opin HIV AIDS* 2011, **6**(4):266-271.
53. Niaura R, Shadel WG, Morrow K *et al*. Human immunodeficiency virus infection, AIDS, and smoking cessation: the time is now. *Clin Infect Dis* 2000, **31**(3):808-812.
54. Barth J, Critchley J, Bengel J. Efficacy of psychosocial interventions for smoking cessation in patients with coronary heart disease: a systematic review and meta-analysis. *Ann Behav Med* 2006, **32**(1):10-20.
55. Currier JS, Havlir DV. Complications of HIV disease and antiretroviral therapy. *Top HIV Med* 2009, **17**(2):57-67.
56. Lloyd-Richardson EE, Stanton CA, Papandonatos GD *et al*. Motivation and patch treatment for HIV+ smokers: a randomized controlled trial. *Addiction* 2009, **104**(11):1891-1900.
57. Roux P, Cohen J, Lascoux-Combe C *et al*. Determinants of the underreporting of alcohol consumption by HIV/HCV co-infected patients during face-to-face medical interviews: the role of the physician. *Drug Alcohol Depend* 2011, **116**(1-3):228-232.

**Table 1. Factors associated with the first occurrence of a major CADE among HIV-infected patients receiving ART (ANRS CO8 APROCO-COPILOTE cohort - univariate and multivariate Cox proportional hazard models, all patients - n=1154, follow-up period M0-M132)**

	% of patients or mean (SD) <sup>@</sup>	% of miss. data	Univariate analyses		Multivariate analysis	
			HR [95% CI]	p-value	AHR [95% CI]	p-value
<b><i>Socio-demographic and psychosocial characteristics</i></b>						
Female gender	22.0	0	0.26 [0.08-0.84]	0.025	0.25 [0.08-0.83]	0.024
Age at M0 <sup>o</sup> - years	37.7 (9.5)	0	1.06 [1.03-1.09]	<10 <sup>-3</sup>	1.07 [1.04-1.10]	<10 <sup>-3</sup>
Secondary-school certificate at M0 <sup>o</sup>	31.3	7.3	0.51 [0.26-1.01]	0.054		
Alcohol consumption at M0 <sup>o</sup>		0				
- abstainers (ref)	18.8		1			
- <=3 AU/day	75.3		0.47 [0.24-0.89]	0.021		
- >3 AU/day	5.9		0.75 [0.21-2.63]	0.648		
Alcohol consumption*		0				
- abstainers (ref)	18.8		1		1	
- <=3 AU/day	75.3		0.44 [0.24-0.81]	0.009	0.38 [0.20-0.71]	0.002
- >3 AU/day	5.9		1.04 [0.30-3.58]	0.953	0.46 [0.13-1.63]	0.229
Tobacco consumption >20 cig./day*	16.4	0.9	3.17 [1.73-5.83]	<10 <sup>-3</sup>	4.19 [2.17-8.11]	<10 <sup>-3</sup>
Depressive symptoms <sup>#*</sup>	37.9	8.5	1.22 [0.67-2.21]	0.512		
Number of self-reported symptoms (excluding lipodystrophy)*	3.8 (2.8) @@	0	1.01 [0.95-1.08]	0.694		
Number of self-reported lipodystrophy symptoms*	1.1 (2.2) @@	0.6	1.07 [0.96-1.18]	0.223		
ART adherence*	57.7 <sup>@@</sup>	0.1	2.42 [1.17-5.02]	0.017		
<b><i>Clinical characteristics</i></b>						
HIV transmission category <sup>o</sup>		0				

- homosexual	40.6		0.99 [0.42-2.34]	0.988		
- injecting drug use	17.8		0.92 [0.50-1.70]	0.793		
- other (ref)	41.6		1			
CDC clinical stage A at M0 <sup>o</sup>	51.2	0	0.44 [0.23-0.85]	0.014		
HCV infection at M0 <sup>o</sup>	22.4	4.3	1.16 [0.59-2.29]	0.655		
Time since HIV diagnosis at M0- years <sup>o</sup>	4.7 (4.2)	0.9	1.01 [0.94-1.08]	0.822		
Duration of exposure to efavirenz - years* <sup>§</sup>	1.0 (2.2) <sup>§</sup>	0	0.86 [0.71-1.03]	0.102		
Duration of exposure to nevirapine - years* <sup>§</sup>	0.9 (2.2) <sup>§</sup>	0	0.91 [0.78-1.07]	0.279		
Duration of exposure to abacavir - years* <sup>§</sup>	1.0 (2.1) <sup>§</sup>	0	0.98 [0.84-1.13]	0.748		
Duration of exposure to lopinavir - years* <sup>§</sup>	0.4 (1.5) <sup>§</sup>	0	1.01 [0.85-1.20]	0.929		
Duration of exposure to PI-based regimen - years* <sup>§</sup>	3.2 (3.1) <sup>§</sup>	0	1.03 [0.92-1.15]	0.615		
Antiretroviral naivety at M0 <sup>o</sup>	44.4	0	1.14 [0.64-2.02]	0.654		
CD4+ cell count $\geq 200$ cells/mm <sup>3</sup> * <sup>o</sup>	65.4	0.1	0.40 [0.19-0.87]	0.020	0.40 [0.18-0.86]	0.020
Detectable viral load*	91.9	0.3	0.99 [0.53-1.84]	0.980		

CADE = coronary or other arterial disease event; ART = antiretroviral therapy; CHD = coronary heart disease

SD = standard deviation; (A)HR = (adjusted) hazard ratio; CI = confidence interval

<sup>o</sup> Fixed variable (measured at M0 or M1); \* Time-varying variable (the last available value before each visit)

@ Percentages and averages were computed at the first date of follow-up for time-varying variables

@@ At M12; § At the end of the follow-up

# Depressive symptoms: the Centre for Epidemiologic Studies Depression Scale (CES-D) scores is  $>17$  for men and  $>23$  for women

**Table 2. Factors associated with the first occurrence of a major CADE among HIV-infected patients receiving ART (ANRS CO8 APROCO-COPILOTE cohort - univariate and multivariate Cox proportional hazard models, patients with available metabolic data - n=675, follow-up period M12-M132)**

	% of patients or mean (SD) <sup>@</sup>	% of miss. data	Univariate analyses		Multivariate analysis	
			HR [95% CI]	p-value	AHR [95% CI]	p-value
<b><i>Socio-demographic and psychosocial characteristics</i></b>						
Female gender	19.0	0	0.33 [0.08-1.40]	0.134		
Age at M0 – years <sup>o</sup>	38.4 (9.5)	0	1.04 [1.01-1.07]	0.013	1.05 [1.02-1.09]	0.003
Secondary-school certificate at M0 <sup>o</sup>	35.4	6.7	0.34 [0.14-0.84]	0.019		
Alcohol consumption at M0 <sup>o</sup>		0				
- abstainers (ref)	15.1		1			
- <=3 AU/day	78.4		0.44 [0.18-1.03]	0.059		
- >3 AU/day	6.5		1.04 [0.26-4.05]	0.959		
Alcohol consumption*		0				
- abstainers (ref)	15.1		1		1	
- <=3 AU/day	78.4		0.27 [0.13-0.58]	0.001	0.23 [0.11-0.49]	<10 <sup>-3</sup>
- >3 AU/day	6.5		1.19 [0.33-4.23]	0.792	0.55 [0.14-2.14]	0.390
Tobacco consumption >20 cig./day*	14.8	1.2	3.58 [1.70-7.54]	0.001	5.59 [2.43-12.8]	<10 <sup>-3</sup>
Depressive symptoms <sup>#*</sup>	36.6	8.0	1.83 [0.90-3.73]	0.094		
Number of self-reported symptoms (excluding lipodystrophy) <sup>*@@</sup>	4.0 (2.9)	0	1.03 [0.95-1.12]	0.463		
Number of self-reported lipodystrophy symptoms <sup>*@@</sup>	1.4 (2.4)	0.2	1.10 [0.98-1.24]	0.111		
ARV adherence <sup>*@@</sup>	56.6	0.2	1.63 [0.70-3.81]	0.260		
<b><i>Clinical characteristics</i></b>						

HIV transmission category <sup>o</sup>		0				
- homosexual (ref)	44.0		1			
- injecting drug use	15.0		2.08 [0.75-5.73]	0.156		
- other	41.0		1.32 [0.59-2.93]	0.499		
CDC clinical stage A at M0 <sup>o</sup>	50.8	0	0.43 [0.19-0.97]	0.041		
HCV infection at M0 <sup>o</sup>	19.8	3.8	2.05 [0.94-4.47]	0.071		
Duration since HIV diagnosis at M0- years <sup>o</sup>	4.7 (4.2)	1.2	1.04 [0.96-1.13]	0.311		
Duration of exposure to efavirenz - years* <sup>§</sup>	1.4 (2.5)	0	0.89 [0.73-1.08]	0.236		
Duration of exposure to nevirapine - years* <sup>§</sup>	1.0 (2.3)	0	0.83 [0.66-1.06]	0.147		
Duration of exposure to abacavir - years* <sup>§</sup>	1.2 (2.3)	0	0.99 [0.85-1.17]	0.971		
Duration of exposure to lopinavir - years* <sup>§</sup>	0.5 (1.5)	0	1.07 [0.88-1.30]	0.505		
Duration of exposure to PI-based regimen - years* <sup>§</sup>	3.9 (3.1)	0	1.03 [0.89-1.18]	0.714		
Antiretroviral naivety at M0 <sup>o</sup>	41.5	0	0.86 [0.41-1.79]	0.683		
CD4+ cell count $\geq 200$ cells/mm <sup>3</sup> *	67.7	0	0.39 [0.15-1.01]	0.052	0.25 [0.09-0.69]	0.007
Detectable viral load*	92.7	0.3	1.24 [0.59-2.59]	0.574		
<b>Metabolic characteristics</b>						
BMI categories <sup>o@@</sup>		1.6				
- underweight: <18.5 (ref)	5.8		1			
- normal weight: 18.5–24.9	72.8		0.65 [0.15-2.76]	0.556		
- overweight or obese: >25	19.8		0.57 [0.11-2.87]	0.498		
Hypertriglyceridemia <sup>o@@</sup>	8.4	0	2.06 [0.79-5.37]	0.141	2.98 [1.11-8.01]	0.030
Hypercholesterolemia <sup>o@@</sup>	6.5	0.1	0.95 [0.22-3.97]	0.939		
Personal history of CHD <sup>o@@</sup>	1.2	0	9.39 [2.22-39.8]	0.002		
Family history of CHD <sup>o@@</sup>	28.0	0	1.82 [0.89-3.71]	0.102	2.25 [1.08-4.71]	0.031

1  
2  
3 Personal history of 6.1 0 2.73 [1.05-7.13] 0.040  
4 hypertension<sup>°@@</sup>  
5  
6

---

7  
8 CADE = coronary or other arterial disease event; ART = antiretroviral therapy; CHD = coronary heart disease

9  
10 SD = standard deviation; (A)HR = (adjusted) hazard ratio; CI = confidence interval

11  
12 <sup>°</sup> Fixed variable (measured at M0, M1 or M12); \* Time-varying variable (the last available value before each visit)

13  
14 <sup>@</sup> Percentages and averages are computed at the first date of follow-up for time-varying variables

15  
16 <sup>@@</sup> At M12; <sup>§</sup> At the end of the follow-up

17  
18 <sup>#</sup> Depressive symptoms: the Centre for Epidemiologic Studies Depression Scale (CES-D) scores is >17 for men  
19 and >23 for women  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
<b>Title and abstract</b>	1	<p><u>(a) Indicate the study's design with a commonly used term in the title or the abstract</u> "Cohort study."</p> <hr/> <p><u>(b) Provide in the abstract an informative and balanced summary of what was done and what was found</u>  <b>"Objective:</b> To investigate the relationship between response to antiretroviral treatment (ART), alcohol use and occurrence of a major coronary or other arterial disease event (CADE) in HIV-infected individuals.  <b>Design:</b> Cohort study. A Cox model was used to identify correlates of a first occurrence of a major CADE.  <b>Setting:</b> The French ANRS CO8 APROCO-COPILOTE cohort was set up in 1997 to study clinical progression and patient-reported outcomes (PRO) after initiating protease inhibitor-containing ART. Clinical data were retrieved from medical records. Self-administered questionnaires collected data on PRO and behaviours, including alcohol use.  <b>Participants:</b> Metabolic data were only available for a subgroup (n=675) of the study group (n=1154).  Main outcomes measures: Major coronary or other arterial disease first event.  <b>Results:</b> Over the 11-year follow-up, 49 major CADE were observed, with an incidence rate [95% CI]=0.75[0.57 to 0.99] per 100 person-years. CD4+ cell count <math>\geq 200</math> cells/mm<sup>3</sup> was associated with a reduced risk of CADE (adjusted hazard ratio AHR[95% CI]=0.40[0.18 to 0.86]) after adjustment for female gender (0.25[0.08 to 0.83]), age (1.07[1.04 to 1.10]) and smoking&gt;20 cigarettes/day (4.19[2.17 to 8.11]). Moreover, individuals with moderate alcohol consumption (<math>\leq 3</math> AU/day) had a lower risk of CADE (0.38[0.20 to 0.71]) than alcohol abstainers, while the risk for those drinking&gt;3 AU/day was not significantly different from this latter group. These associations remained valid after adjustment for metabolic disorders. No significant association with exposure to any specific antiretroviral was detected.  <b>Conclusions:</b> In the long term, CD4+ cell count <math>\geq 200</math> cells/mm<sup>3</sup> and moderate alcohol consumption remain the principal factors associated with a lower risk of CADE. Combined interventions to reduce CADE risk-related behaviours and sustain ART adherence in HIV-infected individuals are now a clinical and public health priority."</p>
<hr/>		
<b>Introduction</b>		
Background/rationale	2	<p><u>Explain the scientific background and rationale for the investigation being reported</u>  "Cardiovascular disease risk factors (including for example hypertension and tobacco use), as well as immunological status are major predictors of atherosclerosis in HIV-infected women and men. Although antiretroviral (ARV) therapy agents have consistently been found to be associated with coronary and other arterial disease events (CADE) in these patients, more recently Butt and colleagues put into evidence the negative effect of HIV viral replication on heart failure. In one study, patients having experienced myocardial infarction (MI) presented lower baseline and proximal CD4+ cell counts than those who did not, while no association was found with specific antiretroviral agents. Moreover, known factors associated with the risk of CADE such as hyperlipidemia and insulin resistance are becoming an increasingly</p>



major clinical concern in ART-treated individuals.

Though excessive alcohol use may be frequent in HIV-infected individuals, its impact on the occurrence of CADE in this population has been less investigated. Excessive alcohol consumption also plays a major role in HIV risk-taking behaviors, particularly in men who have sex with men and drug users. In HIV-infected individuals, excessive alcohol use is known to compromise patients' response to antiretroviral therapy (ART) through reduced adherence and to predict HIV progression and increased mortality, mostly from liver diseases. Some recent cross-sectional analyses in HIV-infected and uninfected men have found that heavy alcohol consumption is associated with a higher risk of CADE. On the other hand, in uninfected adults, moderate alcohol consumption has been found to be associated with a reduced risk, improved lipid profiles, increased insulin sensitivity and reduced risk of MI. However, this association has not yet been studied in longitudinal studies involving HIV-infected populations including women. Moreover, there are as yet no consistent results in the literature regarding the role that alcohol use plays in exacerbating the risk of CADE in ART-treated patients and to what extent it can confound or boost the effect of immuno-virological response to ART, ART-associated dyslipidemia and insulin resistance on the risk of CADE."

Objectives	3	<u>State specific objectives, including any prespecified hypotheses</u> "We used data from the 11-year follow-up of the APROCO-COPILOTE cohort of patients receiving ART since 1997 to investigate the relationship between undetectable viral load, CD4+ cell count, alcohol consumption and the first occurrence of a CADE, after adjustment for known risk factors including metabolic disorders."
<b>Methods</b>		
Study design	4	<u>Present key elements of study design early in the paper</u> "The French APROCO-COPILOTE cohort (ANRS CO8) was designed to study the clinical, immunological, virological, and socio-behavioural course of HIV disease in HIV-1 positive individuals who started the first generation of potent ART (treatment regimens including protease inhibitors (PI)). The study was approved by the Ethics Committee of Cochin Hospital (Paris) and informed consent was obtained from all participants."
Setting	5	<u>Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection</u> "Patients were enrolled in the cohort at their first PI-based ART prescription between May 1997 and June 1999 (n=1281) in 47 French centres, and clinically followed-up every 4 months thereafter, up to month 132 (M132)."
Participants	6	<u>(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up</u> "In the present study were included all patients who had either two alcohol assessment or one alcohol assessment just preceding the CADE over the whole follow-up (n=1154)."  <u>(b) For matched studies, give matching criteria and number of exposed and unexposed</u> [Not applicable.]
Variables	7	<u>Clearly define all outcomes, exposures, predictors, potential confounders, and effect</u>

modifiers. Give diagnostic criteria, if applicable

*“Medical questionnaire*

The medical questionnaire at enrolment (M0) collected retrospective data about patient’s HIV history including HIV transmission category, time since HIV diagnosis, previous exposure to antiretroviral treatment before enrolment, co-infection with hepatitis C virus (HCV). This information was complemented by another medical questionnaire, completed by the HIV physician at each follow-up visit, which collected clinical and laboratory data (plasma HIV RNA level, CD4+ cell count, HIV clinical stage) as well as data on the antiretroviral regimen prescribed. A third form, based on updated medical records, detailed all clinical severe events, including CADE, occurring during the study period. Information on metabolic disorders was available at M12 for a subset of cohorts’ patients, who participated in a parallel cross-sectional survey, designed to study clinical and laboratory metabolic complications. These “metabolic” data included height, weight, hypertriglyceridemia, hypercholesterolemia, personal history of coronary heart disease (CHD) and hypertension, and finally any family history of CHD.

*Outcome*

The clinical severe events occurring during follow-up, including CADE, were initially recovered from medical records and validated by a validation committee. The classification of clinical severe events was based on the 10th Revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10). The major CADE selected for this study were MI, stroke, coronary heart disease, peripheral arterial disease and cardiovascular surgery for coronary disease.

*Self-administered questionnaire*

A self-administered questionnaire collected - at M0, M4, M12 and every 8 months thereafter during the first 5 years of follow-up, then yearly thereafter – data on socio-demographic characteristics including age, gender and educational level. Among other psycho-social and behavioural information, it also collected details on depressive symptoms, tobacco use, alcohol consumption, self-reported ART-related symptoms and adherence to ART.”

---

Data sources/ measurement	8*	<p><u>For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group</u></p> <p>“At each follow-up visit, CD4+ cell count was measured by standardized flow cytometry, and plasma HIV RNA levels were measured using the assay routinely available in each participating centre. HIV clinical stage was defined using the 1993 Centres for Disease Control and Prevention (CDC) clinical classification system. Serum triglyceride and total cholesterol levels were measured after a 12-hour overnight fast. Hypertriglyceridemia was defined as a triglyceride level <math>\geq 2.2</math> mmol/l, while hypercholesterolemia was defined as a total cholesterol level <math>\geq 5.5</math> mmol/l. Depression was measured using the validated French version of the Centre for Epidemiologic Studies Depression Scale (CES-D), which is a 20-item scale commonly used in studies involving HIV-infected patients. Tobacco and alcohol consumption were evaluated during the previous 4 weeks. Alcohol consumption was assessed using two questions about frequency of consumption and quantity consumed daily, if applicable. A 13-item scale comprising the French version of the symptom index validated by Justice et al and described elsewhere collected information about self-reported</p>
------------------------------	----	--

symptoms. Five other questions gathered information about adherence to ART, according to the methodology established by the AIDS Clinical Trial Group.”

Bias	9	<p><u>Describe any efforts to address potential sources of bias</u></p> <p>“As the results of the analysis on the whole dataset (n=1154) could be affected by the lack of important predictors of CADE like hypertriglyceridemia or hypercholesterolemia, we conducted a secondary analysis on a subset of patients who had additional metabolic disorders data.”</p> <p>[This secondary analysis confirmed the same pattern of predictors of CADE events after adjustment for metabolic disorders.]</p>
Study size	10	<p><u>Explain how the study size was arrived at</u></p> <p>“Precisely, two analyses on two different study populations were performed to study predictors of major CADE:</p> <p>1) First analysis: the study population included all patients who had either two alcohol assessment or one alcohol assessment just preceding the event over the whole follow-up (n=1154). The follow-up period was M0-M132.</p> <p>2) Second analysis: the study population was restricted to the subset of patients with available data on metabolic disorders, measured at M12 (n=675). Consequently, only events occurring after M12 were considered in this second analysis.”</p>
Quantitative variables	11	<p><u>Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why</u></p> <p>“The WHO body mass index (BMI) categories were used in the analysis: underweight and overweight/obese patients were defined respectively as having a BMI lower than 18.5 and greater than 25.</p> <p>A cumulative measure of time exposure to specific ARV medications (abacavir, efavirenz, nevirapine, lopinavir and protease inhibitor) was computed from cohort enrolment to the date of each follow-up visit.</p> <p>Tobacco consumption was dichotomized in two categories: more than 20 cigarettes/day vs other. The average number of alcohol units (AU) consumed per day was computed using the two questions on alcohol consumption.</p> <p>Patients were classified as non-adherent if they reported taking less than 100% of prescribed medications during the previous 4 weeks, using a validated algorithm. A patient with a CES-D score value above 17 (men) or 23 (women) was considered as presenting depressive symptoms.”</p> <p>[See references in the paper for the reasons of choosing of these categories].</p>
Statistical methods	12	<p><u>(a) Describe all statistical methods, including those used to control for confounding</u></p> <p>“Incidence rate of major CADE was computed as the number of cases divided by the number of person-years of follow-up. Follow-up duration was calculated as the difference in days from enrolment to the date of the CADE, death or last visit, whichever occurred first. Follow-up of patients experiencing major CADE was censored after the date of the first CADE. We used a Cox proportional hazards model to identify characteristics associated with the first occurrence of a major CADE.</p> <p>Psychosocial characteristics - depressive symptoms, tobacco and alcohol consumption, self-reported symptoms, CD4+ cell count and viral load - were evaluated at each visit and used as time-varying covariates in the statistical analysis.</p> <p>All the other covariates were used as fixed variables (measured at M0, M1 or M12).</p>

For time-varying factors, the last known value was carried forward in the case of missing data at a scheduled visit. In the case of an event occurring between two consecutive follow-up visits, the values for the time-varying variables measured at the visit preceding the event were used. Covariates with a p-value < 0.25 in univariate Cox analyses were considered eligible for the multivariate Cox model, which was built using a backward selection procedure based on the Wald test (p < 0.05). Interaction effects between the factors of the multivariate final model were tested. The proportional-hazards assumption was verified globally for the multivariate models and separately with respect to each covariate, using both Kaplan-Meier estimates and tests based on Schoenfeld residuals. A residual analysis for outliers' detection was performed and the sensitivity of the model to influential outliers was tested. All analyses were performed using Stata Intercooled software, version 10.1."

---

(b) Describe any methods used to examine subgroups and interactions

"Interaction effects between the factors of the multivariate final Cox model were tested."

---

(c) Explain how missing data were addressed

"For time-varying factors, the last known value was carried forward in the case of missing data at a scheduled visit."

---

(d) If applicable, explain how loss to follow-up was addressed

"Follow-up duration was calculated as the difference in days from enrolment to the date of the CADE, death or last visit, whichever occurred first. Follow-up of patients experiencing major CADE was censored after the date of the first CADE."  
[Patients lost to follow-up were dealt as usual in the Cox model (right-censoring).]

---

(e) Describe any sensitivity analyses

"A residual analysis for outliers' detection was performed and the sensitivity of the models to influential outliers was tested."

---

**Results**

Participants	13*	<p><u>(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed</u></p> <p>"A total of 1154 patients were included in the present study, accounting for 9401 person-visits."</p> <hr/> <p><u>(b) Give reasons for non-participation at each stage</u></p> <p>"When comparing the study patients (n=1154) with those included in the cohort, but excluded from the study due to missing alcohol data (n=127), no significant difference was found for gender, age at enrolment, antiretroviral naivety, CDC clinical stage, baseline CD4+ cell counts and HIV viral load at M0 (data not shown)."</p> <hr/> <p><u>(c) Consider use of a flow diagram</u></p> <p>[Not done because the graph is very simple.]</p>
Descriptive data	14*	<p><u>(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders</u></p>

“The distribution of factors associated with major CADE [...] are reported in Table 1 for the entire study population (n=1154). Table 2 focuses instead on the subset of patients with available data on metabolic disorders (n=675).

In the subsample of patients with available metabolic data (Table 2), the majority (73%) had a normal BMI, 17% were classified in the overweight category and a minority was classified in each of the two more extreme categories (6% underweight and 3% obese). About 8% of the patients had hypertriglyceridemia and 6% had hypercholesterolemia at M12. One year after the enrolment in the cohort, 6% of the patients reported a personal history of hypertension. Only 1% and 28% respectively had a personal and family history of CHD.”

---

(b) Indicate number of participants with missing data for each variable of interest

[See Tables 1 and 2, second column.]

---

(c) Summarise follow-up time (eg. average and total amount)

“Median [interquartile range (IQR)] duration of follow-up of the selected patients, from their first visit after the ART prescription (M1) until M132, was 5.9 [1.8-9.4] years.”

Outcome data	15*	<p><u>Report numbers of outcome events or summary measures over time</u></p> <p>“Over the 11-year follow-up of the cohort, a total of 85 CADE were observed. These included 49 major CADE as follows: myocardial infarction (n=30), coronary heart disease (n=4), stroke (n=7), peripheral arterial disease (n=7) and cardiovascular surgery (n=1). The distribution of the other thirty six CADE was as follows: phlebitis/pulmonary embolism (n=22), cardiomyopathy/congestive heart failure (n=5), cardiac dysrhythmia (n=6), cerebral haemorrhage (n=2) and aortic aneurysm (n=1). The incidence rate [95% CI] of all CADE was 1.3 [1.0 to 1.6] per 100 person-years, while for major CADE the incidence rate was 0.75 [0.57 to 0.99] per 100 person-years. Of the 49 major CADE, 40 occurred after M12. Furthermore, the major CADE incidence over the period M12-M132 was 0.89 [0.66 to 1.22] per 100 person-years.”</p>
Main results	16	<p><u>(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg. 95% confidence interval). Make clear which confounders were adjusted for and why they were included</u></p> <p>“[...] the results of univariate and multivariate Cox models, are reported in Table 1 for the entire study population (n=1154). Table 2 focuses instead on the subset of patients with available data on metabolic disorders (n=675). [...]”</p> <p>In the entire study group (n=1154), the following factors were found to be independent predictors of major CADE: older age at baseline (Adjusted Hazard Ratio (AHR)[95% CI]=1.07[1.04 to 1.10]), tobacco consumption&gt;20 cigarettes/day (4.19[2.17 to 8.11]) and CD4+ cell count <math>\geq 200</math> cells/mm<sup>3</sup> (0.40[0.18 to 0.86]) (see Table 1). In addition, a negative association was found between female gender and major CADE (0.25[0.08 to 0.83]). After accounting for the effect of age, gender, tobacco consumption and CD4+ cell count <math>\geq 200</math> cells/mm<sup>3</sup> in the multivariate Cox model, individuals with moderate alcohol consumption (<math>\leq 3</math> AU/day) were at lower risk of major CADE (0.38[0.20 to 0.71]), than alcohol abstainers, while those drinking more than 3 AU/day were not significantly different from abstainers (p=0.229). These results remained valid even when the analysis was restricted to the subgroup of patients with available metabolic data and the follow-up period M12-M132. After</p>

adjusting for age, tobacco consumption, hypertriglyceridemia and a family history of CHD, we consistently found a negative association between moderate alcohol use (0.23[0.11-0.49]), CD4+ cell count  $\geq 200$  cells/mm<sup>3</sup> (0.25[0.09-0.69]) and major CADE one year after enrolment (Table 2).”

(b) Report category boundaries when continuous variables were categorized

[See Tables 1 and 2 for details.]

(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

“The incidence rate [95% CI] of all CADE was 1.3 [1.0 to 1.6] per 100 person-years, while for major CADE the incidence rate was 0.75 [0.57 to 0.99] per 100 person-years. Of the 49 major CADE, 40 occurred after M12. Furthermore, the major CADE incidence over the period M12-M132 was 0.89 [0.66 to 1.22] per 100 person-years.”

Other analyses	17	<p><u>Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses</u></p> <p>“No significant association was found between time of exposure to different ARV drugs and major CADE, the only exceptions being efavirenz and nevirapine, for which a slight negative association was found in univariate analysis only. No significant interaction was found between smoking habits and hypertriglyceridemia or personal history of CHD. Furthermore, detectable viral load was not associated with major CADE in univariate or multivariate analyses.</p> <p>For the Cox models fitted in this study, proportional-hazards assumption remained valid, either globally and with respect to each covariate. The residual analysis did not alter the results of the multivariate model.”</p>
----------------	----	---

**Discussion**

Key results	18	<p><u>Summarise key results with reference to study objectives</u></p> <p>“This longitudinal study clearly confirms that in ART-treated individuals, proximal CD4+ cell count higher than 200 cells/mm<sup>3</sup> remains a major risk factor negatively associated with major coronary and other arterial disease events. This result remains valid even after adjustment for metabolic disorders such as hypertriglyceridemia and family history of CHD, the strength of the association remaining unchanged.”</p>
-------------	----	---

Limitations	19	<p><u>Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias</u></p> <p>“Some limitations of this study need to be acknowledged. First, our definition of CADE includes different types of events which might not share the same pattern of risk factors. However, an additional analysis performed on a restricted dataset and which adjusted for other potential risk factors (such as hypertriglyceridemia) confirmed the pattern found in the main analysis. Second, information on alcohol use was mainly based on self-reports and these may tend to underestimate alcohol consumption. However, it has been reported that HIV-HCV co-infected patients tend to underreport alcohol use more to their hepatologist than to other physicians. As our patients were all followed-up by HIV physicians, it is likely that the degree of underreporting did not greatly affect hazard ratios’ estimates.”</p>
-------------	----	---

Interpretation	20	<u>Give a cautious overall interpretation of results considering objectives, limitations,</u>
----------------	----	---



1 multiplicity of analyses, results from similar studies, and other relevant evidence

2 “The relationship between CADE and CD4+ cell count, in addition to the lack of  
3 association between CADE and specific ARV classes, confirms previous results where  
4 the association between exposure to certain ARV and CADE was no longer evident  
5 after controlling for traditional risk factors and HIV disease markers. Indeed, the  
6 association between specific ARV drugs and major CADE, like myocardial infarctus,  
7 has been shown in very powerful studies, where adjustment for nadir CD4+  
8 lymphocyte count or peak HIV-1 RNA level did not modify the results. However, in  
9 the study cited, no adjustment for proximal CD4+ cell count was performed, and the  
10 association with the class of ARV became weaker after adjustment for serum lipid  
11 levels. Indeed, although ART may modify lipid levels and increase the risk of CADE,  
12 it may also reduce this risk because of CD4+ reconstitution following long-term  
13 suppression of HIV replication or HIV-associated inflammation. The lack of  
14 association with exposure to specific ARV classes in the present study, something  
15 usually associated with an increased risk of CADE, suggests that reduced  
16 immunological response to ART over a long follow-up, as well as known CADE risk  
17 factors may have a more important impact than exposure to a specific antiretroviral  
18 drug.  
19

20 It is also possible that patients with altered lipid profiles were switched to other  
21 classes of antiretroviral drugs during the follow-up. As a consequence, in the long  
22 term, CD4+ cell count  $\geq 200$  cells/mm<sup>3</sup> remain the main correlate of a decreased risk  
23 of CADE, whatever the antiretroviral received.

24 In our study, individuals reporting elevated alcohol consumption exhibited the same  
25 risk of CADE as alcohol abstainers. In contrast, those reporting moderate alcohol  
26 consumptions had a lower risk. This result was confirmed after adjustment for  
27 additional risk factors including tobacco use, age, gender and CD4+ cell count. This  
28 relationship between alcohol consumption and CADE remained significant and J-  
29 shaped, even after adjustment for data on metabolic risk factors- such as having a  
30 history of CHD and hypertriglyceridemia -which was available for a subset of  
31 patients. As highlighted in previous observations of the general population and certain  
32 populations affected by other diseases, these results confirmed that the increased risk  
33 of CADE in HIV-infected patients receiving ART is not attributable to elevated  
34 alcohol use. Furthermore, we highlighted the apparent protective effect of moderate  
35 alcohol consumption in ART treated HIV-infected patients.  
36

37 It is important to note that after the introduction of ART in 1996, the sudden decrease  
38 observed in HIV-related mortality was nonetheless accompanied by an increase in  
39 non-HIV based mortality, cardiovascular diseases becoming increasingly important.  
40 This increase can be explained firstly by a reduction in the competing role of HIV-  
41 related mortality, which in the long term was much more detrimental to health than  
42 other causes of deaths. Secondly, the high prevalence in this population of other risk  
43 factors like tobacco use, together with ART-related morbidity including altered lipid  
44 profiles and triglycerides, may contribute to an increased risk of CADE.  
45

46 The association found between moderate alcohol use and reduced CADE risk is not  
47 consistent with all previous research in HIV-infected patients. Freiberg et al pointed  
48 out that among HIV-infected men in the US, hazardous drinking and both alcohol  
49 abuse and dependence were associated with a higher prevalence of CADE compared  
50 with infrequent and moderate drinking, even after adjusting for traditional risk factors,  
51 antiretroviral therapy and CD4+ cell count. This difference in the results may be due  
52 to the different design of the two studies (longitudinal for ours vs cross-sectional for  
53  
54  
55  
56  
57  
58  
59  
60

Freidberg's), but probably also to the different types of alcohol mainly consumed in the two populations, red wine consumption being more widespread in France than in the US. This difference in the pattern of alcohol use has already been highlighted in a comparative study on CADE in non HIV-infected Irish and French males, showing an increased protective effect of drinking red wine in the latter population. Increased wine consumption probably brings about an increase in high-density lipoprotein cholesterol levels, which helps protect against CADE. On the other hand, beer and spirits consumption are linked to increased triglyceride levels. We do not know to what extent moderate alcohol users are representative of a population with better health status as alcohol use in France is extremely frequent in the general population and this fact may increase the strength of the association found.

While one hypothesis is that excessive alcohol consumption can increase inflammatory markers' levels, which in turn probably leads to a higher risk of CADE and premature aging in HIV patients, this hypothesis was not demonstrated in a study conducted in older adults without cardiovascular disease, where alcohol intake was found to be associated with lower levels of inflammatory markers. In the meantime it is important to remember that individuals with immune suppression are at a greater risk of cancer, a disease whose pattern of risk factors also include alcohol use, even when moderate.

Tobacco smoking has consistently been found to be a major risk factor for CADE. Smoking prevalence and dependence in HIV-infected patients is higher than in the general population. Effective interventions for reducing and quitting smoking, especially for patients with several risk factors, are strongly recommended especially considering the increased CADE risk which exists in HIV-infected smokers receiving ART. However, results from studies reporting on the effectiveness of interventions for quitting smoking in HIV-infected individuals are inconsistent."

---

Generalisability	21	<p><u>Discuss the generalisability (external validity) of the study results</u></p> <p>"This cohort is representative of the first generation of patients receiving potent ART. As cardiovascular disease is a rising issue in all HIV-infected populations receiving ART, these results can give important information about the pattern of risk and protective factors in all treated HIV-infected populations.</p> <p>In conclusion, in the long term, CD4+ cell count <math>\geq 200</math> cells/mm<sup>3</sup> and moderate alcohol consumption remain the principal factors negatively associated with the risk of major CADE. Combined interventions to reduce CADE-risk-related behaviours and assure sustained adherence and response to ART in HIV-infected individuals are now a clinical and public health priority. "</p>
------------------	----	---

---

#### **Other information**

Funding	22	<p><u>Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based</u></p> <p>"Funding sources: The ANRS CO8 (APROCO/COPILOTE) cohort is funded by ANRS (Agence Nationale de Recherches sur le Sida et les hépatites virales) and CMIT (Collège des Universitaires de Maladies Infectieuses et Tropicales), which received research grants from Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences, Pfizer and Roche.</p> <p>The funders were responsible for initiating, managing and financing the cohort, but did not interfere with data analysis and interpretation and dissemination of the scientific results."</p>
---------	----	---

---



---

1  
2  
3 \*Give information separately for exposed and unexposed groups.  
4  
5

6 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and  
7 published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely  
8 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at  
9 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is  
10 available at <http://www.strobe-statement.org>.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Impact of Immunodepression and Moderate Alcohol Consumption on Coronary and other Arterial Disease Events in an 11-year Cohort of HIV-infected Patients on Antiretroviral Therapy**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001155.R1
Article Type:	Research
Date Submitted by the Author:	29-Jun-2012
Complete List of Authors:	Carrieri, Maria Patrizia Protopopescu, Camelia; INSERM, U912 (SESSTIM), Aix Marseille Univ, IRD, UMR-S912, ORS PACA, Observatoire Régional de la Santé Provence Alpes Côte d'Azur Le Moing, Vincent Reboud, Philippe Raffi, François Mahy, Sophie Roux, Perrine Cuzin, Lise Spire, Bruno Leport, Catherine
<b>Primary Subject Heading</b>:	Infectious diseases
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Myocardial infarction < CARDIOLOGY, Coronary heart disease < CARDIOLOGY

1  
2  
3 **Impact of Immunodepression and Moderate Alcohol Consumption on Coronary and**  
4 **other Arterial Disease Events in an 11-year Cohort of HIV-infected Patients on**  
5 **Antiretroviral Therapy**  
6  
7  
8

9  
10  
11  
12  
13 **Maria Patrizia Carrieri<sup>1,2,3\*</sup>, Camelia Protopopescu<sup>1,2,3\*§</sup>, Vincent Le Moing<sup>4</sup>, Philippe**  
14 **Reboud<sup>5</sup>, François Raffi<sup>6</sup>, Sophie Mahy<sup>7</sup>, Perrine Roux<sup>1,8</sup>, Lise Cuzin<sup>9</sup>, Bruno Spire<sup>1,2,3</sup>,**  
15 **Catherine Leport<sup>10,11</sup> and the ANRS CO8 APROCO-COPILOTE Study Group**  
16  
17  
18  
19

20  
21 \* Equal contribution  
22  
23  
24  
25  
26

27 <sup>1</sup> *INSERM, U912 (SESSTIM), Marseille, France*  
28

29 <sup>2</sup> *Aix Marseille Univ, IRD, UMR-S912, Marseille, France*  
30

31 <sup>3</sup> *ORS PACA, Observatoire Régional de la Santé Provence Alpes Côte d'Azur, Marseille,*  
32 *France*  
33

34 <sup>4</sup> *Service de Maladies Infectieuses et Tropicales, CHU de Montpellier, UMI 233 TransVIHMI,*  
35 *IRD, Université Montpellier 1, Montpellier, France*  
36  
37

38 <sup>5</sup> *INSERM, U897; Université Bordeaux Segalen, ISPED, Bordeaux, France*  
39

40 <sup>6</sup> *CHU Hôtel-Dieu, Nantes, France*  
41

42 <sup>7</sup> *CHU de Dijon, Université de Bourgogne, Dijon, France*  
43  
44

45 <sup>8</sup> *Substance Use Research Center, NYSPI, Columbia University, New York, USA*  
46  
47

48 <sup>9</sup> *Service de Maladies Infectieuses et Tropicales, CHU Purpan, Toulouse, France*  
49  
50

51 <sup>10</sup> *Université Paris Diderot, Sorbonne Paris Cité, UMR 738, Paris, France*  
52

53 <sup>11</sup> *INSERM, UMR 738, Paris, France*  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 § Corresponding author address: INSERM U912 – ORS PACA, 23 rue Stanislas Torrents,  
4  
5 13006 Marseille, France

6  
7 📞: +33 4 96 10 28 80    📠: + 33 4 96 10 28 99    @: camelia.protopopescu@inserm.fr  
8  
9

10  
11  
12 *Abstract word count: 285 words*

13  
14  
15 *Text word count: 4326 words*  
16  
17

18  
19  
20  
21 **Funding sources:** The ANRS CO8 (APROCO/COPILOTE) cohort is funded by ANRS  
22 (Agence Nationale de Recherches sur le Sida et les hépatites virales) and CMIT (Collège des  
23 Universitaires de Maladies Infectieuses et Tropicales), which received research grants from  
24 Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences,  
25 Pfizer and Roche.  
26  
27

28  
29  
30  
31  
32 The funders were responsible for initiating, managing and financing the cohort, but did not  
33 interfere with data analysis and interpretation and dissemination of the scientific results.  
34  
35

36  
37  
38 **Competing interests:** All authors have completed the Unified Competing Interest form at  
39 [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) <[http://www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf)> (available on  
40 request from the corresponding author) and declare that (1) they have no support from any  
41 company for the submitted work; (2) they have no relationships with any company that might  
42 have an interest in the submitted work in the previous 3 years; (3) their spouses, partners, or  
43 children have no financial relationships that may be relevant to the submitted work; and (4)  
44 they have no non-financial interests that may be relevant to the submitted work.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Exclusive licence:** The Corresponding Author has the right to grant on behalf of all authors  
4 and does grant on behalf of all authors, an exclusive licence (or non exclusive for government  
5 employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to  
6 permit this article (if accepted) to be published in BMJ editions and any other BMJ PGL  
7 products and sublicences to exploit all subsidiary rights, as set out in our licence  
8 (<http://resources.bmj.com/bmj/authors/checklists-forms/licence-for-publication>).  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

19 **Data sharing:** There is no additional data available.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **Summary**

### **Article Focus**

- Major coronary or other arterial disease events (CADE) are frequent in HIV-infected individuals receiving antiretroviral therapy.
- While some antiretroviral classes can increase the risk of CADE, it is still controversial to what extent immune reconstitution and other factors like moderate alcohol consumption can reduce the risk of CADE in this population.

### **Key Messages**

- Moderate alcohol consumption and absence of immunodepression can be beneficial to reduce the risk of CADE in HIV-infected patients.
- Reduced immunological response to antiretroviral treatment (ART) over a long follow-up may have a more important impact on CADE than exposure to a specific antiretroviral drug.

### **Strengths and Limitations**

- This paper suggests the importance of combined risk reduction interventions including adherence counselling for assuring long term immunological response and decrease the risk of CADE.

## **Short title**

**CD4+, Moderate Alcohol Consumption and Coronary Events in HIV-infected patients**

**Abstract**

**Objective:** To investigate the relationship between response to antiretroviral treatment (ART), alcohol use and occurrence of a major coronary or other arterial disease event (CADE) in HIV-infected individuals.

**Design:** Cohort study. A Cox model was used to identify correlates of a first occurrence of a major CADE.

**Setting:** The French ANRS CO8 APROCO-COPILOTE cohort was set up in 1997 to study clinical progression and patient-reported outcomes (PRO) after initiating protease inhibitor-containing ART. Clinical data were retrieved from medical records. Self-administered questionnaires collected data on PRO and behaviours, including alcohol use.

**Participants:** Metabolic data were only available for a subgroup (n=675) of the study group (n=1154).

**Main outcomes measures:** Major coronary or other arterial disease first event.

**Results:** Over the 11-year follow-up, 49 major CADE were observed, with an incidence rate [95%CI]=0.75[0.57 to 0.99] per 100 person-years. Immunodepression (CD4+ cell count <200 cells/mm<sup>3</sup>) was associated with an increased risk of CADE (Adjusted Hazard Ratio AHR[95% CI]= 2.52[1.15 to 5.48]) after adjustment for female gender (0.25[0.08 to 0.83]), age (1.07[1.04 to 1.10]) and smoking>20 cigarettes/day (4.19[2.17 to 8.11]). Moreover, individuals with moderate alcohol consumption (≤4(3) AU/day for men(women)) had a lower risk of CADE (0.38[0.20 to 0.71]) than alcohol abstainers, while the risk for those drinking>4(3) AU/day for men(women) was not significantly different from this latter group. These associations remained valid after adjustment for metabolic disorders. No significant association with exposure to any specific antiretroviral was detected.

1  
2  
3 **Conclusions:** In the long term, absence of immunodepression and moderate alcohol  
4 consumption remain associated with a lower risk of major CADE. Combined interventions to  
5 reduce CADE risk-related behaviours including adherence counselling for assuring long term  
6 immunological response to ART in HIV-infected individuals are now a clinical and public  
7 health priority.  
8  
9  
10  
11  
12

13  
14  
15  
16  
17  
18 **Key words:** Coronary and other arterial disease events, Alcohol, CD4+ cell count, HIV,  
19 ARV.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Introduction

Cardiovascular disease risk factors (including for example hypertension and tobacco use), as well as immunological status[1] are major predictors of atherosclerosis in HIV-infected women and men. Although some antiretroviral (ARV) therapy drugs[2-5] have consistently been found to be associated with coronary arterial disease or myocardial infarction (MI) in these patients, more recently Butt and colleagues put into evidence the negative effect of HIV viral replication on heart failure[6]. In one study, patients having experienced a MI presented lower baseline and proximal CD4+ cell counts than those who did not, while no association was found between cardiovascular disease events and specific antiretroviral agents[7]. Moreover, known factors associated with cardiovascular risk[8] such as hyperlipidemia and insulin resistance[9-11] are becoming an increasingly major clinical concern in ARV-treated individuals.

Though excessive alcohol use may be frequent in HIV-infected individuals, its impact on the occurrence of cardiovascular disease in this population has been less investigated. Excessive alcohol consumption also plays a major role in HIV risk-taking behaviours, particularly in men who have sex with men and drug users[12, 13]. In HIV-infected individuals, excessive alcohol use is known to compromise patients' response to antiretroviral therapy (ART) through reduced adherence[14-17] and to predict HIV progression and increased mortality[18-21], mostly from liver diseases[22-25]. Some recent cross-sectional analyses in HIV-infected and uninfected men have found that heavy alcohol consumption is associated with a higher risk of cardiovascular disease[26, 27]. On the other hand, in uninfected adults, moderate alcohol consumption has been found to be associated with a reduced cardiovascular mortality[28], improved lipid profiles, increased insulin sensitivity and reduced risk of MI[29]. However, this association has not yet been studied in longitudinal studies involving HIV-infected populations including women. Moreover, there are as yet no consistent results

1  
2  
3 in the literature regarding the role that alcohol use plays in exacerbating cardiovascular risk in  
4  
5 ARV-treated patients and to what extent it can confound or boost the effect of immuno-  
6  
7 virological response to ART, ART-associated dyslipidemia and insulin resistance on the risk  
8  
9 of cardiovascular disease events.  
10

11  
12 We used data from the 11-year follow-up of the APROCO-COPILOTE cohort of patients  
13  
14 receiving ART since 1997 to investigate the relationship between viral load, CD4+ cell count,  
15  
16 alcohol consumption and the first occurrence of a major coronary or other arterial disease  
17  
18 event (CADE), after adjustment for known risk factors including metabolic disorders.  
19  
20

## 21 22 23 24 **Methods**

25  
26  
27 The French APROCO-COPILOTE cohort (ANRS CO8) was designed to study the clinical,  
28  
29 immunological, virological, and socio-behavioural course of HIV disease in HIV-1 positive  
30  
31 individuals who started the first generation of potent ART (treatment regimens including  
32  
33 protease inhibitors (PI)). The study was approved by the Ethics Committee of Cochin  
34  
35 Hospital (Paris) and informed consent was obtained from all participants.  
36  
37

### 38 39 *Setting*

40  
41  
42 Patients were enrolled in the cohort at their first PI-based ART prescription between May  
43  
44 1997 and June 1999 (n=1281) in 47 French centres, and clinically followed-up every 4  
45  
46 months thereafter, up to month 132 (M132).  
47

### 48 49 *Patients*

50  
51  
52 In the present study were included all patients who had either two alcohol assessment or one  
53  
54 alcohol assessment just preceding the CADE over the whole follow-up (n=1154).  
55  
56  
57  
58  
59  
60

### *Medical questionnaire*

The medical questionnaire at enrolment (M0) collected retrospective data about patient's HIV history including HIV transmission category, time since HIV diagnosis, previous exposure to antiretroviral treatment before enrolment, and co-infection with hepatitis C virus (HCV) defined as having positive HCV RNA and/or positive HCV antibodies. This information was complemented by medical questionnaires, completed by the HIV physicians at each follow-up visit, which collected clinical and laboratory data (plasma HIV RNA level, CD4+ cell count, HIV clinical stage, aspartate transaminase (AST) and alanine transaminase (ALT) levels), as well as data on the antiretroviral regimen prescribed. A third form, based on updated medical records, detailed all clinical severe events, including cardiovascular events, occurring during the study period. Information on metabolic disorders was available at M12 for a subset of cohorts' patients, who participated in a parallel cross-sectional survey, designed to study clinical and laboratory metabolic complications[30]. These "metabolic" data included height, weight, hypertriglyceridemia, hypercholesterolemia, personal history of coronary heart disease (CHD) and hypertension, and finally any family history of CHD.

At each follow-up visit, CD4+ cell count was measured by standardized flow cytometry, and plasma HIV RNA levels were measured using the assay routinely available in each participating centre. Immunodepression was defined by CD4+ cell count <200 cells/mm<sup>3</sup>; viral load was classified as detectable if it was greater than the threshold value specific to each centre where the assay was performed. HIV clinical stage was defined using the 1993 Centres for Disease Control and Prevention (CDC) clinical classification system[31].

Serum triglyceride and cholesterol levels were measured after a 12-hour overnight fast.

Hypertriglyceridemia was defined as a triglyceride level  $\geq 2.2$  mmol/l, while

hypercholesterolemia was defined as a total cholesterol level  $\geq 5.5$  mmol/l.

### *Outcome*

The details of all clinical severe events, including cardiovascular events, which occurred during follow-up, were obtained from medical records and validated by the cohort's validation committee[30]. The classification of clinical severe events was based on the 10th Revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10)<sup>i</sup>. An event was considered severe when it required medical intervention, hospitalization, when hospitalization was extended due to the event's occurrence, when it led to a life-threatening condition, or when it resulted in death. A group of cardiologists specifically validated the events selected as outcomes for this study. Among cardiovascular events, only major CADE were selected for this analysis as follows (listed in singular form): MI, stroke, coronary heart disease, peripheral arterial disease and cardiovascular surgery for coronary disease. We excluded the following from the definition of the outcome: heart failure, cardiac arrhythmia, phlebitis, pulmonary embolism, and peripheral venous diseases to keep only severe or life-threatening cardiovascular events in the analysis.

### *Self-administered questionnaire*

A self-administered questionnaire collected - at M0, M4, M12 and every 8 months thereafter during the first 5 years of follow-up, then yearly thereafter – data on socio-demographic characteristics including age, gender and educational level. Among other psycho-social and behavioural information, it also collected details on depressive symptoms, tobacco use, alcohol consumption, self-reported ART-related symptoms and adherence to ART.

Depression was measured using the validated French version of the Centre for Epidemiologic Studies Depression Scale (CES-D), which is a 20-item scale commonly used in studies involving HIV-infected patients[32].

---

<sup>i</sup> <http://www.who.int/classifications/icd/en/>

1  
2  
3 Tobacco and alcohol consumption were evaluated during the previous 4 weeks. Alcohol  
4  
5 consumption was assessed using two questions about frequency of consumption and quantity  
6  
7 consumed daily, if applicable.  
8  
9

10 A 13-item scale comprising the French version of the symptom index validated by Justice *et*  
11  
12 *al*[33] and described elsewhere[34] collected information about self-reported symptoms. Five  
13  
14 other questions gathered information about adherence to ART, according to the methodology  
15  
16 established by the AIDS Clinical Trial Group[35].  
17  
18

### 19 *Statistical analysis*

20  
21  
22 As the results of the analysis on the whole dataset (n=1154) could be affected by the lack of  
23  
24 important predictors of CADE like hypertriglyceridemia or hypercholesterolemia, we  
25  
26 conducted a secondary analysis on a subset of patients who had additional metabolic disorders  
27  
28 data. More specifically, two analyses on the following study populations were performed to  
29  
30 study predictors of major CADE:  
31  
32

33  
34  
35 1) First analysis: the study population included all patients who had either two alcohol  
36  
37 assessment or one alcohol assessment just preceding the event over the whole follow-up  
38  
39 (n=1154). The follow-up period was M0-M132.  
40  
41

42  
43 2) Second analysis: the study population was restricted to the subset of patients with available  
44  
45 data on metabolic disorders, measured at M12 (n=675). Consequently, only events occurring  
46  
47 after M12 were considered in this second analysis.  
48  
49

50 The WHO body mass index (BMI) categories were used in the analysis: underweight and  
51  
52 overweight/obese patients were defined respectively as having a BMI lower than 18.5 and  
53  
54 greater than 25.  
55  
56  
57  
58  
59  
60

1  
2  
3 A time-varying cumulative measure of time exposure to specific ARV medications (abacavir,  
4 efavirenz, nevirapine, lopinavir and protease inhibitors) was computed during which ART  
5 included a specific drug from this list, from cohort enrolment to the date of each follow-up  
6 visit.  
7  
8  
9

10  
11  
12 Tobacco consumption was dichotomized in two categories: more than 20 cigarettes/day vs  
13 other[36]. The average number of alcohol units (AU) consumed per day[37] was computed  
14 using the two questions on alcohol consumption and then recoded in four categories  
15 (abstainers;  $\leq 1$  AU/day;  $> 1$  and  $\leq 4(3)$  AU/day for men(women);  $> 4(3)$  AU/day for  
16 men(women)), in order to test a gradient effect. We used information on AST and ALT liver  
17 enzymes to test their correlation with alcohol consumption as a validation test of self-reported  
18 alcohol consumption. As normal liver enzymes' reference ranges for each laboratory were not  
19 available in our data set, we used a universal cut-off of  $ALT > 50$  units per litre of serum as an  
20 indicator of liver injury, and the AST/ALT ratio (in conjunction with  $ALT > 50$  IU/l) as a  
21 marker of possible cirrhosis and/or alcoholic liver disease (for  $AST/ALT > 1$ ) and advanced  
22 alcoholic liver disease (for  $AST/ALT > 2$ ). We found a positive significant association between  
23 excessive alcohol consumption and these two indicators of liver injury (after adjusting for  
24 HCV status, see Table 1), which would suggest good accuracy of the self-reported data on  
25 alcohol consumption.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 Patients were classified as non-adherent if they reported taking less than 100% of prescribed  
45 medications during the previous 4 weeks, using a validated algorithm[38]. A patient with a  
46 CES-D score value above 17 (men) or 23 (women) was considered as presenting depressive  
47 symptoms[39].  
48  
49  
50  
51  
52

53  
54 Incidence rate of major CADE was computed as the number of cases divided by the number  
55 of person-years of follow-up. Follow-up duration was calculated as the difference in days  
56  
57  
58  
59  
60

1  
2  
3 from enrolment to the date of the CADE, death or last visit, whichever occurred first. Follow-  
4  
5 up of patients experiencing major CADE was censored after the date of the first CADE. We  
6  
7 used a Cox proportional hazards model to identify characteristics associated with the first  
8  
9 occurrence of a major CADE. Psychosocial characteristics - depressive symptoms, tobacco  
10  
11 and alcohol consumption, self-reported symptoms, CD4+ cell count and viral load - were  
12  
13 evaluated at each visit and used as time-varying covariates in the statistical analysis. All the  
14  
15 other covariates were used as fixed variables (measured at M0, M1 or M12). For time-varying  
16  
17 factors, the last known value was carried forward in the case of missing data at a scheduled  
18  
19 visit. In the case of an event occurring between two consecutive follow-up visits, the values  
20  
21 for the time-varying variables measured at the visit preceding the event were used. Covariates  
22  
23 with a p-value<0.25 in univariate Cox analyses were considered eligible for the multivariate  
24  
25 Cox model, which was built using a backward stepwise selection procedure based on the  
26  
27 Wald test (p<0.05). Interaction effects between the factors of the multivariate final model  
28  
29 were tested. The proportional-hazards assumption was verified globally for the multivariate  
30  
31 models and separately with respect to each covariate, using both Kaplan-Meier estimates and  
32  
33 tests based on Schoenfeld residuals[40]. A residual analysis for outliers' detection was  
34  
35 performed and the sensitivity of the model to influential outliers was tested.  
36  
37  
38  
39

40  
41 Several sensitivity analyses were performed. First, we excluded all patients with a history of  
42  
43 CHD and re-ran the model to verify whether the pattern of factors would remain unchanged.

44  
45  
46 Second, the patients who died due to alcoholic cirrhosis were excluded from the study. A third  
47  
48 analysis was performed separately on the subgroups of patients co-infected with HCV and  
49  
50 those not co-infected with HCV.

51  
52  
53  
54 All analyses were performed using Stata Intercooled software, version 12.1.  
55  
56  
57  
58  
59  
60

## Results

A total of 1154 patients were included in the present study, accounting for 9401 person-visits. When comparing the study patients (n=1154) with those included in the cohort, but excluded from the study due to missing alcohol data (n=127), no significant difference was found for gender, age at enrolment, antiretroviral naivety, CDC clinical stage, baseline CD4+ cell counts and HIV viral load at M0 (data not shown).

Median [interquartile range (IQR)] duration of follow-up of the selected patients, from their first visit after the ART prescription (M1) until M132, was 5.9 [1.8-9.4] years. During the 11 years of the study, accounting for 6544 person-years, the loss to follow-up rate [95% CI] was 17.6 [16.3 to 18.7] per 100 person-years.

Over the 11-year follow-up of the cohort, a total of 85 severe cardiovascular events were observed. These included 49 major CADE as follows: myocardial infarction (n=30), coronary heart disease (n=4), stroke (n=7), peripheral arterial disease (n=7) and cardiovascular surgery for coronary disease (n=1). The distribution of the other thirty six severe cardiovascular events was as follows: phlebitis/pulmonary embolism (n=22), cardiomyopathy/congestive heart failure (n=5), cardiac dysrhythmia (n=6), cerebral haemorrhage (n=2) and aortic aneurysm (n=1).

The incidence rate [95% CI] of all severe cardiovascular events was 1.3 [1.0 to 1.6] per 100 person-years, while for major CADE the incidence rate was 0.75 [0.57 to 0.99] per 100 person-years. Of the 49 major CADE, 40 occurred after M12. Furthermore, the major CADE incidence over the period M12-M132 was 0.89 [0.66 to 1.22] per 100 person-years.

The distribution of factors associated with major CADE, as well as the results of univariate and multivariate Cox models, are reported in Table 2 for the entire study population (n=1154).



1  
2  
3 Table 3 focuses instead on the subset of patients with available data on metabolic disorders  
4  
5 (n=675).  
6  
7

8 Women represented 22% of the study population (n=1154) (Table 2). Mean (SD) age at  
9 baseline was 37.7 (9.5) years and approximately one third of the patients had a secondary  
10 school certificate. Individuals HIV-infected through drug use accounted for 18% of the study  
11 patients. At baseline, 44% of all the patients were ARV naive, half were in CDC stage A and  
12 more than three quarters (80%) had not experienced opportunistic infections. Furthermore,  
13 94% had a detectable viral load, 36% had a CD4+ cell count <200 cells/mm<sup>3</sup> and 22% were  
14 co-infected with HCV. Depressive symptoms were reported at baseline in 38% of the patients.  
15 After one year of ART, more than half of the patients (58%) were highly adherent, the median  
16 [IQR] number of self-reported symptoms excluding lipodystrophy was 3 [2 to 6], while this  
17 value was 0 [0 to 1] for lipodystrophy symptoms. Only 16% of the patients declared smoking  
18 more than 20 cigarettes per day at cohort enrolment. Nearly 19% of the patients reported they  
19 were alcohol abstainers, three quarters reported moderate alcohol consumption (54%  
20 reporting less than 1 AU/day and 21% between 1 and 4(3) AU/day for men(women)), while  
21 only a minority of patients (6%) reported elevated alcohol consumption. As the two  
22 intermediate categories (≤1 AU/day; >1 and ≤4(3) AU/day for men(women)) had similar  
23 estimated Adjusted Hazard Ratios (AHR) and p-values in both multivariate analyses, we  
24 decided to aggregate them for model parsimony.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 In the subsample of patients with available metabolic data (Table 3), the majority (73%) had a  
47 normal BMI, 17% were classified in the overweight category and a minority was classified in  
48 each of the two more extreme categories (6% underweight and 3% obese). About 8% of the  
49 patients had hypertriglyceridemia and 6% had hypercholesterolemia at M12. One year after  
50 the enrolment in the cohort, 6% of the patients reported a personal history of hypertension.  
51  
52  
53  
54  
55  
56  
57  
58 Only 1% and 28% respectively had a personal and family history of CHD.  
59  
60

1  
2  
3 In the entire study group (n=1154), the following factors were found to be independent  
4 predictors of major CADE: older age at baseline (AHR[95% CI]=1.07[1.04 to 1.10]), tobacco  
5 consumption >20 cigarettes/day (4.19[2.17 to 8.11]) and CD4+ cell count <200 cells/mm<sup>3</sup> (  
6 2.52[1.15 to 5.48]) (see Table 2). In addition, a negative association was found between  
7 female gender and major CADE (0.25[0.08 to 0.83]). After accounting for the effect of age,  
8 gender, tobacco consumption and CD4+ cell count <200 cells/mm<sup>3</sup> in the multivariate Cox  
9 model, individuals with moderate alcohol consumption (<4(3) AU/day for men(women)) were  
10 at lower risk of major CADE (0.38[0.20 to 0.71]), than alcohol abstainers, while those  
11 drinking more than 4(3) AU/day for men(women) were not significantly different from  
12 abstainers (p=0.229).  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

25  
26 These results remained valid also when the analysis was restricted to the subgroup of patients  
27 with available metabolic data and the follow-up period M12-M132. After adjusting for age,  
28 tobacco consumption, hypertriglyceridemia and family history of CHD, we consistently found  
29 a negative association between moderate alcohol use (0.23[0.11 to 0.49]), and a positive  
30 association between CD4+ cell count <200 cells/mm<sup>3</sup> (4.02[1.45 to 11.1]) and major CADE  
31 after one year after enrolment (Table 3).  
32  
33  
34  
35  
36  
37  
38  
39

40 No significant association was found between time of exposure to different ARV drugs and  
41 major CADE. No significant interaction was found between smoking habits and  
42 hypertriglyceridemia or personal history of CHD. Furthermore, detectable viral load was not  
43 associated with major CADE in univariate or multivariate analyses.  
44  
45  
46  
47  
48

49 For the Cox models fitted in this study, proportional-hazards assumption remained valid,  
50 either globally and with respect to each covariate. The residual analysis did not alter the  
51 results of the multivariate model.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The sensitivity analyses performed by first excluding patients with a history of CHD (n=7),  
4 and then patients who died due to alcoholic cirrhosis (n=6), confirmed the same pattern of risk  
5 factors observed for the whole population. The other sensitivity analyses, performed  
6 separately on the subgroups of patients with HCV co-infection and on those not co-infected  
7 with HCV, revealed the same effect of alcohol consumption on CADE, although some  
8 variables among the other factors were less significant for the co-infected patients (results not  
9 shown, available on request).  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

## 22 **Discussion**

23  
24  
25 This longitudinal study clearly confirms that in ARV-treated individuals, proximal CD4+ cell  
26 count lower than 200 cells/mm<sup>3</sup> remains a risk factor associated with major coronary and  
27 other arterial disease events. This result remains valid even after adjustment for metabolic  
28 disorders such as hypertriglyceridemia and family history of CHD, the strength of the  
29 association remaining unchanged.  
30  
31  
32  
33  
34  
35  
36

37 The relationship between CADE and CD4+ cell count, in addition to the lack of association  
38 between CADE and specific ARV classes, confirms previous results[7] where the association  
39 between exposure to certain ARV and CADE was no longer evident after controlling for  
40 traditional risk factors and HIV disease markers. Indeed, the association between specific  
41 ARV drugs and major CADE, like myocardial infarctus, has been shown in very powerful  
42 studies[5], where adjustment for nadir CD4+ lymphocyte count or peak HIV-1 RNA level did  
43 not modify the results. However, in the study cited, no adjustment for proximal CD4+ cell  
44 count was performed, and the association with the class of ARV became weaker after  
45 adjustment for serum lipid levels[5]. Indeed, although ART may modify lipid levels and  
46 increase the risk of CADE, it may also reduce this risk by reducing HIV-associated  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 inflammation following long-term suppression of HIV replication[41]. The lack of association  
4  
5 with exposure to some specific ARV classes in the present study, factors usually associated  
6  
7 with an increased risk of CADE[42, 43], suggests that reduced immunological response to  
8  
9 ART over a long follow-up, as well as known CADE risk factors may have a more important  
10  
11 impact than exposure to a specific antiretroviral drug.  
12

13  
14  
15 It is also possible that patients with altered lipid profiles were switched to other classes of  
16  
17 antiretroviral drugs during the follow-up. As a consequence, in the long term, CD4+ cell  
18  
19 count <200 cells/mm<sup>3</sup> remain a correlate of an increased risk of CADE, whatever the  
20  
21 antiretroviral received.  
22

23  
24  
25 In our study, individuals reporting elevated alcohol consumption exhibited the same risk of  
26  
27 CADE as alcohol abstainers. In contrast, those reporting moderate alcohol consumptions had  
28  
29 a lower risk. This result was confirmed after adjustment for additional risk factors including  
30  
31 tobacco use, age, gender and CD4+ cell count. This relationship between alcohol  
32  
33 consumption and CADE remained significant and J-shaped, even after adjustment for data on  
34  
35 metabolic risk factors- such as having a history of CHD and hypertriglyceridemia -which was  
36  
37 available for a subset of patients. As highlighted in previous observations in the general  
38  
39 population[28, 44-47] and certain populations affected by other diseases[48], these results  
40  
41 confirmed that the increased risk of CADE in HIV-infected patients receiving ART is not  
42  
43 attributable to elevated alcohol use. Furthermore, we highlighted the apparent protective  
44  
45 effect of moderate alcohol consumption in ART treated HIV-infected patients.  
46  
47  
48

49  
50 It is important to note that after the introduction of ART in 1996, the sudden decrease  
51  
52 observed in HIV-related mortality was nonetheless accompanied by a relative increase of non-  
53  
54 HIV based mortality as a part of the total mortality of HIV-infected patients [49],  
55  
56 cardiovascular diseases becoming increasingly important. This increase can be explained  
57  
58  
59  
60

1  
2  
3 firstly by a reduction in the competing role of HIV-related mortality, which in the long term  
4  
5 was much more detrimental to health than other causes of deaths. Secondly, the high  
6  
7 prevalence in this population of other risk factors like tobacco use, together with ART-related  
8  
9 morbidity including altered lipid profiles and triglycerides, may contribute to an increased risk  
10  
11 of CADE.  
12

13  
14 The association found in our study between moderate alcohol use and reduced CADE risk is  
15  
16 not consistent with all previous research in HIV-infected patients. Freiberg *et al*[26] pointed  
17  
18 out that among HIV-infected men in the US, hazardous drinking and both alcohol abuse and  
19  
20 dependence were associated with a higher prevalence of cardiovascular disease compared  
21  
22 with infrequent and moderate drinking, even after adjusting for traditional risk factors,  
23  
24 antiretroviral therapy and CD4+ cell count. This difference in the results may be due to the  
25  
26 different design of the two studies (longitudinal for ours *vs* cross-sectional for Freiberg's), but  
27  
28 probably also to the different types of alcohol mainly consumed in the two populations, red  
29  
30 wine consumption being more widespread in France than in the US. This difference in the  
31  
32 pattern of alcohol use has already been highlighted in a comparative study on cardiovascular  
33  
34 disease in non HIV-infected Irish and French males, showing an increased protective effect of  
35  
36 drinking red wine in the latter population[50]. Increased wine consumption probably brings  
37  
38 about an increase in high-density lipoprotein cholesterol levels, which helps protect against  
39  
40 cardiovascular events. On the other hand, beer and spirits consumption are linked to increased  
41  
42 triglyceride levels[51]. We do not know to what extent moderate alcohol users are  
43  
44 representative of a population with better health status as alcohol use in France is relatively  
45  
46 frequent in the general population and this fact may increase the strength of the association  
47  
48 found.  
49  
50

51  
52  
53  
54  
55 Another possible hypothesis is that excessive alcohol consumption can increase inflammatory  
56  
57 markers' levels[52], which in turn probably leads to a higher risk of CADE and premature  
58  
59  
60

1  
2  
3 aging in HIV patients. However, this hypothesis was not demonstrated in a study conducted in  
4  
5 older adults without cardiovascular disease, where alcohol intake was found to be associated  
6  
7 with lower levels of inflammatory markers[53]. In the meantime it is important to remember  
8  
9 that individuals with immune suppression are at a greater risk of cancer, a disease whose  
10  
11 pattern of risk factors also include alcohol use, even when moderate[54].  
12  
13

14  
15 Tobacco smoking has consistently been found to be a major risk factor for cardiovascular  
16  
17 disease[55]. Smoking prevalence and dependence in HIV-infected patients is higher than in  
18  
19 the general population[56]. Effective interventions for reducing and quitting smoking[57],  
20  
21 especially for patients with several risk factors, are strongly recommended especially  
22  
23 considering the increased cardiovascular risk which exists in HIV-infected smokers receiving  
24  
25 ART[58]. However, results from studies reporting on the effectiveness of interventions for  
26  
27 quitting smoking in HIV-infected individuals are inconsistent[59].  
28  
29

30  
31 It is worth noting the lack of association between hypercholesterolemia and the risk of CADE  
32  
33 in our study. This result suggests that HIV physicians need to be cautious about basing  
34  
35 clinical decisions merely upon measured lipid levels in HIV-infected patients. Other risk  
36  
37 factors, including behavioural ones, deserve greater consideration for clinical management.  
38

39  
40 Some limitations of this study need to be acknowledged. First, our definition of CADE  
41  
42 includes different types of events which might not share the same pattern of risk factors.  
43  
44 However, an additional analysis performed on a restricted dataset and which adjusted for  
45  
46 other potential risk factors (such as hypertriglyceridemia) confirmed the pattern found in the  
47  
48 main analysis.  
49

50  
51  
52 Second, information on alcohol use was mainly based on self-reports and these may tend to  
53  
54 underestimate alcohol consumption. However, it has been reported that HIV-HCV co-infected  
55  
56 patients tend to underreport alcohol use more to their hepatologist than to other  
57  
58  
59  
60

1  
2  
3 physicians[60]. As our patients were all followed-up by HIV physicians, it is likely that the  
4  
5 degree of underreporting did not greatly affect hazard ratios' estimates. Moreover, the  
6  
7 association found between the excessive alcohol consumption and the biomarkers of alcoholic  
8  
9 liver injury indicate a good accuracy of self-reported data on alcohol consumption.

10  
11  
12 Then, the fact that excessive alcohol users exhibit similar HRs to abstainers may be also  
13  
14 attributable to the two following reasons. First, some individuals with excessive alcohol  
15  
16 consumption may have died due to liver failure before experiencing a cardiovascular event  
17  
18 and this could have reduced the impact of excessive alcohol use on CADE. However, when  
19  
20 we performed a sensitivity analysis excluding patients who died due to alcoholic cirrhosis, the  
21  
22 results remained unchanged. Second, a proportion of abstainers may have been past (heavy)  
23  
24 alcohol users and may have had to stop drinking for health reasons. Unfortunately, we do not  
25  
26 have information about alcohol use before the beginning of the cohort, or about diagnosis of  
27  
28 alcoholism or reasons for quitting alcohol.

29  
30  
31  
32  
33 Finally, it would have been interesting to compute the Framingham risk score[61] and use it  
34  
35 as a covariate in the multivariate model. Unfortunately, as our study was not initially designed  
36  
37 to thoroughly assess the impact of all possible CHD risk factors, some of the variables used in  
38  
39 the construction of this score (such as treated and untreated systolic blood pressure, as well as  
40  
41 total and high-density lipoprotein cholesterol) were not available during the two first years of  
42  
43 our study. Moreover, our results showed a different pattern of factors than those found in the  
44  
45 Framingham study (some of the traditional risk factors, such as BMI and  
46  
47 hypercholesterolemia, were not significant), so using this score would have been less  
48  
49 informative than using all the factors separately.

50  
51  
52  
53  
54 This cohort is representative of the first generation of patients receiving potent ART. As  
55  
56 cardiovascular disease is a rising issue in all HIV-infected populations receiving ART, these  
57  
58  
59  
60

1  
2  
3 results can give important information about the pattern of risk and protective factors in all  
4  
5 treated HIV-infected populations.  
6  
7

8 In conclusion, in the long term, absence of immunodepression and moderate alcohol  
9  
10 consumption remain associated with a lower risk of major CADE. Combined interventions to  
11  
12 reduce CADE-risk-related behaviours including adherence counselling to assure long term  
13  
14 immunological response to ART in HIV-infected individuals are now a clinical and public  
15  
16 health priority.  
17  
18  
19  
20

### 21 **Acknowledgments**

22 The authors would like to thank all participating patients, nurses and physicians in clinical  
23  
24 sites.  
25

26 We would also like to thank Jude Sweeney for the English revision and editing of the  
27  
28 manuscript.  
29  
30

### 31 **Authors' contribution:**

32 Maria Patrizia Carrieri planned the data analyses and wrote the manuscript; Camelia  
33  
34 Protopopescu analyzed the data and wrote the manuscript; Vincent Le Moing contributed to  
35  
36 patients' recruitment and investigation and revised the manuscript; Philippe  
37  
38 Reboud contributed to patients' evaluation; François Raffi was responsible for cohort  
39  
40 initiation, contributed to patients' recruitment and investigation and revised the manuscript;  
41  
42 Sophie Mahy contributed to patients' recruitment and investigation; Perrine Roux contributed  
43  
44 to patients' evaluation and revised the manuscript; Lise Cuzin contributed to patients'  
45  
46 recruitment and investigation; Bruno Spire contributed to data analyses and revised the  
47  
48 manuscript; Catherine Leport was responsible for cohort initiation, contributed to patients'  
49  
50 recruitment and investigation and revised the manuscript. All authors approved the final  
51  
52 version of the manuscript.  
53  
54  
55  
56  
57  
58  
59  
60



**Authors' work position and postal address:**

1  
2  
3  
4  
5  
6  
7 Maria Patrizia Carrieri (PhD) is Senior Public Health Researcher in the “Environments,  
8 Health Systems and Transmitted Diseases (ESSEM)” Team, National Institute of Health  
9 (INSERM), U912 (SESSTIM), 23 rue Stanislas Torrents, 13006 Marseilles, France; Camelia  
10 Protopopescu (PhD) is Senior Biostatistician in the “Environments, Health Systems and  
11 Transmitted Diseases (ESSEM)” Team, National Institute of Health (INSERM), U912  
12 (SESSTIM), 23 rue Stanislas Torrents, 13006 Marseilles, France; Pr Vincent Le Moing (MD,  
13 PhD) is Professor of Infectious Diseases, Department of Infectious and Tropical Diseases,  
14 University Hospital Montpellier, 80 avenue Augustin Fliche, 34295 Montpellier cedex 5,  
15 France; Dr Philippe Reboud (MD) is Project Manager, National Institute of Health  
16 (INSERM), U897, University Victor Segalen Bordeaux 2, 146, rue Léo Saignat – case 11,  
17 33076 Bordeaux cedex, France; Pr François Raffi (MD, PhD) is Professor of Infectious  
18 Diseases, Department of Infectious and Tropical Diseases, University Hospital Nantes – Hôtel  
19 Dieu, Place Alexis Ricordeau, 44093 Nantes cedex 1, France; Dr Sophie Mahy (MD) is  
20 Associate specialist, Department of Infectious and Tropical Diseases, University Hospital  
21 Dijon, boulevard Maréchal-de-Lattre-de-Tassigny, 21000 Dijon, France; Perrine Roux (PhD)  
22 is Senior Public Health Researcher in the “Environments, Health Systems and Transmitted  
23 Diseases (ESSEM)” Team, National Institute of Health (INSERM), U912 (SESSTIM) and  
24 Substance Use Research Center, NYSPI, Columbia University, New York, USA; Dr Lise  
25 Cuzin (MD) is Associate specialist, Department of Infectious and Tropical Diseases,  
26 University Hospital Purpan - COREVIH – Bat TURIAF - TSA 40031, 31059 Toulouse  
27 Cedex, France; Dr Bruno Spire (MD, PhD) is Senior Public Health Researcher and leader of  
28 the “Environments, Health Systems and Transmitted Diseases (ESSEM)” Team, National  
29 Institute of Health (INSERM), U912 (SESSTIM), 23 rue Stanislas Torrents, 13006  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Marseilles, France; Pr Catherine Leport (MD, PhD) is Professor of Infectious Diseases, LRPI-  
4  
5 UMR 738, UFR Médecine site Bichat, 16 rue Henri Huchard, 75018 Paris, France.  
6  
7  
8  
9

10  
11 **The ANRS CO8 APROCO-COPILOTE Study Group is composed of the following:**

12 **Scientific Committee:**

13  
14 • **Steering Committee:**

15  
16 Principal investigators: C. Leport, F. Raffi

17  
18 Methodology: G. Chêne, R. Salamon

19  
20 Social sciences: JP. Moatti, J. Pierret, B. Spire

21  
22 Virology: F. Brun-Vézinet, H. Fleury, B. Masquelier

23  
24 Pharmacology: G. Peytavin, R. Garraffo

25  
26 • **Other members:** D. Costagliola, P. Dellamonica, C. Katlama, L. Meyer, D. Salmon, A.  
27  
28 Sobel.

29  
30 **Events Validation Committee:** L. Cuzin, M. Dupon, X. Duval, V. Le Moing, B. Marchou,  
31  
32 T. May, P. Morlat, C. Rabaud, A. Waldner-Combernoux.

33  
34 **Project coordination:** P. Reboud.

35  
36 **ANRS representatives:** Sandrine Couffin-Cadiergues, Lucie Marchand.

37  
38 **Data monitoring and statistical analysis:** V. Bouteloup, AD. Bouhnik, C. Brunet-François,  
39  
40 V. Caron, MP. Carrieri, M. Courcoul, F. Couturier, L. Hardel, L. Iordache. P. Kurkdji, S.  
41  
42 Martiren, M. Préau, C. Protopopescu, J. Surzyn, A. Taieb, V. Villes.

43  
44 **Promotion:** Agence Nationale de Recherches sur le Sida et les hépatites virales (ANRS,  
45  
46 Action Coordonnée n°7).

47  
48 **Other support:** Collège des Universitaires de Maladies Infectieuses et Tropicales (CMIT ex  
49  
50 APPIT), Sidaction Ensemble contre le Sida and associated pharmaceutical companies:  
51  
52

1  
2  
3 Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences,  
4  
5 Pfizer and Roche.

6  
7 **Clinical Centres (investigators):** Amiens (Pr JL. Schmit), Angers (Dr JM. Chennebault),  
8  
9 Belfort (Dr JP. Faller), Besançon (Pr N. Mgy-Bertrand, Pr B. Hoen, Dr Drobachef), Bobigny  
10  
11 (Pr O. Bouchaud), Bordeaux (Pr M. Dupon, Pr Longy-Boursier, Pr P. Morlat, Pr JM.  
12  
13 Ragnaud), Bourg-en-Bresse (Dr P. Granier), Brest (Pr M. Garré), Caen (Pr R. Verdon),  
14  
15 Compiègne (Dr D. Merrien), Corbeil Essonnes (Dr A. Devidas), Créteil (Pr A. Sobel), Dijon  
16  
17 (Pr L. Piroth), Garches (Pr C. Perronne), Lagny (Dr E. Froguel), Libourne (Dr J. Ceccaldi),  
18  
19 Lyon (Pr D. Peyramond), Meaux (Dr C. Allard), Montpellier (Pr J. Reynes), Nancy (Pr T.  
20  
21 May), Nantes (Pr F. Raffi), Nice (Pr JG Fuzibet, Pr P. Dellamonica), Orléans (Dr P. Arsac),  
22  
23 Paris (Pr E. Bouvet, Pr F. Bricaire, Pr P. Bergmann, Pr J. Cabane, Dr J. Monsonogo, Pr PM.  
24  
25 Girard, Pr L. Guillevin, Pr S. Herson, Pr C. Leport, Pr MC. Meyohas, Pr JM. Molina, Pr G.  
26  
27 Pialoux, Pr D. Salmon), Poitiers (Pr P. Roblot), Reims (Pr R. Jaussaud), Rennes (Pr C.  
28  
29 Michelet), Saint-Etienne (Pr F. Lucht), Saint-Mandé (Pr T. Debord), Strasbourg (Dr D. Rey),  
30  
31  
32  
33  
34 Toulon (Dr JP. De Jaureguiberry), Toulouse (Pr B. Marchou), Tours (Pr L. Bernard).  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Kaplan RC, Kingsley LA, Gange SJ *et al.* Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. *Aids* 2008;**22**(13):1615-24.
2. Henry K, Melroe H, Huebsch J *et al.* Severe premature coronary artery disease with protease inhibitors. *Lancet* 1998;**351**(9112):1328.
3. Lai S, Fishman EK, Lai H *et al.* Long-Term Cocaine Use and Antiretroviral Therapy Are Associated with Silent Coronary Artery Disease in African Americans with HIV Infection Who Have No Cardiovascular Symptoms. *Clin Infect Dis* 2008;**46**:600-610.
4. Mary-Krause M, Cotte L, Simon A *et al.* Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. *Aids* 2003;**17**(17):2479-86.
5. Friis-Moller N, Reiss P, Sabin CA *et al.* Class of antiretroviral drugs and the risk of myocardial infarction. *N Engl J Med* 2007;**356**(17):1723-35.
6. Butt AA, Chang CC, Kuller L *et al.* Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. *Arch Intern Med* 2011;**171**(8):737-43.
7. Lichtenstein KA, Armon C, Buchacz K *et al.* Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. *Clin Infect Dis* 2010;**51**(4):435-47.
8. Mondy KE, de las Fuentes L, Waggoner A *et al.* Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy. *Aids* 2008;**22**(7):849-56.
9. Sax PE. Strategies for management and treatment of dyslipidemia in HIV/AIDS. *AIDS Care* 2006;**18**(2):149-57.
10. Smith CJ, Levy I, Sabin CA *et al.* Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population. *HIV Med* 2004;**5**(2):88-92.
11. Guaraldi G, Squillace N, Stentarelli C *et al.* Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. *Clin Infect Dis* 2008;**47**(2):250-7.
12. Michel L, Carrieri MP, Fugon L *et al.* Harmful alcohol consumption and patterns of substance use in HIV-infected patients receiving antiretrovirals (ANRS-EN12-VESPA Study): relevance for clinical management and intervention. *AIDS Care* 2010;**22**(9):1136-45.
13. Stein M, Herman DS, Trisvan E *et al.* Alcohol use and sexual risk behavior among human immunodeficiency virus-positive persons. *Alcohol Clin Exp Res* 2005;**29**(5):837-43.
14. Braithwaite RS, Conigliaro J, McGinnis KA *et al.* Adjusting alcohol quantity for mean consumption and intoxication threshold improves prediction of nonadherence in HIV patients and HIV-negative controls. *Alcohol Clin Exp Res* 2008;**32**(9):1645-51.
15. Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. *J Acquir Immune Defic Syndr* 2006;**43**(4):411-7.
16. Spire B, Duran S, Souville M *et al.* Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. *Soc Sci Med* 2002;**54**(10):1481-96.
17. Conen A, Fehr J, Glass TR *et al.* Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. *Antivir Ther* 2009;**14**(3):349-57.
18. Braithwaite RS, Conigliaro J, Roberts MS *et al.* Estimating the impact of alcohol consumption on survival for HIV+ individuals. *AIDS Care* 2007;**19**(4):459-66.
19. Galai N, Vlahov D, Baretta JC *et al.* Prognostic factors for survival differ according to CD4+ cell count among HIV-infected injection drug users: pre-HAART and HAART eras. *J Acquir Immune Defic Syndr* 2005;**38**(1):74-81.
20. Hooshyar D, Hanson DL, Wolfe M *et al.* Trends in perimortal conditions and mortality rates among HIV-infected patients. *Aids* 2007;**21**(15):2093-100.
21. Samet JH, Cheng DM, Libman H *et al.* Alcohol consumption and HIV disease progression. *J Acquir Immune Defic Syndr* 2007;**46**(2):194-9.

22. Salmon-Ceron D, Lewden C, Morlat P *et al*. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. *J Hepatol* 2005;**42**(6):799-805.
23. Di Martino V, Rufat P, Boyer N *et al*. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. *Hepatology* 2001;**34**(6):1193-9.
24. Puoti M, Spinetti A, Ghezzi A *et al*. Mortality for liver disease in patients with HIV infection: a cohort study. *J Acquir Immune Defic Syndr* 2000;**24**(3):211-7.
25. Rosenthal E, Pialoux G, Bernard N *et al*. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). *J Viral Hepat* 2007;**14**(3):183-8.
26. Freiberg MS, McGinnis KA, Kraemer K *et al*. The association between alcohol consumption and prevalent cardiovascular diseases among HIV-infected and HIV-uninfected men. *J Acquir Immune Defic Syndr* 2010;**53**(2):247-53.
27. Freiberg MS, Cheng DM, Kraemer KL *et al*. The association between hepatitis C infection and prevalent cardiovascular disease among HIV-infected individuals. *Aids* 2007;**21**(2):193-7.
28. Mukamal KJ, Chen CM, Rao SR *et al*. Alcohol consumption and cardiovascular mortality among U.S. adults, 1987 to 2002. *J Am Coll Cardiol* 2010;**55**(13):1328-35.
29. Mukamal KJ, Conigrave KM, Mittleman MA *et al*. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. *N Engl J Med* 2003;**348**(2):109-18.
30. Saves M, Chene G, Ducimetiere P *et al*. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. *Clin Infect Dis* 2003;**37**(2):292-8.
31. CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *MMWR Recomm Rep*. 1992 Dec 18;41(RR-17):1-19.
32. Radloff L. The CES-D scale: a self-report depression scale for research in the general population. *Applied Psychology Measurement* 1977;**3**:385-491.
33. Justice AC, Holmes W, Gifford AL *et al*. Development and validation of a self-completed HIV symptom index. *J Clin Epidemiol* 2001;**54 Suppl 1**:S77-90.
34. Carrieri MP, Villes V, Raffi F *et al*. Self-reported side-effects of anti-retroviral treatment among IDUs: a 7-year longitudinal study (APROCO-COPILOTE COHORT ANRS CO-8). *Int J Drug Policy* 2007;**18**(4):288-95.
35. Chesney MA, Ickovics JR, Chambers DB *et al*. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). *AIDS Care* 2000;**12**(3):255-66.
36. Ueshima H, Choudhury SR, Okayama A *et al*. Cigarette smoking as a risk factor for stroke death in Japan: NIPPON DATA80. *Stroke* 2004;**35**(8):1836-41.
37. Bissell D, Paton A, Ritson B. ABC of alcohol. Help: referral. *Br Med J (Clin Res Ed)* 1982;**284**(6314):495-7.
38. Carrieri P, Cailleton V, Le Moing V *et al*. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. *J Acquir Immune Defic Syndr* 2001;**28**(3):232-9.
39. Fuhrer R, Rouillon F. La version française de l'échelle CES-D. Description and translation of the autoevaluation scale (in French). *Psychiatrie et Psychobiologie* 1989;**4**:163-166.
40. Therneau TM, Grambsch PM. *Modeling Survival Data: Extending the Cox Model* Springer, 2000.
41. Baker JV, Neuhaus J, Duprez D *et al*. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. *J Acquir Immune Defic Syndr* 2011;**56**(1):36-43.
42. Islam F, Wu J, Jansson J *et al*. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. *HIV Med* 2012[[Epub ahead of print]].

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
43. Friis-Moller N, Thiebaut R, Reiss P *et al*. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. *Eur J Cardiovasc Prev Rehabil* 2010;**17**(5):491-501.
44. Mukamal KJ, Chung H, Jenny NS *et al*. Alcohol use and risk of ischemic stroke among older adults: the cardiovascular health study. *Stroke* 2005;**36**(9):1830-4.
45. Waskiewicz A, Sygnowska E, Drygas W. Relationship between alcohol consumption and cardiovascular mortality--the Warsaw Pol-MONICA Project. *Kardiol Pol* 2004;**60**(6):552-62; discussion 563.
46. Burger M, Mensink G, Bronstrup A *et al*. Alcohol consumption and its relation to cardiovascular risk factors in Germany. *Eur J Clin Nutr* 2004;**58**(4):605-14.
47. Murray RP, Connett JE, Tyas SL *et al*. Alcohol volume, drinking pattern, and cardiovascular disease morbidity and mortality: is there a U-shaped function? *Am J Epidemiol* 2002;**155**(3):242-8.
48. Beulens JW, Algra A, Soedamah-Muthu SS *et al*. Alcohol consumption and risk of recurrent cardiovascular events and mortality in patients with clinically manifest vascular disease and diabetes mellitus: the Second Manifestations of ARterial (SMART) disease study. *Atherosclerosis* 2010;**212**(1):281-6.
49. Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. *HIV Med* 2005;**6**(2):99-106.
50. Marques-Vidal P, Montaye M, Arveiler D *et al*. Alcohol consumption and cardiovascular disease: differential effects in France and Northern Ireland. The PRIME study. *Eur J Cardiovasc Prev Rehabil* 2004;**11**(4):336-43.
51. Foerster M, Marques-Vidal P, Gmel G *et al*. Alcohol drinking and cardiovascular risk in a population with high mean alcohol consumption. *Am J Cardiol* 2009;**103**(3):361-8.
52. Pandrea I, Happel KI, Amedee AM *et al*. Alcohol's Role in HIV Transmission and Disease Progression. *Alcohol Research & Health* 2010;**33**(3):203-218.
53. Mukamal KJ, Cushman M, Mittleman MA *et al*. Alcohol consumption and inflammatory markers in older adults: the Cardiovascular Health Study. *Atherosclerosis* 2004;**173**(1):79-87.
54. Grulich AE, Jin F, Poynten IM *et al*. HIV, cancer, and aging. *Sex Health* 2011;**8**(4):521-5.
55. Palella FJ, Jr., Phair JP. Cardiovascular disease in HIV infection. *Curr Opin HIV AIDS* 2011;**6**(4):266-71.
56. Niaura R, Shadel WG, Morrow K *et al*. Human immunodeficiency virus infection, AIDS, and smoking cessation: the time is now. *Clin Infect Dis* 2000;**31**(3):808-12.
57. Barth J, Critchley J, Bengel J. Efficacy of psychosocial interventions for smoking cessation in patients with coronary heart disease: a systematic review and meta-analysis. *Ann Behav Med* 2006;**32**(1):10-20.
58. Currier JS, Havlir DV. Complications of HIV disease and antiretroviral therapy. *Top HIV Med* 2009;**17**(2):57-67.
59. Lloyd-Richardson EE, Stanton CA, Papandonatos GD *et al*. Motivation and patch treatment for HIV+ smokers: a randomized controlled trial. *Addiction* 2009;**104**(11):1891-900.
60. Roux P, Cohen J, Lascoux-Combe C *et al*. Determinants of the underreporting of alcohol consumption by HIV/HCV co-infected patients during face-to-face medical interviews: the role of the physician. *Drug Alcohol Depend* 2011;**116**(1-3):228-32.
61. D'Agostino RB, Sr., Vasan RS, Pencina MJ *et al*. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation* 2008;**117**(6):743-53.



**Table 1. Association between alcohol consumption and living injury indicators, after adjustment for HCV status, among HIV-infected patients receiving ART (ANRS CO8 APROCO-COPILOTE cohort - random effects logistic models, all patients - n=1154, follow-up period M0-M132)**

	<u>ALT&gt;50 IU/l &amp; AST/ALT&gt;1</u>		<u>ALT&gt;50 IU/l &amp; AST/ALT&gt;2</u>	
	<u>AOR [95%CI]</u>	<u>p-value</u>	<u>AOR [95%CI]</u>	<u>p-value</u>
<b><u>Alcohol consumption*</u></b>				
-abstainers (ref.)	<u>1</u>		<u>1</u>	
-<1 AU/day	<u>0.7 [0.5-1.2]</u>	<u>0.228</u>	<u>2.8 [0.4-18.4]</u>	<u>0.292</u>
->1 and <=4(3) AU/day for men(women)	<u>1.0 [0.6-1.8]</u>	<u>0.847</u>	<u>0.7 [0.0-10.1]</u>	<u>0.772</u>
->4(3) AU/day for men(women)	<u>4.9 [2.4-9.8]</u>	<u>&lt;10<sup>-3</sup></u>	<u>29.0 [3.4-250]</u>	<u>0.002</u>
<b><u>HCV infection at M0</u></b>	<u>12.9 [7.6-21.8]</u>	<u>&lt;10<sup>-3</sup></u>	<u>11.2 [2.7-46.4]</u>	<u>0.001</u>

ART = antiretroviral therapy; ALT= alanine transaminase; AST= aspartate transaminase

AOR = Adjusted Odds-Ratios from a random effects logistic model; CI = confidence interval

\* Time-varying variable (the last available value before each visit)

**Table 2. Factors associated with the first occurrence of a major CADE among HIV-infected patients receiving ART (ANRS CO8 APROCO-COPILOTE cohort - univariate and multivariate Cox proportional hazard models, all patients - n=1154, follow-up period M0-M132)**

	% of patients or mean (SD)	% of miss. data	Univariate analyses		Multivariate analysis	
			HR [95% CI]	p-value	AHR [95% CI]	p-value
<b><i>Socio-demographic and psychosocial characteristics</i></b>						
Female gender	22.0	0	0.26 [0.08-0.84]	0.025	0.25 [0.08-0.83]	0.024
Age at M0° - years	37.7 (9.5)	0	1.06 [1.03-1.09]	<10 <sup>-3</sup>	1.07 [1.04-1.10]	<10 <sup>-3</sup>
Secondary-school certificate at M0°	31.3	7.3	0.51 [0.26-1.01]	0.054		
Alcohol consumption at M0°		0				
- abstainers (ref)	18.8		1			
- <4(3) AU/day for men(women)	75.3		0.47 [0.24-0.89]	0.021		
- >4(3) AU/day for men(women)	5.9		0.75 [0.21-2.63]	0.648		
Alcohol consumption*		0				
- abstainers (ref)	18.8		1		1	
- <4(3) AU/day for men(women)	75.3		0.44 [0.24-0.81]	0.009	0.38 [0.20-0.71]	0.002
- >4(3) AU/day for men(women)	5.9		1.04 [0.30-3.58]	0.953	0.46 [0.13-1.63]	0.229
Tobacco consumption >20 cig./day*	16.4	0.9	3.17 [1.73-5.83]	<10 <sup>-3</sup>	4.19 [2.17-8.11]	<10 <sup>-3</sup>
Depressive symptoms <sup>#*</sup>	37.9	8.5	1.22 [0.67-2.21]	0.512		
Number of self-reported symptoms (excluding lipodystrophy)*@	3.8 (2.8)	0	1.01 [0.95-1.08]	0.694		
Number of self-reported lipodystrophy symptoms*@	1.1 (2.2)	0.6	1.07 [0.96-1.18]	0.223		
ART adherence*@	57.7	0.1	2.42 [1.17-5.02]	0.017		
<b><i>Clinical characteristics</i></b>						
HIV transmission category°		0				
- homosexual	40.6		0.99 [0.42-2.34]	0.988		



- injecting drug use	17.8		0.92 [0.50-1.70]	0.793	
- other (ref)	41.6		1		
CDC clinical stage A at M0 <sup>°</sup>	51.2	0	0.44 [0.23-0.85]	0.014	
HCV infection at M0 <sup>°</sup>	22.4	4.3	1.16 [0.59-2.29]	0.655	
Time since HIV diagnosis at M0- <i>years</i> <sup>°</sup>	4.7 (4.2)	0.9	1.01 [0.94-1.08]	0.822	
Duration of exposure to efavirenz - <i>years</i> * <sup>§</sup>	1.0 (2.2)	0	0.86 [0.71-1.03]	0.102	
Duration of exposure to nevirapine - <i>years</i> * <sup>§</sup>	0.9 (2.2)	0	0.91 [0.78-1.07]	0.279	
Duration of exposure to abacavir - <i>years</i> * <sup>§</sup>	1.0 (2.1)	0	0.98 [0.84-1.13]	0.748	
Duration of exposure to lopinavir - <i>years</i> * <sup>§</sup>	0.4 (1.5)	0	1.01 [0.85-1.20]	0.929	
Duration of exposure to PI-based regimen - <i>years</i> * <sup>§</sup>	3.2 (3.1)	0	1.03 [0.92-1.15]	0.615	
Antiretroviral naivety at M0 <sup>°</sup>	44.4	0	1.14 [0.64-2.02]	0.654	
<u>CD4+ cell count &lt; 200 cells/mm<sup>3</sup> at M0<sup>°</sup></u>	<u>35.9</u>	<u>0.1</u>	<u>0.99 [0.55-1.80]</u>	<u>0.978</u>	
<u>Detectable viral load at M0<sup>°</sup></u>	<u>94.0</u>	<u>0.3</u>	<u>0.81 [0.25-2.61]</u>	<u>0.725</u>	
<u>CD4+ cell count &lt; 200 cells/mm<sup>3</sup>* Detectable viral load*</u>	<u>34.6</u>	0.1	<u>2.48 [1.15-5.33]</u>	0.020	<u>2.52 [1.15-5.48]</u> 0.020

CADE = coronary or other arterial disease event; ART = antiretroviral therapy; CHD = coronary heart disease

SD = standard deviation; (A)HR = (adjusted) hazard ratio; CI = confidence interval

<sup>°</sup> Fixed variable (measured at M0 or M1); <sup>\*</sup> Time-varying variable (the last available value before each visit);

percentages and averages were computed at the first date of follow-up for time-varying variables

@ At M12; <sup>§</sup> At the end of the follow-up (last available visit for each patient)

<sup>#</sup> Depressive symptoms: the Centre for Epidemiologic Studies Depression Scale (CES-D) scores is >17 for men and >23 for women

**Table 3. Factors associated with the first occurrence of a major CADE among HIV-infected patients receiving ART (ANRS CO8 APROCO-COPILOTE cohort - univariate and multivariate Cox proportional hazard models, patients with available metabolic data - n=675, follow-up period M12-M132)**

	% of patients or mean (SD)	% of miss. data	Univariate analyses HR [95% CI]	p-value	Multivariate analysis AHR [95% CI]	p-value
<b><i>Socio-demographic and psychosocial characteristics</i></b>						
Female gender	19.0	0	0.33 [0.08-1.40]	0.134		
Age at M0 – years <sup>o</sup>	38.4 (9.5)	0	1.04 [1.01-1.07]	0.013	1.05 [1.02-1.09]	0.003
Secondary-school certificate at M0 <sup>o</sup>	35.4	6.7	0.34 [0.14-0.84]	0.019		
Alcohol consumption at M0 <sup>o</sup>		0				
- abstainers (ref)	15.1		1			
- <4(3) AU/day for men(women)	78.4		0.44 [0.18-1.03]	0.059		
- >4(3) AU/day for men(women)	6.5		1.04 [0.26-4.05]	0.959		
Alcohol consumption*		0				
- abstainers (ref)	15.1		1		1	
- <4(3) AU/day for men(women)	78.4		0.27 [0.13-0.58]	0.001	0.23 [0.11-0.49]	<10 <sup>-3</sup>
- >4(3) AU/day for men(women)	6.5		1.19 [0.33-4.23]	0.792	0.55 [0.14-2.14]	0.390
Tobacco consumption >20 cig./day*	14.8	1.2	3.58 [1.70-7.54]	0.001	5.59 [2.43-12.8]	<10 <sup>-3</sup>
Depressive symptoms <sup>#*</sup>	36.6	8.0	1.83 [0.90-3.73]	0.094		
Number of self-reported symptoms (excluding lipodystrophy)* <sup>@</sup>	4.0 (2.9)	0	1.03 [0.95-1.12]	0.463		
Number of self-reported lipodystrophy symptoms* <sup>@</sup>	1.4 (2.4)	0.2	1.10 [0.98-1.24]	0.111		
ARV adherence* <sup>@</sup>	56.6	0.2	1.63 [0.70-3.81]	0.260		
<b><i>Clinical characteristics</i></b>						

HIV transmission category <sup>o</sup>		0				
- homosexual (ref)	44.0		1			
- injecting drug use	15.0		2.08 [0.75-5.73]	0.156		
- other	41.0		1.32 [0.59-2.93]	0.499		
CDC clinical stage A at M0 <sup>o</sup>	50.8	0	0.43 [0.19-0.97]	0.041		
HCV infection at M0 <sup>o</sup>	19.8	3.8	2.05 [0.94-4.47]	0.071		
Duration since HIV diagnosis at M0- years <sup>o</sup>	4.7 (4.2)	1.2	1.04 [0.96-1.13]	0.311		
Duration of exposure to efavirenz - years* <sup>§</sup>	1.4 (2.5)	0	0.89 [0.73-1.08]	0.236		
Duration of exposure to nevirapine - years* <sup>§</sup>	1.0 (2.3)	0	0.83 [0.66-1.06]	0.147		
Duration of exposure to abacavir - years* <sup>§</sup>	1.2 (2.3)	0	0.99 [0.85-1.17]	0.971		
Duration of exposure to lopinavir - years* <sup>§</sup>	0.5 (1.5)	0	1.07 [0.88-1.30]	0.505		
Duration of exposure to PI-based regimen - years* <sup>§</sup>	3.9 (3.1)	0	1.03 [0.89-1.18]	0.714		
Antiretroviral naivety at M0 <sup>o</sup>	41.5	0	0.86 [0.41-1.79]	0.683		
<u>CD4+ cell count &lt; 200 cells/mm<sup>3</sup> at M0<sup>o</sup></u>	<u>33.9</u>	<u>0</u>	<u>0.88 [0.41-1.88]</u>	<u>0.749</u>		
<u>Detectable viral load at M0<sup>o</sup></u>	<u>94.8</u>	<u>0.1</u>	<u>0.70 [0.17-2.94]</u>	<u>0.627</u>		
<u>CD4+ cell count &lt; 200 cells/mm<sup>3</sup>*</u>	<u>32.3</u>	0	<u>2.58 [0.99-6.75]</u>	0.052	<u>4.02 [1.45-11.1]</u>	0.007
Detectable viral load*	92.7	0.3	1.24 [0.59-2.59]	0.574		

### Metabolic characteristics

BMI categories <sup>o@</sup>		1.6				
- underweight: <18.5 (ref)	5.8		1			
- normal weight: 18.5–24.9	72.8		0.65 [0.15-2.76]	0.556		
- overweight or obese: >25	19.8		0.57 [0.11-2.87]	0.498		
Hypertriglyceridemia <sup>o@</sup>	8.4	0	2.06 [0.79-5.37]	0.141	2.98 [1.11-8.01]	0.030

Hypercholesterolemia <sup>°@</sup>	6.5	0.1	0.95 [0.22-3.97]	0.939		
Personal history of CHD <sup>°@</sup>	1.2	0	9.39 [2.22-39.8]	0.002		
Family history of CHD <sup>°@</sup>	28.0	0	1.82 [0.89-3.71]	0.102	2.25 [1.08-4.71]	0.031
Personal history of hypertension <sup>°@</sup>	6.1	0	2.73 [1.05-7.13]	0.040		

CADE = coronary or other arterial disease event; ART = antiretroviral therapy; CHD = coronary heart disease

SD = standard deviation; (A)HR = (adjusted) hazard ratio; CI = confidence interval

<sup>°</sup> Fixed variable (measured at M0, M1 or M12); \* Time-varying variable (the last available value before each visit); percentages and averages are computed at the first date of follow-up for time-varying variables

@ At M12; § At the end of the follow-up (last available visit for each patient)

# Depressive symptoms: the Centre for Epidemiologic Studies Depression Scale (CES-D) scores is >17 for men and >23 for women

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
<b>Title and abstract</b>	1	<p><u>(a) Indicate the study's design with a commonly used term in the title or the abstract "Cohort study."</u></p> <hr/> <p><u>(b) Provide in the abstract an informative and balanced summary of what was done and what was found</u></p> <p>“Objective: To investigate the relationship between response to antiretroviral treatment (ART), alcohol use and occurrence of a major coronary or other arterial disease event (CADE) in HIV-infected individuals.</p> <p>Design: Cohort study. A Cox model was used to identify correlates of a first occurrence of a major CADE.</p> <p>Setting: The French ANRS CO8 APROCO-COPILOTE cohort was set up in 1997 to study clinical progression and patient-reported outcomes (PRO) after initiating protease inhibitor-containing ART. Clinical data were retrieved from medical records. Self-administered questionnaires collected data on PRO and behaviours, including alcohol use.</p> <p>Participants: Metabolic data were only available for a subgroup (n=675) of the study group (n=1154).</p> <p>Main outcomes measures: Major coronary or other arterial disease first event.</p> <p>Results: Over the 11-year follow-up, 49 major CADE were observed, with an incidence rate [95%CI]=0.75[0.57 to 0.99] per 100 person-years. <u>Immunodepression (CD4+ cell count &lt;200 cells/mm<sup>3</sup>)</u> was associated with <u>an increased risk of CADE</u> (Adjusted Hazard Ratio AHR[95% CI]= <u>2.52[1.15 to 5.48]</u>) after adjustment for female gender (0.25[0.08 to 0.83]), age (1.07[1.04 to 1.10]) and smoking&gt;20 cigarettes/day (4.19[2.17 to 8.11]). Moreover, individuals with moderate alcohol consumption (<u>≤4(3) AU/day for men(women)</u>) had a lower risk of CADE (0.38[0.20 to 0.71]) than alcohol abstainers, while the risk for those drinking<u>&gt;4(3) AU/day for men(women)</u> was not significantly different from this latter group. These associations remained valid after adjustment for metabolic disorders. No significant association with exposure to any specific antiretroviral was detected.</p> <p>Conclusions: In the long term, <u>absence of immunodepression</u> and moderate alcohol consumption remain associated with a lower risk of <u>major CADE</u>. Combined interventions to reduce CADE risk-related behaviours <u>including adherence counselling for assuring long term immunological response to ART</u> in HIV-infected individuals are now a clinical and public health priority.”</p>
<b>Introduction</b>		
Background/rationale	2	<p><u>Explain the scientific background and rationale for the investigation being reported</u></p> <p>“Cardiovascular disease risk factors (including for example hypertension and tobacco use), as well as immunological status[1] are major predictors of atherosclerosis in HIV-infected women and men. Although <u>some antiretroviral (ARV) therapy drugs</u>[2-5] have consistently been found to be associated with coronary arterial disease <u>or myocardial infarction (MI)</u> in these patients, more recently Butt and colleagues put into evidence the negative effect of HIV viral replication on heart failure[6]. In one study, patients having experienced <u>a MI</u> presented lower baseline and proximal CD4+ cell counts than those who did not, while no association was found <u>between cardiovascular disease events and</u> specific antiretroviral agents[7]. Moreover, known</p>

factors associated with cardiovascular risk[8] such as hyperlipidemia and insulin resistance[9-11] are becoming an increasingly major clinical concern in ARV-treated individuals.

Though excessive alcohol use may be frequent in HIV-infected individuals, its impact on the occurrence of cardiovascular disease in this population has been less investigated. Excessive alcohol consumption also plays a major role in HIV risk-taking behaviours, particularly in men who have sex with men and drug users[12, 13]. In HIV-infected individuals, excessive alcohol use is known to compromise patients' response to antiretroviral therapy (ART) through reduced adherence[14-17] and to predict HIV progression and increased mortality[18-21], mostly from liver diseases[22-25]. Some recent cross-sectional analyses in HIV-infected and uninfected men have found that heavy alcohol consumption is associated with a higher risk of cardiovascular disease[26, 27]. On the other hand, in uninfected adults, moderate alcohol consumption has been found to be associated with a reduced cardiovascular mortality[28], improved lipid profiles, increased insulin sensitivity and reduced risk of MI[29]. However, this association has not yet been studied in longitudinal studies involving HIV-infected populations including women. Moreover, there are as yet no consistent results in the literature regarding the role that alcohol use plays in exacerbating cardiovascular risk in ARV-treated patients and to what extent it can confound or boost the effect of immuno-virological response to ART, ART-associated dyslipidemia and insulin resistance on the risk of cardiovascular disease events."

Objectives	3	<p><u>State specific objectives, including any prespecified hypotheses</u></p> <p>"We used data from the 11-year follow-up of the APROCO-COPILOTE cohort of patients receiving ART since 1997 to investigate the relationship between viral load, CD4+ cell count, alcohol consumption and the first occurrence of a major coronary or other arterial disease event (CADE), after adjustment for known risk factors including metabolic disorders."</p>
<b>Methods</b>		
Study design	4	<p><u>Present key elements of study design early in the paper</u></p> <p>"The French APROCO-COPILOTE cohort (ANRS CO8) was designed to study the clinical, immunological, virological, and socio-behavioural course of HIV disease in HIV-1 positive individuals who started the first generation of potent ART (treatment regimens including protease inhibitors (PI)). The study was approved by the Ethics Committee of Cochin Hospital (Paris) and informed consent was obtained from all participants."</p>
Setting	5	<p><u>Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection</u></p> <p>"Patients were enrolled in the cohort at their first PI-based ART prescription between May 1997 and June 1999 (n=1281) in 47 French centres, and clinically followed-up every 4 months thereafter, up to month 132 (M132)."</p>
Participants	6	<p><u>(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up</u></p> <p>"In the present study were included all patients who had either two alcohol assessment or one alcohol assessment just preceding the CADE over the whole follow-up (n=1154)."</p>

(b) For matched studies, give matching criteria and number of exposed and unexposed  
[Not applicable.]

Variables	7	<p><u>Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable</u></p> <p><i>“Medical questionnaire</i></p> <p>The medical questionnaire at enrolment (M0) collected retrospective data about patient’s HIV history including HIV transmission category, time since HIV diagnosis, previous exposure to antiretroviral treatment before enrolment, and co-infection with hepatitis C virus (HCV) <u>defined as having positive HCV RNA and/or positive HCV antibodies</u>. This information was complemented by <u>medical questionnaires</u>, completed by the HIV <u>physicians</u> at each follow-up visit, which collected clinical and laboratory data (plasma HIV RNA level, CD4+ cell count, HIV clinical stage, <u>aspartate transaminase (AST) and alanine transaminase (ALT) levels</u>), as well as data on the antiretroviral regimen prescribed. A third form, based on updated medical records, detailed all clinical severe events, including <u>cardiovascular events</u>, occurring during the study period. Information on metabolic disorders was available at M12 for a subset of cohorts’ patients, who participated in a parallel cross-sectional survey, designed to study clinical and laboratory metabolic complications[30]. These “metabolic” data included height, weight, hypertriglyceridemia, hypercholesterolemia, personal history of coronary heart disease (CHD) and hypertension, and finally any family history of CHD.</p> <p><i>Outcome</i></p> <p><u>The details of all clinical severe events, including cardiovascular events, which occurred during follow-up, were obtained from medical records and validated by the cohort’s validation committee[30]. The classification of clinical severe events was based on the 10th Revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10)<sup>1</sup>. An event was considered severe when it required medical intervention, hospitalization, when hospitalization was extended due to the event’s occurrence, when it led to a life-threatening condition, or when it resulted in death. A group of cardiologists specifically validated the events selected as outcomes for this study. Among cardiovascular events, only major CADE were selected for this analysis as follows (listed in singular form): MI, stroke, coronary heart disease, peripheral arterial disease and cardiovascular surgery for coronary disease. We excluded the following from the definition of the outcome: heart failure, cardiac arrhythmia, phlebitis, pulmonary embolism, and peripheral venous diseases to keep only severe or life-threatening cardiovascular events in the analysis.</u></p> <p><i>Self-administered questionnaire</i></p> <p>A self-administered questionnaire collected - at M0, M4, M12 and every 8 months thereafter during the first 5 years of follow-up, then yearly thereafter – data on socio-demographic characteristics including age, gender and educational level. Among other psycho-social and behavioural information, it also collected details on depressive symptoms, tobacco use, alcohol consumption, self-reported ART-related symptoms and adherence to ART.”</p>
Data sources/ measurement	8*	<u>For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is</u>

<sup>1</sup> <http://www.who.int/classifications/icd/en/>



more than one group

“At each follow-up visit, CD4+ cell count was measured by standardized flow cytometry, and plasma HIV RNA levels were measured using the assay routinely available in each participating centre. Immunodepression was defined by CD4+ cell count <200 cells/mm<sup>3</sup>; viral load was classified as detectable if it was greater than the threshold value specific to each centre where the assay was performed. HIV clinical stage was defined using the 1993 Centres for Disease Control and Prevention (CDC) clinical classification system[31].

Serum triglyceride and cholesterol levels were measured after a 12-hour overnight fast. Hypertriglyceridemia was defined as a triglyceride level  $\geq 2.2$  mmol/l, while hypercholesterolemia was defined as a total cholesterol level  $\geq 5.5$  mmol/l.

Depression was measured using the validated French version of the Centre for Epidemiologic Studies Depression Scale (CES-D), which is a 20-item scale commonly used in studies involving HIV-infected patients[32].

Tobacco and alcohol consumption were evaluated during the previous 4 weeks.

Alcohol consumption was assessed using two questions about frequency of consumption and quantity consumed daily, if applicable.

A 13-item scale comprising the French version of the symptom index validated by Justice *et al*[33] and described elsewhere[34] collected information about self-reported symptoms. Five other questions gathered information about adherence to ART, according to the methodology established by the AIDS Clinical Trial Group[35].”

Bias	9	<p><u>Describe any efforts to address potential sources of bias</u></p> <p>“As the results of the analysis on the whole dataset (n=1154) could be affected by the lack of important predictors of CADE like hypertriglyceridemia or hypercholesterolemia, we conducted a secondary analysis on a subset of patients who had additional metabolic disorders data.”</p> <p>[This secondary analysis confirmed the same pattern of predictors of CADE events after adjustment for metabolic disorders.]</p>
Study size	10	<p><u>Explain how the study size was arrived at</u></p> <p>“<u>More specifically</u>, two analyses on <u>the following</u> study populations were performed to study predictors of major CADE:</p> <p>1) First analysis: the study population included all patients who had either two alcohol assessment or one alcohol assessment just preceding the event over the whole follow-up (n=1154). The follow-up period was M0-M132.</p> <p>2) Second analysis: the study population was restricted to the subset of patients with available data on metabolic disorders, measured at M12 (n=675). Consequently, only events occurring after M12 were considered in this second analysis.”</p>
Quantitative variables	11	<p><u>Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why</u></p> <p>“The WHO body mass index (BMI) categories were used in the analysis: underweight and overweight/obese patients were defined respectively as having a BMI lower than 18.5 and greater than 25.</p> <p>A <u>time-varying</u> cumulative measure of time exposure to specific ARV medications (abacavir, efavirenz, nevirapine, lopinavir and protease inhibitors) was computed <u>during which ART included a specific drug from this list</u>, from cohort enrolment to the date of each follow-up visit.</p>



Tobacco consumption was dichotomized in two categories: more than 20 cigarettes/day vs other[36]. The average number of alcohol units (AU) consumed per day[37] was computed using the two questions on alcohol consumption and then recoded in four categories (abstainers;  $\leq 1$  AU/day;  $>1$  and  $\leq 4(3)$  AU/day for men(women);  $>4(3)$  AU/day for men(women)), in order to test a gradient effect. We used information on AST and ALT liver enzymes to test their correlation with alcohol consumption as a validation test of self-reported alcohol consumption. As normal liver enzymes' reference ranges for each laboratory were not available in our data set, we used a universal cut-off of ALT $>50$  units per litre of serum as an indicator of liver injury, and the AST/ALT ratio (in conjunction with ALT $>50$  IU/l) as a marker of possible cirrhosis and/or alcoholic liver disease (for AST/ALT $>1$ ) and advanced alcoholic liver disease (for AST/ALT $>2$ ). We found a positive significant association between excessive alcohol consumption and these two indicators of liver injury (after adjusting for HCV status, see Table 1), which would suggest good accuracy of the self-reported data on alcohol consumption.

Patients were classified as non-adherent if they reported taking less than 100% of prescribed medications during the previous 4 weeks, using a validated algorithm[38]. A patient with a CES-D score value above 17 (men) or 23 (women) was considered as presenting depressive symptoms[39]. ”

[See references in the paper for the reasons of choosing of these categories].

---

Statistical methods	12	<p><u>(a) Describe all statistical methods, including those used to control for confounding</u></p> <p>“Incidence rate of major CADE was computed as the number of cases divided by the number of person-years of follow-up. Follow-up duration was calculated as the difference in days from enrolment to the date of the CADE, death or last visit, whichever occurred first. Follow-up of patients experiencing major CADE was censored after the date of the first CADE. We used a Cox proportional hazards model to identify characteristics associated with the first occurrence of a major CADE. Psychosocial characteristics - depressive symptoms, tobacco and alcohol consumption, self-reported symptoms, CD4+ cell count and viral load - were evaluated at each visit and used as time-varying covariates in the statistical analysis. All the other covariates were used as fixed variables (measured at M0, M1 or M12). For time-varying factors, the last known value was carried forward in the case of missing data at a scheduled visit. In the case of an event occurring between two consecutive follow-up visits, the values for the time-varying variables measured at the visit preceding the event were used. Covariates with a p-value<math>&lt;0.25</math> in univariate Cox analyses were considered eligible for the multivariate Cox model, which was built using a backward <u>stepwise</u> selection procedure based on the Wald test (p<math>&lt;0.05</math>). <u>Interaction effects between the factors of the multivariate final model were tested.</u> The proportional-hazards assumption was verified globally for the multivariate models and separately with respect to each covariate, using both Kaplan-Meier estimates and tests based on Schoenfeld residuals[40]. A residual analysis for outliers' detection was performed and the sensitivity of the model to influential outliers was tested. <u>Several sensitivity analyses were performed. First, we excluded all patients with a history of CHD and re-ran the model to verify whether the pattern of factors would remain unchanged.</u> <u>Second, the patients who died due to alcoholic cirrhosis were excluded from the study.</u> <u>A third analysis was performed separately on the subgroups of patients co-infected with HCV and those not co-infected with HCV.</u></p>
---------------------	----	---

All analyses were performed using Stata Intercooled software, version 12.1.”

---

(b) Describe any methods used to examine subgroups and interactions

“Interaction effects between the factors of the multivariate final Cox model were tested.”

---

(c) Explain how missing data were addressed

“For time-varying factors, the last known value was carried forward in the case of missing data at a scheduled visit.”

---

(d) If applicable, explain how loss to follow-up was addressed

“Follow-up duration was calculated as the difference in days from enrolment to the date of the CADE, death or last visit, whichever occurred first. Follow-up of patients experiencing major CADE was censored after the date of the first CADE.”

[Patients lost to follow-up were dealt as usual in the Cox model (right-censoring).]

---

(e) Describe any sensitivity analyses

“Several sensitivity analyses were performed. First, we excluded all patients with a history of CHD and re-ran the model to verify whether the pattern of factors would remain unchanged.

Second, the patients who died due to alcoholic cirrhosis were excluded from the study.

A third analysis was performed separately on the subgroups of patients co-infected with HCV and those not co-infected with HCV.”

---

**Results**

Participants	13*	<p><u>(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed</u></p> <p>“A total of 1154 patients were included in the present study, accounting for 9401 person-visits.”</p> <hr/> <p><u>(b) Give reasons for non-participation at each stage</u></p> <p>“When comparing the study patients (n=1154) with those included in the cohort, but excluded from the study due to missing alcohol data (n=127), no significant difference was found for gender, age at enrolment, antiretroviral naivety, CDC clinical stage, baseline CD4+ cell counts and HIV viral load at M0 (data not shown).”</p> <hr/> <p><u>(c) Consider use of a flow diagram</u></p> <p>[Not done because the graph is very simple.]</p>
Descriptive data	14*	<p><u>(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders</u></p> <p>“The distribution of factors associated with major CADE [...] are reported in Table 2 for the entire study population (n=1154). Table 3 focuses instead on the subset of patients with available data on metabolic disorders (n=675). Women represented 22% of the study population (n=1154) (Table 2). Mean (SD) age at baseline was 37.7 (9.5) years and approximately one third of the patients had a secondary school certificate. Individuals HIV-infected through drug use accounted for 18% of the study patients. At baseline, 44% of all the patients were ARV naive, half</p>

were in CDC stage A and more than three quarters (80%) had not experienced opportunistic infections. Furthermore, 94% had a detectable viral load, 36% had a CD4+ cell count <200 cells/mm<sup>3</sup> and 22% were co-infected with HCV. Depressive symptoms were reported at baseline in 38% of the patients. After one year of ART, more than half of the patients (58%) were highly adherent, the median [IQR] number of self-reported symptoms excluding lipodystrophy was 3 [2 to 6], while this value was 0 [0 to 1] for lipodystrophy symptoms. Only 16% of the patients declared smoking more than 20 cigarettes per day at cohort enrolment. Nearly 19% of the patients reported they were alcohol abstainers, three quarters reported moderate alcohol consumption (54% reporting less than 1 AU/day and 21% between 1 and 4(3) AU/day for men(women)), while only a minority of patients (6%) reported elevated alcohol consumption. As the two intermediate categories (<1 AU/day; >1 and <4(3) AU/day for men(women)) had similar estimated Adjusted Hazard Ratios (AHR) and p-values in both multivariate analyses, we decided to aggregate them for model parsimony.

In the subsample of patients with available metabolic data (Table 3), the majority (73%) had a normal BMI, 17% were classified in the overweight category and a minority was classified in each of the two more extreme categories (6% underweight and 3% obese). About 8% of the patients had hypertriglyceridemia and 6% had hypercholesterolemia at M12. One year after the enrolment in the cohort, 6% of the patients reported a personal history of hypertension. Only 1% and 28% respectively had a personal and family history of CHD.”

---

(b) Indicate number of participants with missing data for each variable of interest [See Tables 2 and 3, second column.]

---

(c) Summarise follow-up time (eg. average and total amount)

“Median [interquartile range (IQR)] duration of follow-up of the selected patients, from their first visit after the ART prescription (M1) until M132, was 5.9 [1.8-9.4] years. During the 11 years of the study, accounting for 6544 person-years, the loss to follow-up rate [95% CI] was 17.6 [16.3 to 18.7] per 100 person-years.”

---

Outcome data	15*	<p><u>Report numbers of outcome events or summary measures over time</u></p> <p>“Over the 11-year follow-up of the cohort, a total of 85 <u>severe cardiovascular events</u> were observed. These included 49 major CADE as follows: myocardial infarction (n=30), coronary heart disease (n=4), stroke (n=7), peripheral arterial disease (n=7) and cardiovascular surgery <u>for coronary disease</u> (n=1). The distribution of the other thirty six <u>severe cardiovascular events</u> was as follows: phlebitis/pulmonary embolism (n=22), cardiomyopathy/congestive heart failure (n=5), cardiac dysrhythmia (n=6), cerebral haemorrhage (n=2) and aortic aneurysm (n=1).</p> <p>The incidence rate [95% CI] of all <u>severe cardiovascular events</u> was 1.3 [1.0 to 1.6] per 100 person-years, while for major CADE the incidence rate was 0.75 [0.57 to 0.99] per 100 person-years. Of the 49 major CADE, 40 occurred after M12.</p> <p>Furthermore, the major CADE incidence over the period M12-M132 was 0.89 [0.66 to 1.22] per 100 person-years.”</p>
Main results	16	<p><u>(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg. 95% confidence interval). Make clear which confounders were adjusted for and why they were included</u></p>

---

“[...] the results of univariate and multivariate Cox models, are reported in Table 2 for the entire study population (n=1154). Table 3 focuses instead on the subset of patients with available data on metabolic disorders (n=675). [...]”

In the entire study group (n=1154), the following factors were found to be independent predictors of major CADE: older age at baseline (AHR[95% CI]=1.07[1.04 to 1.10]), tobacco consumption>20 cigarettes/day (4.19[2.17 to 8.11]) and CD4+ cell count <200 cells/mm<sup>3</sup> ( 2.52[1.15 to 5.48]) (see Table 2). In addition, a negative association was found between female gender and major CADE (0.25[0.08 to 0.83]). After accounting for the effect of age, gender, tobacco consumption and CD4+ cell count <200 cells/mm<sup>3</sup> in the multivariate Cox model, individuals with moderate alcohol consumption (≤4(3) AU/day for men(women)) were at lower risk of major CADE (0.38[0.20 to 0.71]), than alcohol abstainers, while those drinking more than 4(3) AU/day for men(women) were not significantly different from abstainers (p=0.229).

These results remained valid also when the analysis was restricted to the subgroup of patients with available metabolic data and the follow-up period M12-M132. After adjusting for age, tobacco consumption, hypertriglyceridemia and family history of CHD, we consistently found a negative association between moderate alcohol use (0.23[0.11 to 0.49]), and a positive association between CD4+ cell count <200 cells/mm<sup>3</sup> (4.02[1.45 to 11.1]) and major CADE after one year after enrolment (Table 3).”

---

(b) Report category boundaries when continuous variables were categorized

[See Tables 2 and 3 for details.]

---

(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

“The incidence rate [95% CI] of all severe cardiovascular events was 1.3 [1.0 to 1.6] per 100 person-years, while for major CADE the incidence rate was 0.75 [0.57 to 0.99] per 100 person-years. Of the 49 major CADE, 40 occurred after M12. Furthermore, the major CADE incidence over the period M12-M132 was 0.89 [0.66 to 1.22] per 100 person-years.”

---

Other analyses

17

Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

“No significant association was found between time of exposure to different ARV drugs and major CADE. No significant interaction was found between smoking habits and hypertriglyceridemia or personal history of CHD. Furthermore, detectable viral load was not associated with major CADE in univariate or multivariate analyses. For the Cox models fitted in this study, proportional-hazards assumption remained valid, either globally and with respect to each covariate. The residual analysis did not alter the results of the multivariate model.

The sensitivity analyses performed by first excluding patients with a history of CHD (n=7), and then patients who died due to alcoholic cirrhosis (n=6), confirmed the same pattern of risk factors observed for the whole population. The other sensitivity analyses, performed separately on the subgroups of patients with HCV co-infection and on those not co-infected with HCV, revealed the same effect of alcohol consumption on CADE, although some variables among the other factors were less significant for the co-infected patients (results not shown, available on request).”

---

---

**Discussion**


---

1		
2		
3		
4	Key results	18 <u>Summarise key results with reference to study objectives</u>
5		“This longitudinal study clearly confirms that in <u>ARV-treated individuals</u> , proximal
6		CD4+ cell count <u>lower than 200 cells/mm<sup>3</sup></u> remains a <u>risk factor</u> associated with major
7		coronary and other arterial disease events. This result remains valid even after
8		adjustment for metabolic disorders such as hypertriglyceridemia and family history of
9		CHD, the strength of the association remaining unchanged.”
10		
11		
12	Limitations	19 <u>Discuss limitations of the study, taking into account sources of potential bias or</u>
13		<u>imprecision. Discuss both direction and magnitude of any potential bias</u>
14		“Some limitations of this study need to be acknowledged. First, our definition of
15		CADE includes different types of events which might not share the same pattern of
16		risk factors. However, an additional analysis performed on a restricted dataset and
17		which adjusted for other potential risk factors (such as hypertriglyceridemia)
18		confirmed the pattern found in the main analysis.
19		Second, information on alcohol use was mainly based on self-reports and these may
20		tend to underestimate alcohol consumption. However, it has been reported that HIV-
21		HCV co-infected patients tend to underreport alcohol use more to their hepatologist
22		than to other physicians[60]. As our patients were all followed-up by HIV physicians,
23		it is likely that the degree of underreporting did not greatly affect hazard ratios’
24		estimates. <u>Moreover, the association found between the excessive alcohol</u>
25		<u>consumption and the biomarkers of alcoholic liver injury indicate a good accuracy of</u>
26		<u>self-reported data on alcohol consumption.</u>
27		<u>Then, the fact that excessive alcohol users exhibit similar HRs to abstainers may be</u>
28		<u>also attributable to the two following reasons. First, some individuals with excessive</u>
29		<u>alcohol consumption may have died due to liver failure before experiencing a</u>
30		<u>cardiovascular event and this could have reduced the impact of excessive alcohol use</u>
31		<u>on CADE. However, when we performed a sensitivity analysis excluding patients who</u>
32		<u>died due to alcoholic cirrhosis, the results remained unchanged. Second, a proportion</u>
33		<u>of abstainers may have been past (heavy) alcohol users and may have had to stop</u>
34		<u>drinking for health reasons. Unfortunately, we do not have information about alcohol</u>
35		<u>use before the beginning of the cohort, or about diagnosis of alcoholism or reasons for</u>
36		<u>quitting alcohol.</u>
37		<u>Finally, it would have been interesting to compute the Framingham risk score[61] and</u>
38		<u>use it as a covariate in the multivariate model. Unfortunately, as our study was not</u>
39		<u>initially designed to thoroughly assess the impact of all possible CHD risk factors,</u>
40		<u>some of the variables used in the construction of this score (such as treated and</u>
41		<u>untreated systolic blood pressure, as well as total and high-density lipoprotein</u>
42		<u>cholesterol) were not available during the two first years of our study. Moreover, our</u>
43		<u>results showed a different pattern of factors than those found in the Framingham study</u>
44		<u>(some of the traditional risk factors, such as BMI and hypercholesterolemia, were not</u>
45		<u>significant), so using this score would have been less informative than using all the</u>
46		<u>factors separately.”</u>
47		
48		
49		
50		
51		
52		
53		
54		
55		
56	Interpretation	20 <u>Give a cautious overall interpretation of results considering objectives, limitations,</u>
57		<u>multiplicity of analyses, results from similar studies, and other relevant evidence</u>
58		“The relationship between CADE and CD4+ cell count, in addition to the lack of
59		association between CADE and specific ARV classes, confirms previous results[7]
60		

1 where the association between exposure to certain ARV and CADE was no longer  
2 evident after controlling for traditional risk factors and HIV disease markers. Indeed,  
3 the association between specific ARV drugs and major CADE, like myocardial  
4 infarctus, has been shown in very powerful studies[5], where adjustment for nadir  
5 CD4+ lymphocyte count or peak HIV-1 RNA level did not modify the results.  
6 However, in the study cited, no adjustment for proximal CD4+ cell count was  
7 performed, and the association with the class of ARV became weaker after adjustment  
8 for serum lipid levels[5]. Indeed, although ART may modify lipid levels and increase  
9 the risk of CADE, it may also reduce this risk by reducing HIV-associated  
10 inflammation following long-term suppression of HIV replication[41]. The lack of  
11 association with exposure to some specific ARV classes in the present study, factors  
12 usually associated with an increased risk of CADE[42, 43], suggests that reduced  
13 immunological response to ART over a long follow-up, as well as known CADE risk  
14 factors may have a more important impact than exposure to a specific antiretroviral  
15 drug.  
16

17 It is also possible that patients with altered lipid profiles were switched to other  
18 classes of antiretroviral drugs during the follow-up. As a consequence, in the long  
19 term, CD4+ cell count <200 cells/mm<sup>3</sup> remain a correlate of an increased risk of  
20 CADE, whatever the antiretroviral received.

21 In our study, individuals reporting elevated alcohol consumption exhibited the same  
22 risk of CADE as alcohol abstainers. In contrast, those reporting moderate alcohol  
23 consumptions had a lower risk. This result was confirmed after adjustment for  
24 additional risk factors including tobacco use, age, gender and CD4+ cell count. This  
25 relationship between alcohol consumption and CADE remained significant and J-  
26 shaped, even after adjustment for data on metabolic risk factors- such as having a  
27 history of CHD and hypertriglyceridemia -which was available for a subset of  
28 patients. As highlighted in previous observations in the general population[28, 44-47]  
29 and certain populations affected by other diseases[48], these results confirmed that the  
30 increased risk of CADE in HIV-infected patients receiving ART is not attributable to  
31 elevated alcohol use. Furthermore, we highlighted the apparent protective effect of  
32 moderate alcohol consumption in ART treated HIV-infected patients.  
33

34 It is important to note that after the introduction of ART in 1996, the sudden decrease  
35 observed in HIV-related mortality was nonetheless accompanied by a relative increase  
36 of non-HIV based mortality, as a part of the total mortality of HIV-infected patients  
37 [49], cardiovascular diseases becoming increasingly important. This increase can be  
38 explained firstly by a reduction in the competing role of HIV-related mortality, which  
39 in the long term was much more detrimental to health than other causes of deaths.  
40 Secondly, the high prevalence in this population of other risk factors like tobacco use,  
41 together with ART-related morbidity including altered lipid profiles and triglycerides,  
42 may contribute to an increased risk of CADE.  
43

44 The association found in our study between moderate alcohol use and reduced CADE  
45 risk is not consistent with all previous research in HIV-infected patients. Freiberg *et*  
46 *al*[26] pointed out that among HIV-infected men in the US, hazardous drinking and  
47 both alcohol abuse and dependence were associated with a higher prevalence of  
48 cardiovascular disease compared with infrequent and moderate drinking, even after  
49 adjusting for traditional risk factors, antiretroviral therapy and CD4+ cell count. This  
50 difference in the results may be due to the different design of the two studies  
51 (longitudinal for ours *vs* cross-sectional for Freiberg's), but probably also to the  
52 different types of alcohol mainly consumed in the two populations, red wine  
53  
54  
55  
56  
57  
58  
59  
60



consumption being more widespread in France than in the US. This difference in the pattern of alcohol use has already been highlighted in a comparative study on cardiovascular disease in non HIV-infected Irish and French males, showing an increased protective effect of drinking red wine in the latter population[50]. Increased wine consumption probably brings about an increase in high-density lipoprotein cholesterol levels, which helps protect against cardiovascular events. On the other hand, beer and spirits consumption are linked to increased triglyceride levels[51]. We do not know to what extent moderate alcohol users are representative of a population with better health status as alcohol use in France is relatively frequent in the general population and this fact may increase the strength of the association found.

Another possible hypothesis is that excessive alcohol consumption can increase inflammatory markers' levels[52], which in turn probably leads to a higher risk of CADE and premature aging in HIV patients. However, this hypothesis was not demonstrated in a study conducted in older adults without cardiovascular disease, where alcohol intake was found to be associated with lower levels of inflammatory markers[53]. In the meantime it is important to remember that individuals with immune suppression are at a greater risk of cancer, a disease whose pattern of risk factors also include alcohol use, even when moderate[54].

Tobacco smoking has consistently been found to be a major risk factor for cardiovascular disease[55]. Smoking prevalence and dependence in HIV-infected patients is higher than in the general population[56]. Effective interventions for reducing and quitting smoking[57], especially for patients with several risk factors, are strongly recommended especially considering the increased cardiovascular risk which exists in HIV-infected smokers receiving ART[58]. However, results from studies reporting on the effectiveness of interventions for quitting smoking in HIV-infected individuals are inconsistent[59].

It is worth noting the lack of association between hypercholesterolemia and the risk of CADE in our study. This result suggests that HIV physicians need to be cautious about basing clinical decisions merely upon measured lipid levels in HIV-infected patients. Other risk factors, including behavioural ones, deserve greater consideration for clinical management."

---

Generalisability	21	<p><u>Discuss the generalisability (external validity) of the study results</u></p> <p>“This cohort is representative of the first generation of patients receiving potent ART. As cardiovascular disease is a rising issue in all HIV-infected populations receiving ART, these results can give important information about the pattern of risk and protective factors in all treated HIV-infected populations.</p> <p>In conclusion, in the long term, absence of immunodepression and moderate alcohol consumption remain associated with a lower risk of major CADE. Combined interventions to reduce CADE-risk-related behaviours including adherence counselling to assure long term immunological response to ART in HIV-infected individuals are now a clinical and public health priority.”</p>
------------------	----	---

---

#### **Other information**

Funding	22	<p><u>Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based</u></p> <p>“Funding sources: The ANRS CO8 (APROCO/COPILOTE) cohort is funded by ANRS (Agence Nationale de Recherches sur le Sida et les hépatites virales) and CMIT (Collège des Universitaires de Maladies Infectieuses et Tropicales), which</p>
---------	----	--

---

---

1 received research grants from Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb,  
2 GlaxoSmithKline, Gilead Sciences, Pfizer and Roche.  
3 The funders were responsible for initiating, managing and financing the cohort, but  
4 did not interfere with data analysis and interpretation and dissemination of the  
5 scientific results.”  
6  
7

---

8  
9 \*Give information separately for exposed and unexposed groups.  
10

11 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and  
12 published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely  
13 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at  
14 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is  
15 available at <http://www.strobe-statement.org>.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5 27-Apr-2012  
6

7 Dear Dr. Protopopescu:

8 Manuscript ID bmjopen-2012-001155 entitled "CD4+ cell count  $\geq 200$  cells/mm<sup>3</sup>  
9 and Moderate Alcohol Consumption: Evidence of Protection against Coronary  
10 and other Arterial Disease Events in an 11-year Cohort of HIV-infected  
11 Patients on Antiretroviral Therapy" which you submitted to BMJ Open, has  
12 been reviewed. The comments of the reviewer(s) are included at the bottom  
13 of this letter.

14  
15 Articles don't usually receive four reviews but this paper seemed popular  
16 with reviewers!

17  
18 The reviewer(s) have recommended revisions to your manuscript. Therefore,  
19 I invite you to respond to the reviewer(s)' comments and revise your  
20 manuscript. Please remember that the reviewers' comments and the previous  
21 drafts of your manuscript will be published as supplementary information  
22 alongside the final version.

23 To revise your manuscript, log into <http://mc.manuscriptcentral.com/bmjopen>  
24 and enter your Author Center, where you will find your manuscript title  
25 listed under "Manuscripts with Decisions." Under "Actions," click on  
26 "Create a Revision." Your manuscript number has been appended to denote a  
27 revision.

28  
29 You may also click the below link to start the revision process (or  
30 continue the process if you have already started your revision) for your  
31 manuscript. If you use the below link you will not be required to login to  
32 ScholarOne Manuscripts.

33 [http://mc.manuscriptcentral.com/bmjopen?URL\\_MASK=939TbDZtmJ8J4kRmTKHq](http://mc.manuscriptcentral.com/bmjopen?URL_MASK=939TbDZtmJ8J4kRmTKHq)  
34

35  
36 You will be unable to make your revisions on the originally submitted  
37 version of the manuscript. Instead, revise your manuscript using a word  
38 processing program and save it on your computer. Please also highlight the  
39 changes to your manuscript within the document by using the track changes  
40 mode in MS Word or by using bold or colored text. Once the revised  
41 manuscript is prepared, you can upload it and submit it through your Author  
42 Center.

43  
44 When submitting your revised manuscript, you will be able to respond to the  
45 comments made by the reviewer(s) in the space provided. You can use this  
46 space to document any changes you make to the original manuscript. In  
47 order to expedite the processing of the revised manuscript, please be as  
48 specific as possible in your response to the reviewer(s).

49  
50 **IMPORTANT:** Your original files are available to you when you upload your  
51 revised manuscript. Please delete any redundant files before completing  
52 the submission.

53  
54 Because we are trying to facilitate timely publication of manuscripts  
55 submitted to BMJ Open, your revised manuscript should be submitted within  
56 30 days. If it is not possible for you to submit your revision by this  
57 date, we may have to consider your paper as a new submission.

58  
59 Once again, thank you for submitting your manuscript to BMJ Open and I look  
60 forward to receiving your revision.

1  
2  
3  
4 Sincerely,  
5 Mr. Richard Sands  
6 Managing Editor, BMJ Open  
7 [rsands@bmjgroup.com](mailto:rsands@bmjgroup.com)

8 >From the managing editor:

9  
10 Please reword the title to address the research question rather than the  
11 results.

12  
13 *We have changed the title as follows:*

14 **Impact of Immunodepression and Moderate Alcohol Consumption on Coronary and**  
15 **other Arterial Disease Events in an 11-year Cohort of HIV-infected Patients**  
16 **on Antiretroviral Therapy**

17  
18  
19  
20 Reviewer: Shenghan Lai  
21 Johns Hopkins School of Medicine

22 The main outcome was major coronary or other arterial disease first event.  
23 However, the participants with CHD history were included.  
24 The statistical analyses need to be redone. Please see my comments.

25  
26 The topic of this study is important. My concerns with study design and  
27 data analyses are as follows:

28 1. This study was designed to investigate risk factors for coronary  
29 and other arterial disease events (CADE) in HIV-infected men and women.  
30 Thus, those with history of CHD or any other arterial diseases should not  
31 be included in the data analysis.

32  
33 *Some HIV-infected patients have a history of CHD but there seems to be no*  
34 *evident reason why they should be excluded. As our objective was to study*  
35 *all major CADE occurring after starting HAART and as a history of CHD*  
36 *concerned the pre-HAART period, we decided to treat this variable as an*  
37 *additional risk factor; interaction effects between history of CHD and the*  
38 *other factors were also tested. The results showed no interaction effect*  
39 *and that adding this factor into the model did not modify the other*  
40 *effects. Moreover, a personal history of CHD was not significant in the*  
41 *final multivariate model (see Table 3).*  
42 *In addition, to answer the reviewer's request and those of the other*  
43 *reviewers (who did not ask to remove these patients but asked for*  
44 *additional analyses), we performed supplementary "sensitivity analyses"*  
45 *which revealed that the relative impact of the factors was the same once*  
46 *the estimation was performed on patients with no history of CHD (only 7*  
47 *patients were eliminated from the multivariate analysis of Table 3).*  
48 *Another reason why we decided to keep the patients with a history of CHD in*  
49 *the analysis is that this information was not available for all the*  
50 *patients selected for the study, but only for the subgroup of those with*  
51 *available data on metabolic disorders.*  
52 *Therefore we added the following text in the Methods section:*

53 **Several sensitivity analyses were performed. First, we excluded all**  
54 **patients with a history of CHD and re-ran the model to verify whether the**  
55 **pattern of factors would remain unchanged.**

56 *and in the Results section:*

The sensitivity analyses performed by first excluding patients with a history of CHD (n=7), and then patients who died due to alcoholic cirrhosis (n=6), confirmed the same pattern of risk factors observed for the whole population.

2. Since 75% of participants had  $\leq 3$  AU/day, it would be interesting to split this category into two categories: 1 AU/day and 2 AU/day. Then, rerun the analysis.

This is an interesting comment as we initially performed the analyses with alcohol consumption in four categories (abstainers;  $\leq 1$  AU/day;  $>1$  and  $\leq 4$  (3) AU/day for men(women);  $>4$  (3) AU/day for men(women)), in order to test for a gradient effect. As the two categories of moderate consumption ( $\leq 1$  AU/day;  $>1$  and  $\leq 4$  (3) AU/day for men(women)) had similar AHR and p-values in both multivariate analyses, we decided to aggregate them to keep the model parsimonious.

To illustrate this, we present below the comparison of the results of the impact of time-varying alcohol consumption in the four categories on the first occurrence of a major CADE (univariate and multivariate Cox proportional hazard models) - the multivariate results are adjusted for all the factors in each multivariate model presented in the paper.

For the all patients (n=1154), follow-up period M0-M132 (Table 2):

	Univariate analyses		Multivariate analysis	
	HR [95% CI]	p-value	AHR [95% CI]	p-value
<b>Socio-demographic and psychosocial characteristics</b>				
Alcohol consumption*				
- abstainers (ref)	1		1	
- $\leq 1$ AU/day	0.40 [0.21-0.78]	0.007	0.40 [0.21-0.78]	0.007
- $>1$ and $\leq 4$ (3) AU/day for men(women)	0.58 [0.25-1.35]	0.207	0.33 [0.14-0.79]	0.013
- $>4$ (3) AU/day for men(women)	1.04 [0.30-3.58]	0.951	0.45 [0.13-1.62]	0.223

For the subgroup of patients with available metabolic data (n=675), follow-up period M12-M132 (Table 3):

	Univariate analyses		Multivariate analysis	
	HR [95% CI]	p-value	AHR [95% CI]	p-value
<b>Socio-demographic and psychosocial characteristics</b>				
Alcohol consumption*				
- abstainers (ref)	1		1	
- $\leq 1$ AU/day	0.35 [0.17-0.71]	0.004	0.24 [0.11-0.55]	0.001
- $>1$ and $\leq 4$ (3) AU/day for men(women)	0.36 [0.13-1.01]	0.053	0.19 [0.06-0.62]	0.006
- $>4$ (3) AU/day for men(women)	1.09 [0.31-3.81]	0.889	0.54 [0.14-2.11]	0.381

We added the following sentence in the Methods section:

The average number of alcohol units (AU) consumed per day[37] was computed using the two questions on alcohol consumption and then recoded in four categories (abstainers;  $\leq 1$  AU/day;  $>1$  and  $\leq 4$  (3) AU/day for men(women);  $>4$  (3) AU/day for men(women)), in order to test for a gradient effect.

We also added a description of the four categories in the Results section and argued the aggregation of the two intermediate categories as follows:

Nearly 19% of the patients reported they were alcohol abstainers, three quarters reported moderate alcohol consumption (54% reporting less than 1 AU/day and 21% between 1 and 4(3) AU/day for men(women)), while only a minority of patients (6%) reported elevated alcohol consumption. As the two intermediate categories ( $\leq 1$  AU/day;  $>1$  and  $\leq 4(3)$  AU/day for men(women)) had similar estimated Adjusted Hazard Ratios (AHR) and p-values in both multivariate analyses, we decided to aggregate them for model parsimony.

3. Baseline (M0) CD4 count and viral load should be included in the Cox models.

We already tested both of these factors and found that neither was significantly associated with the outcome, nor confounded the effect of the other variables included in the model. In line with strategies for model building, which suggest avoiding unnecessary over adjustment, we decided not to include them in the multivariate model. In addition, the follow-up time was so long that CD4 and VL at baseline have limited clinical value as potential factors having an impact on CADE.

To be more explicit on this subject, we added the univariate results for these factors in Tables 2 and 3 and the following description in the Results section:

**At baseline, [...] 94% had a detectable viral load, 36% had a CD4+ cell count  $<200$  cells/mm<sup>3</sup> and 22% were co-infected with HCV.**

4. Some key risk factors for coronary heart disease, such as blood pressure were missing in the Cox models. I strongly recommend that Framingham risk score be calculated and treated as a covariate in the regression models.

This is a very pertinent comment and it is a limitation of our study as complete data about treated and untreated systolic blood pressure, as well as total and high-density lipoprotein cholesterol were not available during the first part of the cohort follow-up. Because of this the Framingham risk score could not be used as a covariate in our models. Only partial information about these factors was available during all the follow-up period, and only for the subgroup of patients with available data on metabolic disorders. This partial information concerned the variables used in our analysis: hypertriglyceridemia, hypercholesterolemia, and hypertension. Moreover, our results showed a different pattern of factors than those found in the Framingham study (some of the traditional risk factors, such as BMI and hypercholesterolemia, were not significant), so using this score would have been less informative than using all the factors separately.

We added this limitation to the Discussion section as follows:

**Finally, it would have been interesting to compute the Framingham risk score[61] and use it as a covariate in the multivariate model. Unfortunately, as our study was not initially designed to thoroughly assess the impact of all possible CHD risk factors, some of the variables used in the construction of this score (such as treated and untreated systolic blood pressure, as well as total and high-density lipoprotein cholesterol) were not available during the two first years of our study. Moreover, our results showed a different pattern of factors than those found in the Framingham study (some of the traditional risk factors, such as BMI and**

1  
2  
3 **hypercholesterolemia, were not significant), so using this score would have**  
4 **been less informative than using all the factors separately.**  
5

6  
7 Reviewer: Robert Kaplan  
8 Professor  
9 Albert Einstein College of Medicine  
10 Bronx NY USA  
11

12 This report from a french cohort of HIV-infected adults examined risk  
13 factors for the occurrence of cardiovascular disease events including  
14 myocardial infarction, heart failure, and various other arterial and venous  
15 events. The authors identified several independent risk factors for  
16 incident CVD events, including low CD4 count, age, sex, and a protective  
17 effect of moderate alcohol consumption. They conclude that risk behaviors  
18 are important determinants of CVD events in HIV-infected adults, while  
19 antiretroviral drugs did not have an association with CVD and moreover that  
20 any influence of ARVs on cardiovascular disease is likely mediated by  
21 immune responses to the medications.  
22

#### 23 General comments

24 The research addresses an important question, and the authors have  
25 assembled a well-characterized cohort with incident events -- while the  
26 study is relatively small in terms of the number of events, it adds  
27 importantly to the literature which contains a small number of such prior  
28 cohort studies.

#### 29 Specific comments

30 With alcohol use as a protective cardiovascular risk factor being a major  
31 finding of the paper, the authors need to pay more attention to potential  
32 risks associated with alcohol consumption:

33 1. They need to draw attention to the fact that liver disease is a major  
34 cause of death in HIV-infected patients. They also might address the  
35 possibility that competing risks may explain their findings for alcohol  
36 use, as liver-related deaths among drinkers may be an important competing  
37 risk that produced an artifactual association with lower CVD risks.

38 2. Were patients queried about past alcohol use, diagnosis of alcoholism,  
39 or reasons for quitting alcohol (ie because of health reasons or physicians  
40 advice). This is important because their reference group of abstainers may  
41 be enriched by a high-CVD-risk group who has quit drinking for health  
42 reasons. The potential for this kind of bias must be emphasized, and it is  
43 difficult to exclude.  
44

45 *We completely agree with the reviewer's points of view, as liver disease*  
46 *has become a leading cause of death among people with HIV and alcohol may*  
47 *have played a role in liver-related mortality of our cohort, especially in*  
48 *HIV-HCV co-infected individuals.*

49 *For these reasons we explored deaths due to liver diseases in the cohort.*  
50 *Among the study patients, 6 died because of alcoholic cirrhosis and 11*  
51 *other deaths were due to non alcoholic liver-related causes (HCV, HCB,*  
52 *hepatocellular carcinoma, cirrhosis). More than half of the observations*  
53 *for the 6 patients with alcoholic cirrhosis were classified under excessive*  
54 *alcohol consumption, and one of the patients experienced a CADE. No*  
55 *excessive consumption of alcohol was reported by the 11 other patients*  
56 *mentioned above. We performed a sensitivity analysis, removing the 6*  
57 *patients with alcoholic cirrhosis from the study, and found the same*  
58 *pattern of risk factors for CADE. However, the small number of deaths*  
59 *limited the possibility of estimating a competing risk model.*  
60

The patients were not asked about alcohol use before inclusion in the cohort, or about diagnosis of alcoholism or their reasons for quitting alcohol.

To take into account both comments above, we introduced the following sentence about this sensitivity analysis in the Methods section:

Several sensitivity analyses were performed. First, we excluded all patients with a history of CHD and re-ran the model to verify whether the pattern of factors would remain unchanged. Second, the patients who died due to alcoholic cirrhosis were excluded from the study.

and in the Results section:

The sensitivity analyses performed by first excluding patients with a history of CHD (n=7), and then patients who died due to alcoholic cirrhosis (n=6), confirmed the same pattern of risk factors observed for the whole population.

We added also the following limitation in the Discussion section:

[...] the fact that excessive alcohol users exhibit similar HRs to abstainers may be also attributable to the two following reasons. First, some individuals with excessive alcohol consumption may have died due to liver failure before experiencing a cardiovascular event and this could have reduced the impact of excessive alcohol use on CADE. However, when we performed a sensitivity analysis excluding patients who died due to alcoholic cirrhosis, the results remained unchanged. Second, a proportion of abstainers may have been past (heavy) alcohol users and may have had to stop drinking for health reasons. Unfortunately, we do not have information about alcohol use before the beginning of the cohort, or about diagnosis of alcoholism or reasons for quitting alcohol.

3. Was there information on ALT, AST, or other markers of liver injury or fibrosis?

Yes, AST and ALT levels were available at each visit during follow-up, but this was not the case for other markers of liver injury. We used information on liver enzymes as a validation test of self-reported alcohol consumption. This is stated in the following paragraph, added to the Methods section (also see the Table below):

We used information on AST and ALT liver enzymes to test their correlation with alcohol consumption as a validation test of self-reported alcohol consumption. As normal liver enzymes' reference ranges for each laboratory were not available in our data set, we used a universal cut-off of ALT>50 units per litre of serum as an indicator of liver injury, and the AST/ALT ratio (in conjunction with ALT>50 IU/l) as a marker of possible cirrhosis and/or alcoholic liver disease (for AST/ALT>1) and advanced alcoholic liver disease (for AST/ALT>2). We found a positive significant association between excessive alcohol consumption and these two indicators of liver injury (after adjusting for HCV status, see Table 1), which would suggest good accuracy of the self-reported data on alcohol consumption.

	ALT>50 IU/l & AST/ALT>1		ALT>50 IU/l & AST/ALT>2	
	aOR* [95%CI]	p-value	aOR* [95%CI]	p-value
Alcohol consumption -abstainers (ref.)	1		1	



-≤1 AU/day	0.7 [0.5-1.2]	0.228	2.8 [0.4-18.4]	0.292
->1 and ≤4(3) AU/day for men (women)	1.0 [0.6-1.8]	0.847	0.7 [0.0-10.1]	0.772
->4(3) AU/day for men (women)	4.9 [2.4-9.8]	<10 <sup>-3</sup>	29.0 [3.4-250]	0.002
<b>HCV infection at M0</b>	12.9 [7.6-21.8]	<10 <sup>-3</sup>	11.2 [2.7-46.4]	0.001

*\*adjusted Odds-Ratios from a random effects logistic model.*

However neither indicator of liver disease was associated with the risk of CADE - something highlighted by univariate analyses - and neither modified the pattern of the other factors in any of the multivariate models. This latter result is not mentioned in the paper.

4. The HCV-coinfected subgroup is important to examine in secondary analyses. Subgroup analysis based on HCV status should be reported. Please clarify whether HCV was defined by active infection, or only by antibodies.

*We added the following definition of HCV infection in the Methods section:*

**The medical questionnaire at enrolment (M0) collected retrospective data about patient's HIV history [...], and co-infection with hepatitis C virus (HCV) defined as having positive HCV RNA and/or positive HCV antibodies.**

*To answer the question above, despite the lack of statistical power of the group of HIV-HCV infected patients, we performed subgroup analyses based on HCV status. We added the following text in the Methods section:*

**Several sensitivity analyses were performed. [...] A third analysis was performed separately on the subgroups of patients co-infected with HCV and those not co-infected with HCV.**

*and in the Results section:*

**The other sensitivity analyses, performed separately on the subgroups of patients with HCV co-infection and on those not co-infected with HCV, revealed the same effect of alcohol consumption on CADE, although some variables among the other factors were less significant for the co-infected patients (results not shown, available on request).**

Table 2: The lack of association between hypercholesterolemia and risk of CADE is very interesting and important. Because LDL-c and TC are low in HIV-infected patients, providers need to be careful about basing clinical decisions upon measured lipid levels in HIV-infected patients. It is striking that most traditional CVD risk factors (smoking, age, gender, hypertension) predicted CADE in this study, but hypercholesterolemia did not, and this is worthy of comment in the discussion.

*We thank the reviewer for noting this additional result which may be important in clinical practice.*

*Taking into account his suggestion we added the following sentence in the Discussion section:*

**It is worth noting the lack of association between hypercholesterolemia and the risk of CADE in our study. This result suggests that HIV physicians need to be cautious about basing clinical decisions merely upon measured lipid levels in HIV-infected patients. Other risk factors, including behavioural ones, deserve greater consideration for clinical management.**

1  
2  
3 The discussion section mentions several potential mechanisms relating to  
4 effects of alcohol on lipid metabolism. In this regard, it will be  
5 interesting to present the association between alcohol use and levels of  
6 HDL-c, triglycerides, etc

7  
8 *Unfortunately, information on total and high-density lipoprotein (HDL)*  
9 *cholesterol and triglycerides was available in the data set only from the*  
10 *M28 visit onwards, and even then it was not collected systematically. For*  
11 *this reason it was not possible to comment on the association between*  
12 *alcohol use and lipid metabolism over the whole follow-up.*

13 Page 14, the authors seem to indicate that an association was found between  
14 efavirez and nevirapine and risk of CADE, but the results presented in the  
15 Table do not support this (ie nonsignificant p-values).

16  
17 *We removed the sentence and inserted the following one:*

18 **No significant association was found between time of exposure to different**  
19 **ARV drugs and major CADE.**

20  
21 While they describe the outcome as the first CADE event, it was unclear  
22 whether patients with a baseline history of prior CVD events were excluded.

23  
24 *As stated in the response to the first reviewer, we decided to keep the*  
25 *patients with a history of CHD in the analysis. As our objective was to*  
26 *study all major CADE occurring after starting HAART and as the history of*  
27 *CHD concerned the pre-HAART period, we decided to treat this variable as an*  
28 *additional risk factor; interaction effects between history of CHD and the*  
29 *other factors were also tested. The results showed no interaction effect*  
30 *and that the addition of this factor to the model did not modify the other*  
31 *effects. Moreover, personal history of CHD is not significant in the final*  
32 *multivariate model (see Table 3). Furthermore, the information on CHD*  
33 *history was not available for all the patients selected for the study, but*  
34 *only for the subgroup of those with available data on metabolic disorders.*  
35 *In addition, we performed a sensitivity analysis which revealed that the*  
36 *relative impact of the factors was the same when the estimation was*  
37 *performed on patients with no history of CHD. Therefore we added the*  
38 *following text in the Methods section:*

39 **Several sensitivity analyses were performed. First, we excluded all**  
40 **patients with a history of CHD and re-ran the model to verify whether the**  
41 **pattern of factors would remain unchanged.**

42 *and in the Results section:*

43  
44 **The sensitivity analyses performed by first excluding patients with a**  
45 **history of CHD (n=7), and then patients who died due to alcoholic cirrhosis**  
46 **(n=6), confirmed the same pattern of risk factors observed for the whole**  
47 **population.**

48  
49 What was the methodology and criteria for CADE event adjudication. 1, how  
50 were potential cardiovascular events identified (ie, what triggered the  
51 collection and review of medical records)? 2, were events classified as  
52 either primary (ie reason for admission) or secondary (ie occurred during a  
53 hospitalization for some other disease, occurred during surgery, occurred  
54 in a septic patient, occurred due to arterial spasm associated with cocaine  
55 use?

56  
57 *We have now explained the methodology of severe events recording and*  
58 *validation in our cohort more thoroughly, as well as the selection*



1  
2  
3 methodology of major CADE as a part of all cardiovascular events. The  
4 rewritten Outcome paragraph in the Methods section is as follows:

5  
6 **The details of all severe clinical events, including cardiovascular events,**  
7 **which occurred during follow-up, were obtained from medical records and**  
8 **validated by the cohort's validation committee[30]. The classification of**  
9 **severe clinical events was based on the 10th Revision of the International**  
10 **Statistical Classification of Diseases and Related Health Problems (ICD-**  
11 **10)<sup>i</sup>. An event was considered severe when it required medical intervention,**  
12 **hospitalization, when hospitalization was extended due to the event's**  
13 **occurrence, when it led to a life-threatening condition, or when it**  
14 **resulted in death. A group of cardiologists specifically validated the**  
15 **events selected as outcomes for this study. Among cardiovascular events,**  
16 **only major CADE were selected for this analysis as follows (listed in**  
17 **singular form): MI, stroke, coronary heart disease, peripheral arterial**  
18 **disease and cardiovascular surgery for coronary disease. We excluded the**  
19 **following from the definition of the outcome: heart failure, cardiac**  
20 **arrhythmia, phlebitis, pulmonary embolism, and peripheral venous diseases**  
21 **to keep only severe or life-threatening cardiovascular events in the**  
22 **analysis.**

23  
24 What was loss-to-followup rate in the cohort?

25  
26 We added the loss to follow-up rate in the Results section as follows:

27  
28 **During the 11 years of the study, accounting for 6544 person-years, the**  
29 **loss to follow-up rate was 17.6 [16.3 to 18.7] per 100 person-years.**

30  
31 Minor comments

32  
33 Abstract, it is unclear why they call CD4 count and alcohol consumption  
34 the "principal factors" associated with CADE, since several other risk  
35 factors were identified which seem just as strongly related to CADE.

36  
37 We agree with the reviewer, so we have modified the abstract and the  
38 conclusion of the paper, as follows:

39  
40 **In the long term, absence of immunodepression and moderate alcohol**  
41 **consumption remain associated with a lower risk of major CADE.**

42  
43 The terminology of "CADE" (coronary or other arterial disease events) to  
44 denote the major endpoint is somewhat non-standard, and moreover is not  
45 accurate terminology given that deep venous thrombosis was one of the  
46 captured outcomes.

47  
48 The terminology of "CADE" (coronary or other arterial disease event) was  
49 chosen in coordination with a group of cardiologists which validated the  
50 selection of the events. It is true that the terminology is somewhat non-  
51 standard, but we preferred it instead of the general terminology  
52 "cardiovascular events" as the events selected as outcomes included only  
53 "MI, stroke, coronary heart disease, peripheral arterial disease and  
54 cardiovascular surgery for coronary disease, but not "deep venous  
55 thrombosis" (page 7). See also our response above on CADE selection.

56  
57 Reviewer: Prof. Hansjakob Furrer, MD  
58 Chief a.i.  
59 University Clinic of Infectious Diseases  
60 Bern University Hospital and University of Bern  
Switzerland

No competing interest.

1  
2  
3  
4 The credibility of the results is reduced by the fact, that over 90% of the  
5 patients follow-up viral loads are said to be detectable. This should be  
6 reassessed (cf. comment 3d). This may be typo in the tables but need  
7 explanation.  
8 Otherwise, the results are credible.

9  
10 *Please see response to comment 3d below.*

11 General comments:

- 12 1. This is an interesting paper assessing factors associated with  
13 coronary and other arterial disease events (CADE) in a cohort of French  
14 patients with HIV infection who started antiretroviral therapy using a  
15 protease inhibitor containing regime. Because they have data on alcohol  
16 consumption in the their database they are able to analyse the effect of  
17 this behaviour on CADE and find that moderate alcohol consumption is  
18 associated with reduced CADE risk in HIV infected persons. They also find  
19 CD4 counts below 200 associated with CADE risk, but not detectable viral  
20 load or antiretroviral drug classes.  
21 2. The statistical approach (Cox regression with baseline and time-  
22 updated co-variates) is sound, done by experts in the field, and they  
23 pretend that the proportional hazards assumptions are not violated.  
24 3. There are some weaker points in the paper  
25 a. CADE definitions: CADE also include phlebitis, congestive heart  
26 failure, cardiac arrhythmia; difficult for me to see these as "coronary and  
27 other arterial disease events". Then a subgroup of major was chosen. Was  
28 the definition of a major CADE made a priori?

29 *The terminology of "CADE" (coronary or other arterial disease event) was  
30 chosen in coordination with a group of cardiologists who validated the  
31 selection of the events. We chose this particular terminology, rather than  
32 "cardiovascular events", because our outcome included only "MI, stroke,  
33 coronary heart disease, peripheral arterial disease and cardiovascular  
34 surgery for coronary disease" as stated at page 7 of the paper. We excluded  
35 heart failure, cardiac arrhythmia, phlebitis, pulmonary embolism, and  
36 peripheral venous diseases from the selected events to keep only major  
37 (severe or life-threatening) cardiovascular events in the analysis.*

38 *We explained the selection of events in the "Outcome" paragraph of the  
39 Methods section more thoroughly, as follows:*

40 **A group of cardiologists specifically validated the events selected as  
41 outcomes for this study. Among cardiovascular events, only major CADE were  
42 selected for this analysis as follows (listed in singular form): MI,  
43 stroke, coronary heart disease, peripheral arterial disease and  
44 cardiovascular surgery for coronary disease. We excluded the following from  
45 the definition of the outcome: heart failure, cardiac arrhythmia,  
46 phlebitis, pulmonary embolism, and peripheral venous diseases to keep only  
47 severe or life-threatening cardiovascular events in the analysis.**

48 b. Only "severe" CADE are taken into account, but we lack a definition  
49 what a "severe" CADE is, especially what is e.g. a severe peripheral artery  
50 disease, or a severe coronary disease other than MI or cardiovascular  
51 surgery for coronary disease. Also coronary angioplasty should be included  
52 in the list.

53 *We added the definition of a severe event (in general) to the "Outcome"  
54 paragraph of the Methods section:*

55 **An event was considered severe when it required medical intervention,  
56 hospitalization, when hospitalization was extended due to the event's**

1  
2  
3 **occurrence, when it led to a life-threatening condition, or when it**  
4 **resulted in death.**

5  
6 *Among all severe events recorded in the cohort, we first selected*  
7 *cardiovascular events - according to the ICD-10 classification. Then, among*  
8 *the latter, we selected those corresponding to major CADE as defined for*  
9 *this study. We included coronary angioplasty in the definition of the*  
10 *outcome (one event was recorded in our cohort), which we labelled as*  
11 *"cardiovascular surgery for coronary disease".*

12  
13  
14 c. The analysis is performed by an experienced team, but I'm surprised  
15 that they chose a two step covariate elimination strategy, eliminating  
16 first covariables who had a  $p < 0.25$ , therefore missing masked associations.  
17 Secondly they chose a backward elimination procedure in the multivariable  
18 model, a very controversial strategy suspicious of "data mining" . I think  
19 that in studying diseases such as CADE one should a priori define the  
20 covariates, knowing about the risk factors of arteriosclerosis, and not  
21 eliminate them if they do not seem to be significant.

22  
23 *We completely agree with the reviewer about the selection procedure. It is*  
24 *true that the use of a backward elimination procedure among a large set of*  
25 *covariables may be a controversial strategy. But our strategy was to first*  
26 *pre-select covariables before statistical modelling, in accordance with the*  
27 *literature on the risk factors for cardiovascular events. We then used the*  
28 *0.25 cut-off as a standard threshold point - something suggested in many*  
29 *multivariate books - in order to choose variables eligible for the*  
30 *multivariate model. To build this model we compared several strategies,*  
31 *including a backward stepwise elimination procedure, choosing the 0.05 cut-*  
32 *off point as the significance level for the final model. Moreover, in this*  
33 *revised version of the paper we also used the selection strategy based on*  
34 *information criteria, and found identical results. We think that including*  
35 *variables which do not significantly improve the model - even if reported*  
36 *in the literature - may also be controversial, and generally, strategies*  
37 *for model building strongly recommend avoiding unnecessary over adjustment.*  
38 *The issue is that if some variables do not significantly contribute to*  
39 *explain the outcome, it is possible that modest associations are not*  
40 *highlighted due to the lack of power of the study. This may be the case for*  
41 *hypercholesterolemia which is interesting because its impact here is much*  
42 *lower than for other behavioural risk factors and the lack of a strong*  
43 *association may provide a strong note of caution to physicians not to use*  
44 *only this factor for clinical decisions (we added a comment about this in*  
45 *the discussion section).*

46  
47 d. There is a problem with the database or with building up the  
48 tables: I can't believe that in a treated population in France detectable  
49 viral loads are found in more than 90% of the measurements (Table 1 and 2).  
50 Such a mistake could explain the somewhat unexpected missing association if  
51 HIV replication and increased CADE risk. In addition, I miss a definition  
52 of undetectable viral load.

53  
54 *As stated in the notes at the bottom of these tables, renumbered as Tables*  
55 *2 and 3, for all time-varying variables, percentages and averages are*  
56 *computed at the first date of follow-up (we have not give a value for the*  
57 *entire duration of follow-up for these time-varying variables). Therefore*  
58 *the descriptive statistics in the two tables correspond to the moment*  
59 *preceding the first PI-based ART prescription (M0), which explains the*  
60 *large percentage of detectable viral load in our population.*

We added a definition for undetectable viral load and immunodepression in the Methods section:

**Immunodepression was defined by CD4+ cell count <200 cells/mm<sup>3</sup>; viral load was classified as detectable if it was greater than the threshold value specific to each centre where the assay was performed.**

4. Moderate alcohol consumption is found to be associated with a lower CADE risk in this cohort. This is only one side of the coin: The impact of this finding would be much stronger, if moderate alcohol consumption was associated with a reduced overall mortality or at least not associated with a higher mortality. I propose to include such an analysis in the paper.

*This is an interesting comment, but a mortality analysis lies beyond the limit of the object of our study. In addition, moderate alcohol consumption is known to prevent cardiovascular events in the general population but not other events leading to death which are frequent in the HIV population. For example, alcohol use may be associated with death due to liver failure, especially in co-infected individuals. As all the reviewers think that the results need to be reinforced, we conducted several sensitivity analyses: the first excluded patients with a history of CHD, the second excluded those who died due to liver-related diseases and in the third we selected HIV-HCV co-infected patients. The same pattern of alcohol consumption as a risk factor was consistently found in all these sensitivity analyses.*

Minor comments

5. Page 7, introduction, 1st para: Antiretroviral drugs have not been consistently found to be associated with CADE, only some of them. Antiretroviral therapy has been associated with lower incidence of CADE (SMART trial)

*The sentence in the Introduction referred not to antiretroviral therapy in general, but to antiretroviral (ARV) therapy agents. For more clarity, we have modified the sentence as follows:*

**Although some antiretroviral (ARV) therapy drugs[2-5] have consistently been found to be associated with coronary arterial disease or myocardial infarction (MI) in these patients [...].**

6. Page 9 last para: What does the first sentence mean: Were events only initially validated or were all events validated?

*All events were validated; we have rewritten the sentence, as follows:*

**The details of all severe clinical events, including cardiovascular events, which occurred during follow-up, were obtained from medical records and validated by the cohort's validation committee.**

7. Page 11 first para: the two study population are not entirely different, but one is a sub-group of the other.

*The sentence has been rephrased as follows:*

**More specifically, two analyses on the following study populations were performed in order to study predictors of major CADE:**

8. Page 12: why were CD4 count and viral load taken as binary variables and not as continuous ones,. And if binary, why CD4 of 200 as strata limit.

1  
2  
3  
4 A cut-off of 200 cells/mm<sup>3</sup> was chosen for CD4+ because this threshold was  
5 found to be the most associated with the outcome. Moreover, as well as the  
6 detectability threshold for the viral load, CD4+ <200 cells/mm<sup>3</sup> is a  
7 standard cut-off used to indicate risk of HIV progression.

8 9. Page 14, last sentence 2nd para should read: ... and major CADE  
9 after one year after enrolment.

10 We have corrected the sentence.

11  
12  
13 10. Page 15 2nd para : "it may also reduce this risk because of CD4+  
14 reconstitution following long-term suppression of HIV replication or HIV-  
15 associated inflammation" , is not correctly written, rather: "it may also  
16 reduce the risk by reducing HIV-associated inflammation following long-term  
17 suppression of HV-replication (and give some references about reduced  
18 inflammation markers on ART).

19 We thank the reviewer for noting this and suggesting rephrasing. We have  
20 modified the sentence accordingly:

21  
22 **Indeed, although ART may modify lipid levels and increase the risk of CADE,**  
23 **it may also reduce this risk by reducing HIV-associated inflammation**  
24 **following long-term suppression of HIV replication[49].**

25 We also added a reference [49] about reduced inflammation markers during  
26 ART.

27  
28 11. Page 16, 3rd para: I don't think that there are clear data that age  
29 adjusted Non-HIV associated mortality has increased in the cART era. In  
30 fact, in the cited paper (47) is not age adjusted and gives no statistics  
31 in this regards, and the cardiovascular mortality rather decreased in the  
32 cited paper.

33  
34 The cited sentence referred to the relative increase of the mortality due  
35 to the non-HIV causes as a part of the total mortality of HIV-infected  
36 patients, which has decreased in the cART era. For more clarity, the  
37 sentence has been rephrased as follows:

38  
39 **It is important to note that after the introduction of ART in 1996, the**  
40 **sudden decrease observed in HIV-related mortality was nonetheless**  
41 **accompanied by a relative increase of the non-HIV based mortality as a part**  
42 **of the total mortality of HIV-infected patients[49], cardiovascular**  
43 **diseases becoming increasingly important.**

44 12. Page 17, 2nd para: reference the "one hypothesis".

45  
46 We added the reference number 52 about the impact of excessive alcohol  
47 consumption on inflammatory markers' levels, as follows:

48  
49 **Another possible hypothesis is that excessive alcohol consumption can**  
50 **increase inflammatory markers' levels[52], which in turn probably leads to**  
51 **a higher risk of CADE and premature aging in HIV patients.**

52  
53 Reviewer: Enrico Girardi  
54 Director, Department of Epidemiology  
55 Istituto nazionale per le malattie infettive "L. Spallanzani"  
56 Roma, Italy

57  
58 I have no competing interest in raltion to this paper

1  
2  
3  
4 As far as I understand, alcohol consumption was included in the  
5 multivariable model as a time-varying covariate. However this approach does  
6 not take into account the history of alcohol consumption which may be  
7 relevant for any detrimental or protective effect of alcohol. For example  
8 what about a persons who has been reporting alcohol consumption at each  
9 visit for 3 years but not at the visit preceding a CHD event?

10  
11 *To verify the result on the protective effect of alcohol on CADE, we*  
12 *performed another sensitivity analysis based on the individual patient*  
13 *alcohol histories. We addressed the problem in two ways. The first approach*  
14 *was to use a time-lagged alcohol covariate. At the first two visits (M0 and*  
15 *M1), the baseline alcohol status was used. For subsequent visits, the next*  
16 *to last follow-up value was used rather than the last assessment. The*  
17 *second approach used the percentage of the follow-up period during which*  
18 *the patient had been classified in each of the four alcohol consumption*  
19 *categories. Both these sensitivity analyses (not presented in the paper)*  
20 *resulted in similar patterns of risk factors on CADE to that for the*  
21 *principal analysis.*

22 The authors did not find any association between specific ARV drugs and the  
23 risk of CHD. The association between ARV and CHD has been demonstrated in  
24 several studies, see for example the review by Islam et al (HIV Medicine  
25 2012) which demonstrate that persons with HIV without ART have an increased  
26 risk compared with HIV-uninfected people with treatment-naïve persons and  
27 that lopinavir/ritonavir and abacavir were associated with the greater risk  
28 and the relative risk of MI for PI-based versus non-PI-based ART was 1.41.

29  
30 *We already acknowledged in the Introduction and the Discussion of the paper*  
31 *that some specific antiretroviral (ARV) therapy drugs have consistently*  
32 *been found to be associated with coronary and other arterial disease events*  
33 *(CADE) or myocardial infarction (MI) in HIV-patients; we added the*  
34 *reference suggested by the reviewer.*

35  
36 In the manuscript the analysis of the role of single ARV is not clearly  
37 presented. In particular it is not clear what is compared to what.

38  
39 *We tested the effect of a time-varying variable "duration of exposure to*  
40 *specific ARV drugs" on the risk of CADE. We explained the construction of*  
41 *this variable in the Methods section in greater detail, as follows:*

42 **A time-varying cumulative measure of time exposure to specific ARV**  
43 **medications (abacavir, efavirenz, nevirapine, lopinavir and protease**  
44 **inhibitors) was computed as the number of years during which ART included a**  
45 **specific drug from this list, from cohort enrolment to the date of each**  
46 **follow-up visit.**

47  
48 Moreover the number of patients receiving different drugs ( or the person-  
49 time spent on different drugs) is not reported. This aspect needs further  
50 clarification and more in-depth discussion.

51  
52 *Descriptive statistics (mean, standard deviation) for duration of exposure*  
53 *to each specific drug are reported at the end of the follow-up (last*  
54 *available visit for each patient), in Tables 2 and 3.*

55  
56 I wonder whether the use of CD4cell count and HIV viremia as time-varying  
57 covariates is appropriate in this analysis. A commonly accepted theory  
58 holds that chronic inflammation, which may be reflected by the time spent  
59 with uncontrolled viremia (or "Viremia Copy-Years" as suggested by Mugavero  
60



et al. Clin Infect Dis 2012) and probably with low CD4, may contribute to accelerate vascular damage. This phenomenon may not be captured by single transversal measures. This point should also be addressed in the discussion.

To answer this question we performed another sensitivity analysis (not shown in the paper), using the percentage of the follow-up period that the patient had both a detectable viral load and a CD4+ <200 cells/mm<sup>3</sup> instead of the values at each visit for the two time-varying covariables. This analysis confirmed the results of the main analysis.

A table describing the characteristics of individuals include in the analysis may be useful

The characteristics of individuals are described in the first column of the Tables 2 and 3.

Some issue should be discussed in greater detail, see above

We have provided an additional paragraph with the description of the study population's characteristics in the first section of the results section, as follows:

Women represented 22% of the study population (n=1154) (Table 2). Mean (SD) age at baseline was 37.7 (9.5) years and approximately one third of the patients had a secondary school certificate. Individuals HIV-infected through drug use accounted for 18% of the study patients. At baseline, 44% of all the patients were ARV naive, half were in CDC stage A and more than three quarters (80%) had not experienced opportunistic infections. Furthermore, 94% had a detectable viral load, 36% had a CD4+ cell count <200 cells/mm<sup>3</sup> and 22% were co-infected with HCV. Depressive symptoms were reported at baseline in 38% of the patients. After one year of ART, more than half of the patients (58%) were highly adherent, the median [IQR] number of self-reported symptoms excluding lipodystrophy was 3 [2 to 6], while this value was 0 [0 to 1] for lipodystrophy symptoms. Only 16% of the patients declared smoking more than 20 cigarettes per day at cohort enrolment. Nearly 19% of the patients reported they were alcohol abstainers, three quarters reported moderate alcohol consumption (54% reporting less than 1 AU/day and 21% between 1 and 4(3) AU/day for men(women)), while only a minority of patients (6%) reported elevated alcohol consumption. As the two intermediate categories (≤1 AU/day; >1 and ≤4(3) AU/day for men(women)) had similar estimated Adjusted Hazard Ratios (AHR) and p-values in both multivariate analyses, we decided to aggregate them for model parsimony.

The conclusions about the role of adherence is not clear to me

To be clearer, we modified the abstract and the conclusion of the paper as follows:

Combined interventions to reduce CADE-risk-related behaviours, including adherence counselling to assure long term immunological response to ART in HIV-infected individuals, are now a clinical and public health priority.



**Impact of Immunodepression and Moderate Alcohol Consumption on Coronary and other Arterial Disease Events in an 11-year Cohort of HIV-infected Patients on Antiretroviral Therapy**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001155.R2
Article Type:	Research
Date Submitted by the Author:	07-Sep-2012
Complete List of Authors:	Carrieri, Maria Patrizia Protopopescu, Camelia; INSERM, U912 (SESSTIM), Aix Marseille Univ, IRD, UMR-S912, ORS PACA, Observatoire Régional de la Santé Provence Alpes Côte d'Azur Le Moing, Vincent Reboud, Philippe Raffi, François Mahy, Sophie Roux, Perrine Cuzin, Lise Spire, Bruno Leport, Catherine
<b>Primary Subject Heading</b>:	Infectious diseases
Secondary Subject Heading:	Cardiovascular medicine, HIV/AIDS, Nutrition and metabolism
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Myocardial infarction < CARDIOLOGY, Coronary heart disease < CARDIOLOGY



STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
<b>Title and abstract</b>	1	<p><u>(a) Indicate the study's design with a commonly used term in the title or the abstract "Cohort study."</u></p> <hr/> <p><u>(b) Provide in the abstract an informative and balanced summary of what was done and what was found</u></p> <p>“Objective: To investigate the relationship between response to antiretroviral treatment (ART), alcohol use and occurrence of a major coronary or other arterial disease event (CADE) in HIV-infected individuals.</p> <p>Design: Cohort study. A Cox model was used to identify correlates of a first occurrence of a major CADE.</p> <p>Setting: The French ANRS CO8 APROCO-COPILOTE cohort was set up in 1997 to study clinical progression and patient-reported outcomes (PRO) after initiating protease inhibitor-containing ART. Clinical data were retrieved from medical records. Self-administered questionnaires collected data on PRO and behaviours, including alcohol use.</p> <p>Participants: Metabolic data were only available for a subgroup (n=675) of the study group (n=1154).</p> <p>Main outcomes measures: Major coronary or other arterial disease first event.</p> <p>Results: Over the 11-year follow-up, 49 major CADE were observed, with an incidence rate [95%CI]=0.75[0.57 to 0.99] per 100 person-years. <u>Immunodepression (CD4+ cell count &lt;200 cells/mm<sup>3</sup>)</u> was associated with <u>an increased</u> risk of CADE (Adjusted Hazard Ratio AHR[95% CI]= <u>2.52[1.15 to 5.48]</u>) after adjustment for female gender (0.25[0.08 to 0.83]), age (1.07[1.04 to 1.10]) and smoking&gt;20 cigarettes/day (4.19[2.17 to 8.11]). Moreover, individuals with moderate alcohol consumption (<u>≤4(3) AU/day for men(women)</u>) had a lower risk of CADE (0.38[0.20 to 0.71]) than alcohol abstainers, while the risk for those drinking<u>&gt;4(3) AU/day for men(women)</u> was not significantly different from this latter group. These associations remained valid after adjustment for metabolic disorders. No significant association with exposure to any specific antiretroviral was detected.</p> <p>Conclusions: In the long term, <u>absence of immunodepression</u> and moderate alcohol consumption remain associated with a lower risk of <u>major</u> CADE. Combined interventions to reduce CADE risk-related behaviours <u>including adherence counselling for assuring long term immunological response to ART</u> in HIV-infected individuals are now a clinical and public health priority.”</p>
<b>Introduction</b>		
Background/rationale	2	<p><u>Explain the scientific background and rationale for the investigation being reported</u></p> <p>“Cardiovascular disease risk factors (including for example hypertension and tobacco use), as well as immunological status[1] are major predictors of atherosclerosis in HIV-infected women and men. Although <u>some</u> antiretroviral (ARV) therapy <u>drugs</u>[2-5] have consistently been found to be associated with coronary arterial disease <u>or myocardial infarction (MI)</u> in these patients, more recently Butt and colleagues put into evidence the negative effect of HIV viral replication on heart failure[6]. In one study, patients having experienced <u>a MI</u> presented lower baseline and proximal CD4+ cell counts than those who did not, while no association was found <u>between cardiovascular disease events and</u> specific antiretroviral agents[7]. Moreover, known</p>

factors associated with cardiovascular risk[8] such as hyperlipidemia and insulin resistance[9-11] are becoming an increasingly major clinical concern in ARV-treated individuals.

Though excessive alcohol use may be frequent in HIV-infected individuals, its impact on the occurrence of cardiovascular disease in this population has been less investigated. Excessive alcohol consumption also plays a major role in HIV risk-taking behaviours, particularly in men who have sex with men and drug users[12, 13]. In HIV-infected individuals, excessive alcohol use is known to compromise patients' response to antiretroviral therapy (ART) through reduced adherence[14-17] and to predict HIV progression and increased mortality[18-21], mostly from liver diseases[22-25]. Some recent cross-sectional analyses in HIV-infected and uninfected men have found that heavy alcohol consumption is associated with a higher risk of cardiovascular disease[26, 27]. On the other hand, in uninfected adults, moderate alcohol consumption has been found to be associated with a reduced cardiovascular mortality[28], improved lipid profiles, increased insulin sensitivity and reduced risk of MI[29]. However, this association has not yet been studied in longitudinal studies involving HIV-infected populations including women. Moreover, there are as yet no consistent results in the literature regarding the role that alcohol use plays in exacerbating cardiovascular risk in ARV-treated patients and to what extent it can confound or boost the effect of immuno-virological response to ART, ART-associated dyslipidemia and insulin resistance on the risk of cardiovascular disease events."

Objectives	3	<p><u>State specific objectives, including any prespecified hypotheses</u></p> <p>"We used data from the 11-year follow-up of the APROCO-COPILOTE cohort of patients receiving ART since 1997 to investigate the relationship between viral load, CD4+ cell count, alcohol consumption and the first occurrence of a major coronary or other arterial disease event (CADE), after adjustment for known risk factors including metabolic disorders."</p>
<b>Methods</b>		
Study design	4	<p><u>Present key elements of study design early in the paper</u></p> <p>"The French APROCO-COPILOTE cohort (ANRS CO8) was designed to study the clinical, immunological, virological, and socio-behavioural course of HIV disease in HIV-1 positive individuals who started the first generation of potent ART (treatment regimens including protease inhibitors (PI)). The study was approved by the Ethics Committee of Cochin Hospital (Paris) and informed consent was obtained from all participants."</p>
Setting	5	<p><u>Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection</u></p> <p>"Patients were enrolled in the cohort at their first PI-based ART prescription between May 1997 and June 1999 (n=1281) in 47 French centres, and clinically followed-up every 4 months thereafter, up to month 132 (M132)."</p>
Participants	6	<p><u>(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up</u></p> <p>"In the present study were included all patients who had either two alcohol assessment or one alcohol assessment just preceding the CADE over the whole follow-up (n=1154)."</p>

(b) For matched studies, give matching criteria and number of exposed and unexposed  
[Not applicable.]

Variables	7	<p><u>Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable</u></p> <p><i>“Medical questionnaire</i></p> <p>The medical questionnaire at enrolment (M0) collected retrospective data about patient’s HIV history including HIV transmission category, time since HIV diagnosis, previous exposure to antiretroviral treatment before enrolment, and co-infection with hepatitis C virus (HCV) <u>defined as having positive HCV RNA and/or positive HCV antibodies</u>. This information was complemented by <u>medical questionnaires</u>, completed by the HIV <u>physicians</u> at each follow-up visit, which collected clinical and laboratory data (plasma HIV RNA level, CD4+ cell count, HIV clinical stage, <u>aspartate transaminase (AST) and alanine transaminase (ALT) levels</u>), as well as data on the antiretroviral regimen prescribed. A third form, based on updated medical records, detailed all clinical severe events, including <u>cardiovascular events</u>, occurring during the study period. Information on metabolic disorders was available at M12 for a subset of cohorts’ patients, who participated in a parallel cross-sectional survey, designed to study clinical and laboratory metabolic complications[30]. These “metabolic” data included height, weight, hypertriglyceridemia, hypercholesterolemia, personal history of coronary heart disease (CHD) and hypertension, and finally any family history of CHD.</p> <p><i>Outcome</i></p> <p><u>The details of all clinical severe events, including cardiovascular events, which occurred during follow-up, were obtained from medical records and validated by the cohort’s validation committee[30]. The classification of clinical severe events was based on the 10th Revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10)<sup>1</sup>. An event was considered severe when it required medical intervention, hospitalization, when hospitalization was extended due to the event’s occurrence, when it led to a life-threatening condition, or when it resulted in death. A group of cardiologists specifically validated the events selected as outcomes for this study. Among cardiovascular events, only major CADE were selected for this analysis as follows (listed in singular form): MI, stroke, coronary heart disease, peripheral arterial disease and cardiovascular surgery for coronary disease. We excluded the following from the definition of the outcome: heart failure, cardiac arrhythmia, phlebitis, pulmonary embolism, and peripheral venous diseases to keep only severe or life-threatening cardiovascular events in the analysis.</u></p> <p><i>Self-administered questionnaire</i></p> <p>A self-administered questionnaire collected - at M0, M4, M12 and every 8 months thereafter during the first 5 years of follow-up, then yearly thereafter – data on socio-demographic characteristics including age, gender and educational level. Among other psycho-social and behavioural information, it also collected details on depressive symptoms, tobacco use, alcohol consumption, self-reported ART-related symptoms and adherence to ART.”</p>
Data sources/ measurement	8*	<u>For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is</u>

<sup>1</sup> <http://www.who.int/classifications/icd/en/>

more than one group

“At each follow-up visit, CD4+ cell count was measured by standardized flow cytometry, and plasma HIV RNA levels were measured using the assay routinely available in each participating centre. Immunodepression was defined by CD4+ cell count <200 cells/mm<sup>3</sup>; viral load was classified as detectable if it was greater than the threshold value specific to each centre where the assay was performed. HIV clinical stage was defined using the 1993 Centres for Disease Control and Prevention (CDC) clinical classification system[31].

Serum triglyceride and cholesterol levels were measured after a 12-hour overnight fast. Hypertriglyceridemia was defined as a triglyceride level  $\geq 2.2$  mmol/l, while hypercholesterolemia was defined as a total cholesterol level  $\geq 5.5$  mmol/l.

Depression was measured using the validated French version of the Centre for Epidemiologic Studies Depression Scale (CES-D), which is a 20-item scale commonly used in studies involving HIV-infected patients[32].

Tobacco and alcohol consumption were evaluated during the previous 4 weeks.

Alcohol consumption was assessed using two questions about frequency of consumption and quantity consumed daily, if applicable.

A 13-item scale comprising the French version of the symptom index validated by Justice *et al*[33] and described elsewhere[34] collected information about self-reported symptoms. Five other questions gathered information about adherence to ART, according to the methodology established by the AIDS Clinical Trial Group[35].”

Bias	9	<p><u>Describe any efforts to address potential sources of bias</u></p> <p>“As the results of the analysis on the whole dataset (n=1154) could be affected by the lack of important predictors of CADE like hypertriglyceridemia or hypercholesterolemia, we conducted a secondary analysis on a subset of patients who had additional metabolic disorders data.”</p> <p>[This secondary analysis confirmed the same pattern of predictors of CADE events after adjustment for metabolic disorders.]</p>
Study size	10	<p><u>Explain how the study size was arrived at</u></p> <p>“<u>More specifically</u>, two analyses on <u>the following</u> study populations were performed to study predictors of major CADE:</p> <p>1) First analysis: the study population included all patients who had either two alcohol assessment or one alcohol assessment just preceding the event over the whole follow-up (n=1154). The follow-up period was M0-M132.</p> <p>2) Second analysis: the study population was restricted to the subset of patients with available data on metabolic disorders, measured at M12 (n=675). Consequently, only events occurring after M12 were considered in this second analysis.”</p>
Quantitative variables	11	<p><u>Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why</u></p> <p>“The WHO body mass index (BMI) categories were used in the analysis: underweight and overweight/obese patients were defined respectively as having a BMI lower than 18.5 and greater than 25.</p> <p>A <u>time-varying</u> cumulative measure of time exposure to specific ARV medications (abacavir, efavirenz, nevirapine, lopinavir and protease inhibitors) was computed <u>during which ART included a specific drug from this list</u>, from cohort enrolment to the date of each follow-up visit.</p>

Tobacco consumption was dichotomized in two categories: more than 20 cigarettes/day vs other[36]. The average number of alcohol units (AU) consumed per day[37] was computed using the two questions on alcohol consumption and then recoded in four categories (abstainers;  $\leq 1$  AU/day;  $>1$  and  $\leq 4(3)$  AU/day for men(women);  $>4(3)$  AU/day for men(women)), in order to test a gradient effect. We used information on AST and ALT liver enzymes to test their correlation with alcohol consumption as a validation test of self-reported alcohol consumption. As normal liver enzymes' reference ranges for each laboratory were not available in our data set, we used a universal cut-off of ALT $>50$  units per litre of serum as an indicator of liver injury, and the AST/ALT ratio (in conjunction with ALT $>50$  IU/l) as a marker of possible cirrhosis and/or alcoholic liver disease (for AST/ALT $>1$ ) and advanced alcoholic liver disease (for AST/ALT $>2$ ). We found a positive significant association between excessive alcohol consumption and these two indicators of liver injury (after adjusting for HCV status, see Table 1), which would suggest good accuracy of the self-reported data on alcohol consumption.

Patients were classified as non-adherent if they reported taking less than 100% of prescribed medications during the previous 4 weeks, using a validated algorithm[38]. A patient with a CES-D score value above 17 (men) or 23 (women) was considered as presenting depressive symptoms[39]. ”

[See references in the paper for the reasons of choosing of these categories].

---

Statistical methods	12	<p><u>(a) Describe all statistical methods, including those used to control for confounding</u></p> <p>“Incidence rate of major CADE was computed as the number of cases divided by the number of person-years of follow-up. Follow-up duration was calculated as the difference in days from enrolment to the date of the CADE, death or last visit, whichever occurred first. Follow-up of patients experiencing major CADE was censored after the date of the first CADE. We used a Cox proportional hazards model to identify characteristics associated with the first occurrence of a major CADE. Psychosocial characteristics - depressive symptoms, tobacco and alcohol consumption, self-reported symptoms, CD4+ cell count and viral load - were evaluated at each visit and used as time-varying covariates in the statistical analysis. All the other covariates were used as fixed variables (measured at M0, M1 or M12). For time-varying factors, the last known value was carried forward in the case of missing data at a scheduled visit. In the case of an event occurring between two consecutive follow-up visits, the values for the time-varying variables measured at the visit preceding the event were used. Covariates with a p-value<math>&lt;0.25</math> in univariate Cox analyses were considered eligible for the multivariate Cox model, which was built using a backward <u>stepwise</u> selection procedure based on the Wald test (p<math>&lt;0.05</math>). <u>Interaction effects between the factors of the multivariate final model were tested.</u> The proportional-hazards assumption was verified globally for the multivariate models and separately with respect to each covariate, using both Kaplan-Meier estimates and tests based on Schoenfeld residuals[40]. A residual analysis for outliers' detection was performed and the sensitivity of the model to influential outliers was tested. <u>Several sensitivity analyses were performed. First, we excluded all patients with a history of CHD and re-ran the model to verify whether the pattern of factors would remain unchanged.</u> <u>Second, the patients who died due to alcoholic cirrhosis were excluded from the study.</u> <u>A third analysis was performed separately on the subgroups of patients co-infected with HCV and those not co-infected with HCV.</u></p>
---------------------	----	---

All analyses were performed using Stata Intercooled software, version 12.1.”

---

(b) Describe any methods used to examine subgroups and interactions

“Interaction effects between the factors of the multivariate final Cox model were tested.”

---

(c) Explain how missing data were addressed

“For time-varying factors, the last known value was carried forward in the case of missing data at a scheduled visit.”

---

(d) If applicable, explain how loss to follow-up was addressed

“Follow-up duration was calculated as the difference in days from enrolment to the date of the CADE, death or last visit, whichever occurred first. Follow-up of patients experiencing major CADE was censored after the date of the first CADE.”

[Patients lost to follow-up were dealt as usual in the Cox model (right-censoring).]

---

(e) Describe any sensitivity analyses

“Several sensitivity analyses were performed. First, we excluded all patients with a history of CHD and re-ran the model to verify whether the pattern of factors would remain unchanged.

Second, the patients who died due to alcoholic cirrhosis were excluded from the study. A third analysis was performed separately on the subgroups of patients co-infected with HCV and those not co-infected with HCV.”

---

**Results**

Participants	13*	<p><u>(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed</u></p> <p>“A total of 1154 patients were included in the present study, accounting for 9401 person-visits.”</p> <hr/> <p><u>(b) Give reasons for non-participation at each stage</u></p> <p>“When comparing the study patients (n=1154) with those included in the cohort, but excluded from the study due to missing alcohol data (n=127), no significant difference was found for gender, age at enrolment, antiretroviral naivety, CDC clinical stage, baseline CD4+ cell counts and HIV viral load at M0 (data not shown).”</p> <hr/> <p><u>(c) Consider use of a flow diagram</u></p> <p>[Not done because the graph is very simple.]</p>
Descriptive data	14*	<p><u>(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders</u></p> <p>“The distribution of factors associated with major CADE [...] are reported in Table 2 for the entire study population (n=1154). Table 3 focuses instead on the subset of patients with available data on metabolic disorders (n=675). Women represented 22% of the study population (n=1154) (Table 2). Mean (SD) age at baseline was 37.7 (9.5) years and approximately one third of the patients had a secondary school certificate. Individuals HIV-infected through drug use accounted for 18% of the study patients. At baseline, 44% of all the patients were ARV naive, half</p>



were in CDC stage A and more than three quarters (80%) had not experienced opportunistic infections. Furthermore, 94% had a detectable viral load, 36% had a CD4+ cell count <200 cells/mm<sup>3</sup> and 22% were co-infected with HCV. Depressive symptoms were reported at baseline in 38% of the patients. After one year of ART, more than half of the patients (58%) were highly adherent, the median [IQR] number of self-reported symptoms excluding lipodystrophy was 3 [2 to 6], while this value was 0 [0 to 1] for lipodystrophy symptoms. Only 16% of the patients declared smoking more than 20 cigarettes per day at cohort enrolment. Nearly 19% of the patients reported they were alcohol abstainers, three quarters reported moderate alcohol consumption (54% reporting less than 1 AU/day and 21% between 1 and 4(3) AU/day for men(women)), while only a minority of patients (6%) reported elevated alcohol consumption. As the two intermediate categories (<1 AU/day; >1 and <4(3) AU/day for men(women)) had similar estimated Adjusted Hazard Ratios (AHR) and p-values in both multivariate analyses, we decided to aggregate them for model parsimony.

In the subsample of patients with available metabolic data (Table 3), the majority (73%) had a normal BMI, 17% were classified in the overweight category and a minority was classified in each of the two more extreme categories (6% underweight and 3% obese). About 8% of the patients had hypertriglyceridemia and 6% had hypercholesterolemia at M12. One year after the enrolment in the cohort, 6% of the patients reported a personal history of hypertension. Only 1% and 28% respectively had a personal and family history of CHD.”

---

(b) Indicate number of participants with missing data for each variable of interest [See Tables 2 and 3, second column.]

---

(c) Summarise follow-up time (eg. average and total amount)

“Median [interquartile range (IQR)] duration of follow-up of the selected patients, from their first visit after the ART prescription (M1) until M132, was 5.9 [1.8-9.4] years. During the 11 years of the study, accounting for 6544 person-years, the loss to follow-up rate [95% CI] was 17.6 [16.3 to 18.7] per 100 person-years.”

---

Outcome data	15*	<p><u>Report numbers of outcome events or summary measures over time</u></p> <p>“Over the 11-year follow-up of the cohort, a total of 85 <u>severe cardiovascular events</u> were observed. These included 49 major CADE as follows: myocardial infarction (n=30), coronary heart disease (n=4), stroke (n=7), peripheral arterial disease (n=7) and cardiovascular surgery <u>for coronary disease</u> (n=1). The distribution of the other thirty six <u>severe cardiovascular events</u> was as follows: phlebitis/pulmonary embolism (n=22), cardiomyopathy/congestive heart failure (n=5), cardiac dysrhythmia (n=6), cerebral haemorrhage (n=2) and aortic aneurysm (n=1).</p> <p>The incidence rate [95% CI] of all <u>severe cardiovascular events</u> was 1.3 [1.0 to 1.6] per 100 person-years, while for major CADE the incidence rate was 0.75 [0.57 to 0.99] per 100 person-years. Of the 49 major CADE, 40 occurred after M12.</p> <p>Furthermore, the major CADE incidence over the period M12-M132 was 0.89 [0.66 to 1.22] per 100 person-years.”</p>
Main results	16	<p><u>(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg. 95% confidence interval). Make clear which confounders were adjusted for and why they were included</u></p>

---

“[...] the results of univariate and multivariate Cox models, are reported in Table 2 for the entire study population (n=1154). Table 3 focuses instead on the subset of patients with available data on metabolic disorders (n=675). [...]”

In the entire study group (n=1154), the following factors were found to be independent predictors of major CADE: older age at baseline (AHR[95% CI]=1.07[1.04 to 1.10]), tobacco consumption>20 cigarettes/day (4.19[2.17 to 8.11]) and CD4+ cell count <200 cells/mm<sup>3</sup> ( 2.52[1.15 to 5.48]) (see Table 2). In addition, a negative association was found between female gender and major CADE (0.25[0.08 to 0.83]). After accounting for the effect of age, gender, tobacco consumption and CD4+ cell count <200 cells/mm<sup>3</sup> in the multivariate Cox model, individuals with moderate alcohol consumption (≤4(3) AU/day for men(women)) were at lower risk of major CADE (0.38[0.20 to 0.71]), than alcohol abstainers, while those drinking more than 4(3) AU/day for men(women) were not significantly different from abstainers (p=0.229).

These results remained valid also when the analysis was restricted to the subgroup of patients with available metabolic data and the follow-up period M12-M132. After adjusting for age, tobacco consumption, hypertriglyceridemia and family history of CHD, we consistently found a negative association between moderate alcohol use (0.23[0.11 to 0.49]), and a positive association between CD4+ cell count <200 cells/mm<sup>3</sup> (4.02[1.45 to 11.1]) and major CADE after one year after enrolment (Table 3).”

---

(b) Report category boundaries when continuous variables were categorized

[See Tables 2 and 3 for details.]

---

(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

“The incidence rate [95% CI] of all severe cardiovascular events was 1.3 [1.0 to 1.6] per 100 person-years, while for major CADE the incidence rate was 0.75 [0.57 to 0.99] per 100 person-years. Of the 49 major CADE, 40 occurred after M12. Furthermore, the major CADE incidence over the period M12-M132 was 0.89 [0.66 to 1.22] per 100 person-years.”

---

Other analyses

17

Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

“No significant association was found between time of exposure to different ARV drugs and major CADE. No significant interaction was found between smoking habits and hypertriglyceridemia or personal history of CHD. Furthermore, detectable viral load was not associated with major CADE in univariate or multivariate analyses. For the Cox models fitted in this study, proportional-hazards assumption remained valid, either globally and with respect to each covariate. The residual analysis did not alter the results of the multivariate model.

The sensitivity analyses performed by first excluding patients with a history of CHD (n=7), and then patients who died due to alcoholic cirrhosis (n=6), confirmed the same pattern of risk factors observed for the whole population. The other sensitivity analyses, performed separately on the subgroups of patients with HCV co-infection and on those not co-infected with HCV, revealed the same effect of alcohol consumption on CADE, although some variables among the other factors were less significant for the co-infected patients (results not shown, available on request).”

---



---

**Discussion**


---

1		
2		
3		
4	Key results	18 <u>Summarise key results with reference to study objectives</u>
5		“This longitudinal study clearly confirms that in <u>ARV-treated individuals</u> , proximal
6		CD4+ cell count <u>lower than 200 cells/mm<sup>3</sup></u> remains a <u>risk factor</u> associated with major
7		coronary and other arterial disease events. This result remains valid even after
8		adjustment for metabolic disorders such as hypertriglyceridemia and family history of
9		CHD, the strength of the association remaining unchanged.”
10		
11		
12	Limitations	19 <u>Discuss limitations of the study, taking into account sources of potential bias or</u>
13		<u>imprecision. Discuss both direction and magnitude of any potential bias</u>
14		“Some limitations of this study need to be acknowledged. First, our definition of
15		CADE includes different types of events which might not share the same pattern of
16		risk factors. However, an additional analysis performed on a restricted dataset and
17		which adjusted for other potential risk factors (such as hypertriglyceridemia)
18		confirmed the pattern found in the main analysis.
19		Second, information on alcohol use was mainly based on self-reports and these may
20		tend to underestimate alcohol consumption. However, it has been reported that HIV-
21		HCV co-infected patients tend to underreport alcohol use more to their hepatologist
22		than to other physicians[60]. As our patients were all followed-up by HIV physicians,
23		it is likely that the degree of underreporting did not greatly affect hazard ratios’
24		estimates. <u>Moreover, the association found between the excessive alcohol</u>
25		<u>consumption and the biomarkers of alcoholic liver injury indicate a good accuracy of</u>
26		<u>self-reported data on alcohol consumption.</u>
27		<u>Then, the fact that excessive alcohol users exhibit similar HRs to abstainers may be</u>
28		<u>also attributable to the two following reasons. First, some individuals with excessive</u>
29		<u>alcohol consumption may have died due to liver failure before experiencing a</u>
30		<u>cardiovascular event and this could have reduced the impact of excessive alcohol use</u>
31		<u>on CADE. However, when we performed a sensitivity analysis excluding patients who</u>
32		<u>died due to alcoholic cirrhosis, the results remained unchanged. Second, a proportion</u>
33		<u>of abstainers may have been past (heavy) alcohol users and may have had to stop</u>
34		<u>drinking for health reasons. Unfortunately, we do not have information about alcohol</u>
35		<u>use before the beginning of the cohort, or about diagnosis of alcoholism or reasons for</u>
36		<u>quitting alcohol.</u>
37		<u>Finally, it would have been interesting to compute the Framingham risk score[61] and</u>
38		<u>use it as a covariate in the multivariate model. Unfortunately, as our study was not</u>
39		<u>initially designed to thoroughly assess the impact of all possible CHD risk factors,</u>
40		<u>some of the variables used in the construction of this score (such as treated and</u>
41		<u>untreated systolic blood pressure, as well as total and high-density lipoprotein</u>
42		<u>cholesterol) were not available during the two first years of our study. Moreover, our</u>
43		<u>results showed a different pattern of factors than those found in the Framingham study</u>
44		<u>(some of the traditional risk factors, such as BMI and hypercholesterolemia, were not</u>
45		<u>significant), so using this score would have been less informative than using all the</u>
46		<u>factors separately.”</u>
47		
48		
49		
50		
51		
52		
53		
54		
55		
56	Interpretation	20 <u>Give a cautious overall interpretation of results considering objectives, limitations,</u>
57		<u>multiplicity of analyses, results from similar studies, and other relevant evidence</u>
58		“The relationship between CADE and CD4+ cell count, in addition to the lack of
59		association between CADE and specific ARV classes, confirms previous results[7]
60		

1 where the association between exposure to certain ARV and CADE was no longer  
2 evident after controlling for traditional risk factors and HIV disease markers. Indeed,  
3 the association between specific ARV drugs and major CADE, like myocardial  
4 infarctus, has been shown in very powerful studies[5], where adjustment for nadir  
5 CD4+ lymphocyte count or peak HIV-1 RNA level did not modify the results.  
6 However, in the study cited, no adjustment for proximal CD4+ cell count was  
7 performed, and the association with the class of ARV became weaker after adjustment  
8 for serum lipid levels[5]. Indeed, although ART may modify lipid levels and increase  
9 the risk of CADE, it may also reduce this risk by reducing HIV-associated  
10 inflammation following long-term suppression of HIV replication[41]. The lack of  
11 association with exposure to some specific ARV classes in the present study, factors  
12 usually associated with an increased risk of CADE[42, 43], suggests that reduced  
13 immunological response to ART over a long follow-up, as well as known CADE risk  
14 factors may have a more important impact than exposure to a specific antiretroviral  
15 drug.  
16

17 It is also possible that patients with altered lipid profiles were switched to other  
18 classes of antiretroviral drugs during the follow-up. As a consequence, in the long  
19 term, CD4+ cell count <200 cells/mm<sup>3</sup> remain a correlate of an increased risk of  
20 CADE, whatever the antiretroviral received.

21 In our study, individuals reporting elevated alcohol consumption exhibited the same  
22 risk of CADE as alcohol abstainers. In contrast, those reporting moderate alcohol  
23 consumptions had a lower risk. This result was confirmed after adjustment for  
24 additional risk factors including tobacco use, age, gender and CD4+ cell count. This  
25 relationship between alcohol consumption and CADE remained significant and J-  
26 shaped, even after adjustment for data on metabolic risk factors- such as having a  
27 history of CHD and hypertriglyceridemia -which was available for a subset of  
28 patients. As highlighted in previous observations in the general population[28, 44-47]  
29 and certain populations affected by other diseases[48], these results confirmed that the  
30 increased risk of CADE in HIV-infected patients receiving ART is not attributable to  
31 elevated alcohol use. Furthermore, we highlighted the apparent protective effect of  
32 moderate alcohol consumption in ART treated HIV-infected patients.  
33

34 It is important to note that after the introduction of ART in 1996, the sudden decrease  
35 observed in HIV-related mortality was nonetheless accompanied by a relative increase  
36 of non-HIV based mortality as a part of the total mortality of HIV-infected patients  
37 [49], cardiovascular diseases becoming increasingly important. This increase can be  
38 explained firstly by a reduction in the competing role of HIV-related mortality, which  
39 in the long term was much more detrimental to health than other causes of deaths.  
40 Secondly, the high prevalence in this population of other risk factors like tobacco use,  
41 together with ART-related morbidity including altered lipid profiles and triglycerides,  
42 may contribute to an increased risk of CADE.  
43

44 The association found in our study between moderate alcohol use and reduced CADE  
45 risk is not consistent with all previous research in HIV-infected patients. Freiberg *et*  
46 *al*[26] pointed out that among HIV-infected men in the US, hazardous drinking and  
47 both alcohol abuse and dependence were associated with a higher prevalence of  
48 cardiovascular disease compared with infrequent and moderate drinking, even after  
49 adjusting for traditional risk factors, antiretroviral therapy and CD4+ cell count. This  
50 difference in the results may be due to the different design of the two studies  
51 (longitudinal for ours *vs* cross-sectional for Freiberg's), but probably also to the  
52 different types of alcohol mainly consumed in the two populations, red wine  
53  
54  
55  
56  
57  
58  
59  
60

consumption being more widespread in France than in the US. This difference in the pattern of alcohol use has already been highlighted in a comparative study on cardiovascular disease in non HIV-infected Irish and French males, showing an increased protective effect of drinking red wine in the latter population[50]. Increased wine consumption probably brings about an increase in high-density lipoprotein cholesterol levels, which helps protect against cardiovascular events. On the other hand, beer and spirits consumption are linked to increased triglyceride levels[51]. We do not know to what extent moderate alcohol users are representative of a population with better health status as alcohol use in France is relatively frequent in the general population and this fact may increase the strength of the association found.

Another possible hypothesis is that excessive alcohol consumption can increase inflammatory markers' levels[52], which in turn probably leads to a higher risk of CADE and premature aging in HIV patients. However, this hypothesis was not demonstrated in a study conducted in older adults without cardiovascular disease, where alcohol intake was found to be associated with lower levels of inflammatory markers[53]. In the meantime it is important to remember that individuals with immune suppression are at a greater risk of cancer, a disease whose pattern of risk factors also include alcohol use, even when moderate[54].

Tobacco smoking has consistently been found to be a major risk factor for cardiovascular disease[55]. Smoking prevalence and dependence in HIV-infected patients is higher than in the general population[56]. Effective interventions for reducing and quitting smoking[57], especially for patients with several risk factors, are strongly recommended especially considering the increased cardiovascular risk which exists in HIV-infected smokers receiving ART[58]. However, results from studies reporting on the effectiveness of interventions for quitting smoking in HIV-infected individuals are inconsistent[59].

It is worth noting the lack of association between hypercholesterolemia and the risk of CADE in our study. This result suggests that HIV physicians need to be cautious about basing clinical decisions merely upon measured lipid levels in HIV-infected patients. Other risk factors, including behavioural ones, deserve greater consideration for clinical management."

---

Generalisability	21	<p><u>Discuss the generalisability (external validity) of the study results</u></p> <p>“This cohort is representative of the first generation of patients receiving potent ART. As cardiovascular disease is a rising issue in all HIV-infected populations receiving ART, these results can give important information about the pattern of risk and protective factors in all treated HIV-infected populations.</p> <p>In conclusion, in the long term, absence of immunodepression and moderate alcohol consumption remain associated with a lower risk of major CADE. Combined interventions to reduce CADE-risk-related behaviours including adherence counselling to assure long term immunological response to ART in HIV-infected individuals are now a clinical and public health priority.”</p>
------------------	----	---

---

#### **Other information**

Funding	22	<p><u>Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based</u></p> <p>“Funding sources: The ANRS CO8 (APROCO/COPILOTE) cohort is funded by ANRS (Agence Nationale de Recherches sur le Sida et les hépatites virales) and CMIT (Collège des Universitaires de Maladies Infectieuses et Tropicales), which</p>
---------	----	--

---

---

1 received research grants from Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb,  
2 GlaxoSmithKline, Gilead Sciences, Pfizer and Roche.  
3 The funders were responsible for initiating, managing and financing the cohort, but  
4 did not interfere with data analysis and interpretation and dissemination of the  
5 scientific results.”  
6  
7

---

8  
9 \*Give information separately for exposed and unexposed groups.  
10

11 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and  
12 published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely  
13 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at  
14 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is  
15 available at <http://www.strobe-statement.org>.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Impact of Immunodepression and Moderate Alcohol Consumption on Coronary and**  
4 **other Arterial Disease Events in an 11-year Cohort of HIV-infected Patients on**  
5 **Antiretroviral Therapy**  
6  
7  
8

9  
10  
11  
12  
13 **Maria Patrizia Carrieri<sup>1,2,3\*</sup>, Camelia Protopopescu<sup>1,2,3\*§</sup>, Vincent Le Moing<sup>4</sup>, Philippe**  
14 **Reboud<sup>5</sup>, François Raffi<sup>6</sup>, Sophie Mahy<sup>7</sup>, Perrine Roux<sup>1,8</sup>, Lise Cuzin<sup>9</sup>, Bruno Spire<sup>1,2,3</sup>,**  
15 **Catherine Leport<sup>10,11</sup> and the ANRS CO8 APROCO-COPILOTE Study Group**  
16  
17  
18  
19

20  
21 \* Equal contribution  
22  
23  
24  
25  
26

27 <sup>1</sup> *INSERM, U912 (SESSTIM), Marseille, France*  
28

29 <sup>2</sup> *Aix Marseille Univ, IRD, UMR-S912, Marseille, France*  
30

31 <sup>3</sup> *ORS PACA, Observatoire Régional de la Santé Provence Alpes Côte d'Azur, Marseille,*  
32 *France*  
33

34 <sup>4</sup> *Service de Maladies Infectieuses et Tropicales, CHU de Montpellier, UMI 233 TransVIHMI,*  
35 *IRD, Université Montpellier 1, Montpellier, France*  
36  
37

38 <sup>5</sup> *INSERM, U897; Université Bordeaux Segalen, ISPED, Bordeaux, France*  
39

40 <sup>6</sup> *CHU Hôtel-Dieu, Nantes, France*  
41

42 <sup>7</sup> *CHU de Dijon, Université de Bourgogne, Dijon, France*  
43  
44

45 <sup>8</sup> *Substance Use Research Center, NYSPI, Columbia University, New York, USA*  
46  
47

48 <sup>9</sup> *Service de Maladies Infectieuses et Tropicales, CHU Purpan, Toulouse, France*  
49

50 <sup>10</sup> *Université Paris Diderot, Sorbonne Paris Cité, UMR 738, Paris, France*  
51

52 <sup>11</sup> *INSERM, UMR 738, Paris, France*  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 § Corresponding author address: INSERM U912 – ORS PACA, 23 rue Stanislas Torrents,  
4  
5 13006 Marseille, France

6  
7 📞: +33 4 96 10 28 80    📠: + 33 4 96 10 28 99    @: camelia.protopopescu@inserm.fr  
8  
9

10  
11  
12 *Abstract word count: 285 words*

13  
14  
15 *Text word count: 4548 words*  
16  
17

18  
19  
20  
21 **Funding sources:** The ANRS CO8 (APROCO/COPILOTE) cohort is funded by ANRS  
22 (Agence Nationale de Recherches sur le Sida et les hépatites virales) and CMIT (Collège des  
23 Universitaires de Maladies Infectieuses et Tropicales), which received research grants from  
24 Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences,  
25 Pfizer and Roche.  
26  
27

28  
29  
30  
31  
32 The funders were responsible for initiating, managing and financing the cohort, but did not  
33 interfere with data analysis and interpretation and dissemination of the scientific results.  
34  
35

36  
37  
38 **Competing interests:** All authors have completed the Unified Competing Interest form at  
39 [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) <[http://www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf)> (available on  
40 request from the corresponding author) and declare that (1) they have no support from any  
41 company for the submitted work; (2) they have no relationships with any company that might  
42 have an interest in the submitted work in the previous 3 years; (3) their spouses, partners, or  
43 children have no financial relationships that may be relevant to the submitted work; and (4)  
44 they have no non-financial interests that may be relevant to the submitted work.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Exclusive licence:** The Corresponding Author has the right to grant on behalf of all authors  
4 and does grant on behalf of all authors, an exclusive licence (or non exclusive for government  
5 employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to  
6 permit this article (if accepted) to be published in BMJ editions and any other BMJPG  
7 products and sublicences to exploit all subsidiary rights, as set out in our licence  
8 (<http://resources.bmj.com/bmj/authors/checklists-forms/licence-for-publication>).  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

20 **Data sharing:** There is no additional data available.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Summary

### Article Focus

- Major coronary or other arterial disease events (CADE) are frequent in HIV-infected individuals receiving antiretroviral therapy.
- While some antiretroviral classes can increase the risk of CADE, it is still controversial to what extent immune reconstitution and other factors like moderate alcohol consumption can reduce the risk of CADE in this population.

### Key Messages

- Moderate alcohol consumption and absence of immunodepression can be beneficial to reduce the risk of CADE in HIV-infected patients.
- Reduced immunological response to antiretroviral treatment (ART) over a long follow-up may have a more important impact on CADE than exposure to a specific antiretroviral drug.

### Strengths and Limitations

- This paper suggests the importance of combined risk reduction interventions including adherence counselling for assuring long term immunological response and decrease the risk of CADE.

### Short title

**CD4+, Moderate Alcohol Consumption and Coronary Events in HIV-infected patients**

**Abstract**

**Objective:** To investigate the relationship between response to antiretroviral treatment (ART), alcohol use and occurrence of a major coronary or other arterial disease event (CADE) in HIV-infected individuals.

**Design:** Cohort study. A Cox model was used to identify correlates of a first occurrence of a major CADE.

**Setting:** The French ANRS CO8 APROCO-COPILOTE cohort was set up in 1997 to study clinical progression and patient-reported outcomes (PRO) after initiating protease inhibitor-containing ART. Clinical data were retrieved from medical records. Self-administered questionnaires collected data on PRO and behaviours, including alcohol use.

**Participants:** Metabolic data were only available for a subgroup (n=675) of the study group (n=1154).

**Main outcomes measures:** Major coronary or other arterial disease first event.

**Results:** Over the 11-year follow-up, 49 major CADE were observed, with an incidence rate [95%CI]=0.75[0.57 to 0.99] per 100 person-years. Immunodepression (CD4+ cell count <200 cells/mm<sup>3</sup>) was associated with an increased risk of CADE (Adjusted Hazard Ratio AHR[95% CI]= 2.52[1.15 to 5.48]) after adjustment for female gender (0.25[0.08 to 0.83]), age (1.07[1.04 to 1.10]) and smoking>20 cigarettes/day (4.19[2.17 to 8.11]). Moreover, individuals with moderate alcohol consumption ( $\leq 4(3)$  AU/day for men(women)) had a lower risk of CADE (0.38[0.20 to 0.71]) than alcohol abstainers, while the risk for those drinking>4(3) AU/day for men(women) was not significantly different from this latter group. These associations remained valid after adjustment for metabolic disorders. No significant association with exposure to any specific antiretroviral was detected.

1  
2  
3 **Conclusions:** In the long term, absence of immunodepression and moderate alcohol  
4  
5 consumption remain associated with a lower risk of major CADE. Combined interventions to  
6  
7 reduce CADE risk-related behaviours including adherence counselling for assuring long term  
8  
9 immunological response to ART in HIV-infected individuals are now a clinical and public  
10  
11 health priority.  
12

13  
14  
15  
16  
17  
18 **Key words:** Coronary and other arterial disease events, Alcohol, CD4+ cell count, HIV,  
19  
20 ARV.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Cardiovascular disease risk factors (including for example hypertension and tobacco use), as well as immunological status[1] are major predictors of atherosclerosis in HIV-infected women and men. Although some antiretroviral (ARV) therapy drugs[2-5] have consistently been found to be associated with coronary arterial disease or myocardial infarction (MI) in these patients, more recently Butt and colleagues put into evidence the negative effect of HIV viral replication on heart failure[6]. In one study, patients having experienced a MI presented lower baseline and proximal CD4+ cell counts than those who did not, while no association was found between cardiovascular disease events and specific antiretroviral agents[7]. Moreover, known factors associated with cardiovascular risk[8] such as hyperlipidemia and insulin resistance[9-11] are becoming an increasingly major clinical concern in ARV-treated individuals.

Though excessive alcohol use may be frequent in HIV-infected individuals, its impact on the occurrence of cardiovascular disease in this population has been less investigated. Excessive alcohol consumption also plays a major role in HIV risk-taking behaviours, particularly in men who have sex with men and drug users[12, 13]. In HIV-infected individuals, excessive alcohol use is known to compromise patients' response to antiretroviral therapy (ART) through reduced adherence[14-17] and to predict HIV progression and increased mortality[18-21], mostly from liver diseases[22-25]. Some recent cross-sectional analyses in HIV-infected and uninfected men have found that heavy alcohol consumption is associated with a higher risk of cardiovascular disease[26, 27]. On the other hand, in uninfected adults, moderate alcohol consumption has been found to be associated with a reduced cardiovascular mortality[28], improved lipid profiles, increased insulin sensitivity and reduced risk of MI[29]. However, this association has not yet been studied in longitudinal studies involving HIV-infected populations including women. Moreover, there are as yet no consistent results

1  
2  
3 in the literature regarding the role that alcohol use plays in exacerbating cardiovascular risk in  
4  
5 ARV-treated patients and to what extent it can confound or boost the effect of immuno-  
6  
7 virological response to ART, ART-associated dyslipidemia and insulin resistance on the risk  
8  
9 of cardiovascular disease events.  
10

11  
12 We used data from the 11-year follow-up of the APROCO-COPILOTE cohort of patients  
13  
14 receiving ART since 1997 to investigate the relationship between viral load, CD4+ cell count,  
15  
16 alcohol consumption and the first occurrence of a major coronary or other arterial disease  
17  
18 event (CADE), after adjustment for known risk factors including metabolic disorders.  
19  
20

## 21 22 23 24 **Methods**

25  
26  
27 The French APROCO-COPILOTE cohort (ANRS CO8) was designed to study the clinical,  
28  
29 immunological, virological, and socio-behavioural course of HIV disease in HIV-1 positive  
30  
31 individuals who started the first generation of potent ART (treatment regimens including  
32  
33 protease inhibitors (PI)). The study was approved by the Ethics Committee of Cochin  
34  
35 Hospital (Paris) and informed consent was obtained from all participants.  
36  
37

### 38 39 *Setting*

40  
41  
42 Patients were enrolled in the cohort at their first PI-based ART prescription between May  
43  
44 1997 and June 1999 (n=1281) in 47 French centres, and clinically followed-up every 4  
45  
46 months thereafter, up to month 132 (M132).  
47

### 48 49 *Patients*

50  
51  
52 In the present study were included all patients who had either two alcohol assessment or one  
53  
54 alcohol assessment just preceding the CADE over the whole follow-up (n=1154).  
55  
56  
57  
58  
59  
60

### *Medical questionnaire*

The medical questionnaire at enrolment (M0) collected retrospective data about patient's HIV history including HIV transmission category, time since HIV diagnosis, previous exposure to antiretroviral treatment before enrolment, and co-infection with hepatitis C virus (HCV) defined as having positive HCV RNA and/or positive HCV antibodies. This information was complemented by medical questionnaires, completed by the HIV physicians at each follow-up visit, which collected clinical and laboratory data (plasma HIV RNA level, CD4+ cell count, HIV clinical stage, aspartate transaminase (AST) and alanine transaminase (ALT) levels), as well as data on the antiretroviral regimen prescribed. A third form, based on updated medical records, detailed all clinical severe events, including cardiovascular events, occurring during the study period. Information on metabolic disorders was available at M12 for a subset of cohorts' patients, who participated in a parallel cross-sectional survey, designed to study clinical and laboratory metabolic complications[30]. These "metabolic" data included height, weight, hypertriglyceridemia, hypercholesterolemia, personal history of coronary heart disease (CHD) and hypertension, and finally any family history of CHD.

At each follow-up visit, CD4+ cell count was measured by standardized flow cytometry, and plasma HIV RNA levels were measured using the assay routinely available in each participating centre. Immunodepression was defined by CD4+ cell count  $<200$  cells/mm<sup>3</sup>; viral load was classified as detectable if it was greater than the threshold value specific to each centre where the assay was performed and to each period. The detectability threshold of the viral load ranged from 20 to 500 copies/ml for the M0-M20 period and from 20 to 400 copies/ml for the rest of the follow-up. HIV clinical stage was defined using the 1993 Centres for Disease Control and Prevention (CDC) clinical classification system[31].

1  
2  
3 Serum triglyceride and cholesterol levels were measured after a 12-hour overnight fast.

4  
5 Hypertriglyceridemia was defined as a triglyceride level  $\geq 2.2$  mmol/l, while

6  
7 hypercholesterolemia was defined as a total cholesterol level  $\geq 5.5$  mmol/l.

8  
9  
10 *Outcome*

11  
12 The details of all clinical severe events, including cardiovascular events, which occurred

13  
14 during follow-up, were obtained from medical records and validated by the cohort's

15  
16 validation committee[30]. The classification of clinical severe events was based on the 10th

17  
18 Revision of the International Statistical Classification of Diseases and Related Health

19  
20 Problems (ICD-10)<sup>i</sup>. An event was considered severe when it required medical intervention,

21  
22 hospitalization, when hospitalization was extended due to the event's occurrence, when it led

23  
24 to a life-threatening condition, or when it resulted in death. A group of cardiologists

25  
26 specifically validated the events selected as outcomes for this study. Among cardiovascular

27  
28 events, only major CADE were selected for this analysis as follows (listed in singular form):

29  
30 MI, stroke, coronary heart disease, peripheral arterial disease and cardiovascular surgery for

31  
32 coronary disease. We excluded the following from the definition of the outcome: heart failure,

33  
34 cardiac arrhythmia, phlebitis, pulmonary embolism, and peripheral venous diseases to keep

35  
36 only severe or life-threatening cardiovascular events in the analysis.

37  
38  
39 *Self-administered questionnaire*

40  
41 A self-administered questionnaire collected - at M0, M4, M12 and every 8 months thereafter

42  
43 during the first 5 years of follow-up, then yearly thereafter – data on socio-demographic

44  
45 characteristics including age, gender and educational level. Among other psycho-social and

46  
47 behavioural information, it also collected details on depressive symptoms, tobacco use,

48  
49 alcohol consumption, self-reported ART-related symptoms and adherence to ART.

50  
51  
52  
53  
54  
55  
56  
57  
58 <sup>i</sup> <http://www.who.int/classifications/icd/en/>



1  
2  
3 Depression was measured using the validated French version of the Centre for Epidemiologic  
4  
5 Studies Depression Scale (CES-D), which is a 20-item scale commonly used in studies  
6  
7 involving HIV-infected patients[32].  
8  
9

10 Tobacco and alcohol consumption were evaluated during the previous 4 weeks. Alcohol  
11  
12 consumption was assessed using two questions about frequency of consumption and quantity  
13  
14 consumed daily, if applicable.  
15  
16

17  
18 A 13-item scale comprising the French version of the symptom index validated by Justice *et*  
19  
20 *al*[33] and described elsewhere[34] collected information about self-reported symptoms. Five  
21  
22 other questions gathered information about adherence to ART, according to the methodology  
23  
24 established by the AIDS Clinical Trial Group[35].  
25  
26

### 27 *Statistical analysis*

28  
29  
30 As the results of the analysis on the whole dataset (n=1154) could be affected by the lack of  
31  
32 important predictors of CADE like hypertriglyceridemia or hypercholesterolemia, we  
33  
34 conducted a secondary analysis on a subset of patients who had additional metabolic disorders  
35  
36 data. More specifically, two analyses on the following study populations were performed to  
37  
38 study predictors of major CADE:  
39  
40

41  
42 1) First analysis: the study population included all patients who had either two alcohol  
43  
44 assessment or one alcohol assessment just preceding the event over the whole follow-up  
45  
46 (n=1154). The follow-up period was M0-M132.  
47  
48

49  
50 2) Second analysis: the study population was restricted to the subset of patients with available  
51  
52 data on metabolic disorders, measured at M12 (n=675). Consequently, only events occurring  
53  
54 after M12 were considered in this second analysis.  
55  
56  
57  
58  
59  
60

1  
2  
3 The WHO body mass index (BMI) categories were used in the analysis: underweight and  
4  
5 overweight/obese patients were defined respectively as having a BMI lower than 18.5 and  
6  
7 greater than 25.  
8  
9

10 A time-varying cumulative measure of time exposure to specific ARV medications (abacavir,  
11  
12 efavirenz, nevirapine, lopinavir and protease inhibitors) was computed during which ART  
13  
14 included a specific drug from this list, from cohort enrolment to the date of each follow-up  
15  
16 visit.  
17  
18

19  
20 CD4+ cell count was tested either as a continuous variable or recoded in categories. The  
21  
22 dichotomous variable using the cut-off of 200 cells/mm<sup>3</sup> was found to be the most predictive  
23  
24 of the outcome (using Cox models and bias corrected Akaike's information criterion  
25  
26 AICc[36].  
27  
28

29 Tobacco consumption was dichotomized in two categories: more than 20 cigarettes/day vs  
30  
31 other[37]. The average number of alcohol units (AU) consumed per day[38] was computed  
32  
33 using the two questions on alcohol consumption and then recoded in four categories  
34  
35 (abstainers;  $\leq 1$  AU/day;  $> 1$  and  $\leq 4(3)$  AU/day for men(women);  $> 4(3)$  AU/day for  
36  
37 men(women)), in order to test a gradient effect. We used information on AST and ALT liver  
38  
39 enzymes to test their correlation with alcohol consumption as a validation test of self-reported  
40  
41 alcohol consumption. As normal liver enzymes' reference ranges for each laboratory were not  
42  
43 available in our data set, we used a universal cut-off of ALT $> 50$  units per litre of serum as an  
44  
45 indicator of liver injury, and the AST/ALT ratio (in conjunction with ALT $> 50$  IU/l) as a  
46  
47 marker of possible cirrhosis and/or alcoholic liver disease (for AST/ALT $> 1$ ) and advanced  
48  
49 alcoholic liver disease (for AST/ALT $> 2$ ). We found a positive significant association between  
50  
51 excessive alcohol consumption and these two indicators of liver injury (after adjusting for  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 HCV status, see Table 1), which would suggest good accuracy of the self-reported data on  
4  
5 alcohol consumption.  
6

7  
8 Patients were classified as non-adherent if they reported taking less than 100% of prescribed  
9  
10 medications during the previous 4 weeks, using a validated algorithm[39]. A patient with a  
11  
12 CES-D score value above 17 (men) or 23 (women) was considered as presenting depressive  
13  
14 symptoms[40].  
15

16  
17 Incidence rate of major CADE was computed as the number of cases divided by the number  
18  
19 of person-years of follow-up. Follow-up duration was calculated as the difference in days  
20  
21 from enrolment to the date of the CADE, death or last visit, whichever occurred first. Follow-  
22  
23 up of patients experiencing major CADE was censored after the date of the first CADE. We  
24  
25 used a Cox proportional hazards model to identify characteristics associated with the first  
26  
27 occurrence of a major CADE. Psychosocial characteristics - depressive symptoms, tobacco  
28  
29 and alcohol consumption, self-reported symptoms, CD4+ cell count and viral load - were  
30  
31 evaluated at each visit and used as time-varying covariates in the statistical analysis. All the  
32  
33 other covariates were used as fixed variables (measured at M0, M1 or M12). For time-varying  
34  
35 factors, the last known value was carried forward in the case of missing data at a scheduled  
36  
37 visit. In the case of an event occurring between two consecutive follow-up visits, the values  
38  
39 for the time-varying variables measured at the visit preceding the event were used. Covariates  
40  
41 with a p-value<0.25 in univariate Cox analyses were considered eligible for the multivariate  
42  
43 Cox model. Three building strategies for the final model were compared: a backward stepwise  
44  
45 selection procedure based on the Wald test (p<0.05), a selection procedure based on the  
46  
47 second-order or bias-corrected Akaike's information criterion AICc[36], and finally a  
48  
49 selection procedure based on the Schwartz Bayesian information criterion BIC[41]. All three  
50  
51 strategies selected the same final multivariate model. Interaction effects between the factors of  
52  
53 the multivariate final model were tested. The proportional-hazards assumption was verified  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 globally for the multivariate models and separately with respect to each covariate, using both  
4  
5 Kaplan-Meier estimates and tests based on Schoenfeld residuals[42]. A residual analysis for  
6  
7 outliers' detection was performed and the sensitivity of the model to influential outliers was  
8  
9 tested.

10  
11  
12 Several sensitivity analyses were performed. First, we excluded all patients with a history of  
13  
14 CHD and re-ran the model to verify whether the pattern of factors would remain unchanged.

15  
16  
17 Second, the patients who died due to alcoholic cirrhosis were excluded from the study. A third  
18  
19 analysis was performed separately on the subgroups of patients co-infected with HCV and  
20  
21 those not co-infected with HCV.  
22  
23

24  
25 All analyses were performed using Stata Intercooled software, version 12.1.  
26  
27  
28  
29  
30

## 31 **Results**

32  
33  
34 A total of 1154 patients were included in the present study, accounting for 9401 person-visits.  
35  
36 When comparing the study patients (n=1154) with those included in the cohort, but excluded  
37  
38 from the study due to missing alcohol data (n=127), no significant difference was found for  
39  
40 gender, age at enrolment, antiretroviral naivety, CDC clinical stage, baseline CD4+ cell  
41  
42 counts and HIV viral load at M0 (data not shown).  
43  
44

45  
46 Median [interquartile range (IQR)] duration of follow-up of the selected patients, from their  
47  
48 first visit after the ART prescription (M1) until M132, was 5.9 [1.8-9.4] years. The loss to  
49  
50 follow-up of the cohort was 0.14% at M12, 0.31% at M36, 0.44% at M60 and 0.76% at  
51  
52 M120.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Over the 11-year follow-up of the cohort, a total of 85 severe cardiovascular events were  
4  
5 observed. These included 49 major CADE as follows: myocardial infarction (n=30), coronary  
6  
7 heart disease (n=4), stroke (n=7), peripheral arterial disease (n=7) and cardiovascular surgery  
8  
9 for coronary disease (n=1). The distribution of the other thirty six severe cardiovascular  
10  
11 events was as follows: phlebitis/pulmonary embolism (n=22), cardiomyopathy/congestive  
12  
13 heart failure (n=5), cardiac dysrhythmia (n=6), cerebral haemorrhage (n=2) and aortic  
14  
15 aneurysm (n=1).  
16  
17

18  
19 The incidence rate [95% CI] of all severe cardiovascular events was 1.3 [1.0 to 1.6] per 100  
20  
21 person-years, while for major CADE the incidence rate was 0.75 [0.57 to 0.99] per 100  
22  
23 person-years. Of the 49 major CADE, 40 occurred after M12. Furthermore, the major CADE  
24  
25 incidence over the period M12-M132 was 0.89 [0.66 to 1.22] per 100 person-years.  
26  
27

28  
29 The distribution of factors associated with major CADE, as well as the results of univariate  
30  
31 and multivariate Cox models, are reported in Table 2 for the entire study population (n=1154).  
32  
33 Table 3 focuses instead on the subset of patients with available data on metabolic disorders  
34  
35 (n=675).  
36  
37

38  
39 Women represented 22% of the study population (n=1154) (Table 2). Mean (SD) age at  
40  
41 baseline was 37.7 (9.5) years and approximately one third of the patients had a secondary  
42  
43 school certificate. Individuals HIV-infected through injecting drug use accounted for 18% of  
44  
45 the study patients. At baseline, 44% of all the patients were ARV naive, half were in CDC  
46  
47 stage A, more than three quarters (80%) had not experienced opportunistic infections and  
48  
49 22% were co-infected with HCV. The selected patients had a detectable viral load at 43% of  
50  
51 the follow-up visits, had a CD4+ cell count <200 cells/mm<sup>3</sup> at 14% and reported depressive  
52  
53 symptoms at 32% of them. The median [IQR] of CD4+ cell count was 442 [284-633]  
54  
55 cells/mm<sup>3</sup> during the follow-up. During ART, more than half of the patients (63%) were  
56  
57  
58  
59  
60

1  
2  
3 highly adherent, and after one year of ART the median [IQR] number of self-reported  
4 symptoms excluding lipodystrophy was 4 [2 to 7], while this value was 1 [0 to 5] for  
5 lipodystrophy symptoms. Only 16% of the patients declared smoking more than 20 cigarettes  
6 per day during cohort follow-up. Nearly 19% of the patients reported they were alcohol  
7 abstainers, three quarters reported moderate alcohol consumption (59% reporting less than 1  
8 AU/day and 18% between 1 and 4(3) AU/day for men(women)), while only a minority of  
9 patients (4%) reported elevated alcohol consumption. As the two intermediate categories ( $\leq 1$   
10 AU/day;  $>1$  and  $\leq 4(3)$  AU/day for men(women)) had similar estimated Adjusted Hazard  
11 Ratios (AHR) and p-values in both multivariate analyses, we decided to aggregate them for  
12 model parsimony.

13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26 In the subsample of patients with available metabolic data (Table 3), the majority (73%) had a  
27 normal BMI, 17% were classified in the overweight category and a minority was classified in  
28 each of the two more extreme categories (6% underweight and 3% obese). About 8% of the  
29 patients had hypertriglyceridemia and 6% had hypercholesterolemia at M12. One year after  
30 the enrolment in the cohort, 6% of the patients reported a personal history of hypertension.  
31  
32  
33  
34  
35  
36  
37 Only 1% and 28% respectively had a personal and family history of CHD.

38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
In the entire study group (n=1154), the following factors were found to be independent  
predictors of major CADE: older age at baseline (AHR[95% CI]=1.07[1.04 to 1.10]), tobacco  
consumption  $>20$  cigarettes/day (4.19[2.17 to 8.11]) and CD4+ cell count  $<200$  cells/mm<sup>3</sup> (  
2.52[1.15 to 5.48]) (see Table 2). In addition, a negative association was found between  
female gender and major CADE (0.25[0.08 to 0.83]). After accounting for the effect of age,  
gender, tobacco consumption and CD4+ cell count  $<200$  cells/mm<sup>3</sup> in the multivariate Cox  
model, individuals with moderate alcohol consumption ( $\leq 4(3)$  AU/day for men(women)) were  
at lower risk of major CADE (0.38[0.20 to 0.71]), than alcohol abstainers, while those

1  
2  
3 drinking more than 4(3) AU/day for men(women) were not significantly different from  
4  
5 abstainers (p=0.229).  
6

7  
8 These results remained valid also when the analysis was restricted to the subgroup of patients  
9  
10 with available metabolic data and the follow-up period M12-M132. After adjusting for age,  
11  
12 tobacco consumption, hypertriglyceridemia and family history of CHD, we consistently found  
13  
14 a negative association between moderate alcohol use (0.23[0.11 to 0.49]), and a positive  
15  
16 association between CD4+ cell count <200 cells/mm<sup>3</sup> (4.02[1.45 to 11.1]) and major CADE  
17  
18 after one year after enrolment (Table 3).  
19  
20

21  
22 No significant association was found between time of exposure to different ARV drugs and  
23  
24 major CADE. No significant interaction was found between smoking habits and  
25  
26 hypertriglyceridemia or personal history of CHD. Furthermore, detectable viral load was not  
27  
28 associated with major CADE in univariate or multivariate analyses.  
29  
30

31  
32 For the Cox models fitted in this study, proportional-hazards assumption remained valid,  
33  
34 either globally and with respect to each covariate. The residual analysis did not alter the  
35  
36 results of the multivariate model.  
37  
38

39  
40 The sensitivity analyses performed by first excluding patients with a history of CHD (n=7),  
41  
42 and then patients who died due to alcoholic cirrhosis (n=6), confirmed the same pattern of risk  
43  
44 factors observed for the whole population. The other sensitivity analyses, performed  
45  
46 separately on the subgroups of patients with HCV co-infection and on those not co-infected  
47  
48 with HCV, revealed the same effect of alcohol consumption on CADE, although some  
49  
50 variables among the other factors were less significant for the co-infected patients (results not  
51  
52 shown, available on request).  
53  
54  
55  
56  
57  
58  
59  
60



## Discussion

This longitudinal study clearly confirms that in ARV-treated individuals, proximal CD4+ cell count lower than 200 cells/mm<sup>3</sup> remains a risk factor associated with major coronary and other arterial disease events. This result remains valid even after adjustment for metabolic disorders such as hypertriglyceridemia and family history of CHD, the strength of the association remaining unchanged.

The relationship between CADE and CD4+ cell count, in addition to the lack of association between CADE and specific ARV classes, confirms previous results[7] where the association between exposure to certain ARV and CADE was no longer evident after controlling for traditional risk factors and HIV disease markers. Indeed, the association between specific ARV drugs and major CADE, like myocardial infarctus, has been shown in very powerful studies[5], where adjustment for nadir CD4+ lymphocyte count or peak HIV-1 RNA level did not modify the results. However, in the study cited, no adjustment for proximal CD4+ cell count was performed, and the association with the class of ARV became weaker after adjustment for serum lipid levels[5]. Indeed, although ART may modify lipid levels and increase the risk of CADE, it may also reduce this risk by reducing HIV-associated inflammation following long-term suppression of HIV replication[43]. The lack of association with exposure to some specific ARV classes in the present study, factors usually associated with an increased risk of CADE[44, 45], suggests that reduced immunological response to ART over a long follow-up, as well as known CADE risk factors may have a more important impact than exposure to a specific antiretroviral drug.

It is also possible that patients with altered lipid profiles were switched to other classes of antiretroviral drugs during the follow-up. As a consequence, in the long term, CD4+ cell

1  
2  
3 count  $<200$  cells/mm<sup>3</sup> remain a correlate of an increased risk of CADE, whatever the  
4  
5 antiretroviral received.  
6

7  
8 In our study, individuals reporting elevated alcohol consumption exhibited the same risk of  
9  
10 CADE as alcohol abstainers. In contrast, those reporting moderate alcohol consumptions had  
11  
12 a lower risk. This result was confirmed after adjustment for additional risk factors including  
13  
14 tobacco use, age, gender and CD4+ cell count. This relationship between alcohol  
15  
16 consumption and CADE remained significant and J-shaped, even after adjustment for data on  
17  
18 metabolic risk factors- such as having a history of CHD and hypertriglyceridemia -which was  
19  
20 available for a subset of patients. As highlighted in previous observations in the general  
21  
22 population[28, 46-49] and certain populations affected by other diseases[50], these results  
23  
24 confirmed that the increased risk of CADE in HIV-infected patients receiving ART is not  
25  
26 attributable to elevated alcohol use. Furthermore, we highlighted the apparent protective  
27  
28 effect of moderate alcohol consumption in ART treated HIV-infected patients.  
29  
30  
31

32  
33 It is important to note that after the introduction of ART in 1996, the sudden decrease  
34  
35 observed in HIV-related mortality was nonetheless accompanied by a relative increase of non-  
36  
37 HIV based mortality as a part of the total mortality of HIV-infected patients [51],  
38  
39 cardiovascular diseases becoming increasingly important. This increase can be explained  
40  
41 firstly by a reduction in the competing role of HIV-related mortality, which in the long term  
42  
43 was much more detrimental to health than other causes of deaths. Secondly, the high  
44  
45 prevalence in this population of other risk factors like tobacco use, together with ART-related  
46  
47 morbidity including altered lipid profiles and triglycerides, may contribute to an increased risk  
48  
49 of CADE.  
50  
51

52  
53  
54 The association found in our study between moderate alcohol use and reduced CADE risk is  
55  
56 not consistent with all previous research in HIV-infected patients. Freiberg *et al*[26] pointed  
57  
58  
59  
60

1  
2  
3 out that among HIV-infected men in the US, hazardous drinking and both alcohol abuse and  
4  
5 dependence were associated with a higher prevalence of cardiovascular disease compared  
6  
7 with infrequent and moderate drinking, even after adjusting for traditional risk factors,  
8  
9 antiretroviral therapy and CD4+ cell count. This difference in the results may be due to the  
10  
11 different design of the two studies (longitudinal for ours vs cross-sectional for Freiberg's), but  
12  
13 probably also to the different types of alcohol mainly consumed in the two populations, red  
14  
15 wine consumption being more widespread in France than in the US. This difference in the  
16  
17 pattern of alcohol use has already been highlighted in a comparative study on cardiovascular  
18  
19 disease in non HIV-infected Irish and French males, showing an increased protective effect of  
20  
21 drinking red wine in the latter population[52]. Increased wine consumption probably brings  
22  
23 about an increase in high-density lipoprotein cholesterol levels, which helps protect against  
24  
25 cardiovascular events. On the other hand, beer and spirits consumption are linked to increased  
26  
27 triglyceride levels[53]. We do not know to what extent moderate alcohol users are  
28  
29 representative of a population with better health status as alcohol use in France is relatively  
30  
31 frequent in the general population and this fact may increase the strength of the association  
32  
33 found.  
34  
35  
36  
37  
38

39 Another possible hypothesis is that excessive alcohol consumption can increase inflammatory  
40  
41 markers' levels[54], which in turn probably leads to a higher risk of CADE and premature  
42  
43 aging in HIV patients. However, this hypothesis was not demonstrated in a study conducted in  
44  
45 older adults without cardiovascular disease, where alcohol intake was found to be associated  
46  
47 with lower levels of inflammatory markers[55]. In the meantime it is important to remember  
48  
49 that individuals with immune suppression are at a greater risk of cancer, a disease whose  
50  
51 pattern of risk factors also include alcohol use, even when moderate[56].  
52  
53  
54

55 Tobacco smoking has consistently been found to be a major risk factor for cardiovascular  
56  
57 disease[57]. Smoking prevalence and dependence in HIV-infected patients is higher than in  
58  
59  
60

1  
2  
3 the general population[58]. Effective interventions for reducing and quitting smoking[59],  
4 especially for patients with several risk factors, are strongly recommended especially  
5 considering the increased cardiovascular risk which exists in HIV-infected smokers receiving  
6 ART[60]. However, results from studies reporting on the effectiveness of interventions for  
7 quitting smoking in HIV-infected individuals are inconsistent[61].  
8  
9

10  
11  
12  
13  
14 It is worth noting the lack of association between hypercholesterolemia and the risk of CADE  
15 in our study. This result suggests that HIV physicians need to be cautious about basing  
16 clinical decisions merely upon measured lipid levels in HIV-infected patients. Other risk  
17 factors, including behavioural ones, deserve greater consideration for clinical management.  
18  
19 Some limitations of this study need to be acknowledged. First, our definition of CADE  
20 includes different types of events which might not share the same pattern of risk factors.  
21  
22 However, an additional analysis performed on a restricted dataset and which adjusted for  
23 other potential risk factors (such as hypertriglyceridemia) confirmed the pattern found in the  
24 main analysis.  
25  
26

27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Second, information on alcohol use was mainly based on self-reports and these may tend to underestimate alcohol consumption. However, it has been reported that HIV-HCV co-infected patients tend to underreport alcohol use more to their hepatologist than to other physicians[62]. As our patients were all followed-up by HIV physicians, it is likely that the degree of underreporting did not greatly affect hazard ratios' estimates. Moreover, the association found between the excessive alcohol consumption and the biomarkers of alcoholic liver injury indicate a good accuracy of self-reported data on alcohol consumption.

Then, the fact that excessive alcohol users exhibit similar HRs to abstainers may be also attributable to the two following reasons. First, some individuals with excessive alcohol consumption may have died due to liver failure before experiencing a cardiovascular event

1  
2  
3 and this could have reduced the impact of excessive alcohol use on CADE. However, when  
4  
5 we performed a sensitivity analysis excluding patients who died due to alcoholic cirrhosis, the  
6  
7 results remained unchanged. Second, a proportion of abstainers may have been past (heavy)  
8  
9 alcohol users and may have had to stop drinking for health reasons. Unfortunately, we do not  
10  
11 have information about alcohol use before the beginning of the cohort, or about diagnosis of  
12  
13 alcoholism or reasons for quitting alcohol.  
14

15  
16  
17 Finally, it would have been interesting to compute the Framingham risk score[61] and use it  
18  
19 as a covariate in the multivariate model. Unfortunately, as our study was not initially designed  
20  
21 to thoroughly assess the impact of all possible CHD risk factors, some of the variables used in  
22  
23 the construction of this score (such as treated and untreated systolic blood pressure, as well as  
24  
25 total and high-density lipoprotein (HDL) cholesterol) were not available during the two first  
26  
27 years of our study. Moreover, our results showed a different pattern of factors than those  
28  
29 found in the Framingham study (some of the traditional risk factors, such as BMI and  
30  
31 hypercholesterolemia, were not significant), so using this score would have been less  
32  
33 informative than using all the factors separately.  
34  
35

36  
37  
38 It is surprising that the classical risk factor hypercholesterolemia was not found to be  
39  
40 associated with CADE risk in this study. This may be due to the fact that rather low-density  
41  
42 lipoprotein cholesterol and/or the total/HDL cholesterol quotient may be predictors of CADE  
43  
44 risk but not total cholesterol. Unfortunately, the complete data regarding cholesterol levels  
45  
46 were not available during the two first years of our study, and therefore these factors could not  
47  
48 be assessed in this analysis.  
49

50  
51  
52 This cohort is representative of the first generation of patients receiving potent ART. As  
53  
54 cardiovascular disease is a rising issue in all HIV-infected populations receiving ART, these  
55  
56  
57  
58  
59  
60

1  
2  
3 results can give important information about the pattern of risk and protective factors in all  
4  
5 treated HIV-infected populations.  
6  
7

8 In conclusion, in the long term, absence of immunodepression and moderate alcohol  
9  
10 consumption remain associated with a lower risk of major CADE. Combined interventions to  
11  
12 reduce CADE-risk-related behaviours including adherence counselling to assure long term  
13  
14 immunological response to ART in HIV-infected individuals are now a clinical and public  
15  
16 health priority.  
17  
18  
19  
20

### 21 **Acknowledgments**

22 The authors would like to thank all participating patients, nurses and physicians in clinical  
23  
24 sites.  
25

26 We would also like to thank Jude Sweeney for the English revision and editing of the  
27  
28 manuscript.  
29  
30

### 31 **Authors' contribution:**

32 Maria Patrizia Carrieri planned the data analyses and wrote the manuscript; Camelia  
33  
34 Protopopescu analyzed the data and wrote the manuscript; Vincent Le Moing contributed to  
35  
36 patients' recruitment and investigation and revised the manuscript; Philippe  
37  
38 Reboud contributed to patients' evaluation; François Raffi was responsible for cohort  
39  
40 initiation, contributed to patients' recruitment and investigation and revised the manuscript;  
41  
42 Sophie Mahy contributed to patients' recruitment and investigation; Perrine Roux contributed  
43  
44 to patients' evaluation and revised the manuscript; Lise Cuzin contributed to patients'  
45  
46 recruitment and investigation; Bruno Spire contributed to data analyses and revised the  
47  
48 manuscript; Catherine Leport was responsible for cohort initiation, contributed to patients'  
49  
50 recruitment and investigation and revised the manuscript. All authors approved the final  
51  
52 version of the manuscript.  
53  
54  
55  
56  
57  
58  
59  
60

**Authors' work position and postal address:**

1  
2  
3  
4  
5  
6  
7 Maria Patrizia Carrieri (PhD) is Senior Public Health Researcher in the “Environments,  
8 Health Systems and Transmitted Diseases (ESSEM)” Team, National Institute of Health  
9 (INSERM), U912 (SESSTIM), 23 rue Stanislas Torrents, 13006 Marseilles, France; Camelia  
10 Protopopescu (PhD) is Senior Biostatistician in the “Environments, Health Systems and  
11 Transmitted Diseases (ESSEM)” Team, National Institute of Health (INSERM), U912  
12 (SESSTIM), 23 rue Stanislas Torrents, 13006 Marseilles, France; Pr Vincent Le Moing (MD,  
13 PhD) is Professor of Infectious Diseases, Department of Infectious and Tropical Diseases,  
14 University Hospital Montpellier, 80 avenue Augustin Fliche, 34295 Montpellier cedex 5,  
15 France; Dr Philippe Reboud (MD) is Project Manager, National Institute of Health  
16 (INSERM), U897, University Victor Segalen Bordeaux 2, 146, rue Léo Saignat – case 11,  
17 33076 Bordeaux cedex, France; Pr François Raffi (MD, PhD) is Professor of Infectious  
18 Diseases, Department of Infectious and Tropical Diseases, University Hospital Nantes – Hôtel  
19 Dieu, Place Alexis Ricordeau, 44093 Nantes cedex 1, France; Dr Sophie Mahy (MD) is  
20 Associate specialist, Department of Infectious and Tropical Diseases, University Hospital  
21 Dijon, boulevard Maréchal-de-Lattre-de-Tassigny, 21000 Dijon, France; Perrine Roux (PhD)  
22 is Senior Public Health Researcher in the “Environments, Health Systems and Transmitted  
23 Diseases (ESSEM)” Team, National Institute of Health (INSERM), U912 (SESSTIM) and  
24 Substance Use Research Center, NYSPI, Columbia University, New York, USA; Dr Lise  
25 Cuzin (MD) is Associate specialist, Department of Infectious and Tropical Diseases,  
26 University Hospital Purpan - COREVIH – Bat TURIAF - TSA 40031, 31059 Toulouse  
27 Cedex, France; Dr Bruno Spire (MD, PhD) is Senior Public Health Researcher and leader of  
28 the “Environments, Health Systems and Transmitted Diseases (ESSEM)” Team, National  
29 Institute of Health (INSERM), U912 (SESSTIM), 23 rue Stanislas Torrents, 13006  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 Marseilles, France; Pr Catherine Leport (MD, PhD) is Professor of Infectious Diseases, LRPI-  
4  
5 UMR 738, UFR Médecine site Bichat, 16 rue Henri Huchard, 75018 Paris, France.  
6  
7  
8  
9

10  
11 **The ANRS CO8 APROCO-COPILOTE Study Group is composed of the following:**

12 **Scientific Committee:**

13  
14 • **Steering Committee:**

15  
16 Principal investigators: C. Leport, F. Raffi

17  
18 Methodology: G. Chêne, R. Salamon

19  
20 Social sciences: JP. Moatti, J. Pierret, B. Spire

21  
22 Virology: F. Brun-Vézinet, H. Fleury, B. Masquelier

23  
24 Pharmacology: G. Peytavin, R. Garraffo

25  
26 • **Other members:** D. Costagliola, P. Dellamonica, C. Katlama, L. Meyer, D. Salmon, A.  
27  
28 Sobel.

29  
30 **Events Validation Committee:** L. Cuzin, M. Dupon, X. Duval, V. Le Moing, B. Marchou,  
31  
32 T. May, P. Morlat, C. Rabaud, A. Waldner-Combernoux.

33  
34 **Project coordination:** P. Reboud.

35  
36 **ANRS representatives:** Sandrine Couffin-Cadiergues, Lucie Marchand.

37  
38 **Data monitoring and statistical analysis:** V. Bouteloup, AD. Bouhnik, C. Brunet-François,  
39  
40 V. Caron, MP. Carrieri, M. Courcoul, F. Couturier, L. Hardel, L. Iordache. P. Kurkdji, S.  
41  
42 Martiren, M. Préau, C. Protopopescu, J. Surzyn, A. Taieb, V. Villes.

43  
44 **Promotion:** Agence Nationale de Recherches sur le Sida et les hépatites virales (ANRS,  
45  
46 Action Coordonnée n°7).

47  
48 **Other support:** Collège des Universitaires de Maladies Infectieuses et Tropicales (CMIT ex  
49  
50 APPIT), Sidaction Ensemble contre le Sida and associated pharmaceutical companies:  
51  
52

1  
2  
3 Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences,  
4  
5 Pfizer and Roche.

6  
7 **Clinical Centres (investigators):** Amiens (Pr JL. Schmit), Angers (Dr JM. Chennebault),  
8  
9 Belfort (Dr JP. Faller), Besançon (Pr N. Mgy-Bertrand, Pr B. Hoen, Dr Drobachef), Bobigny  
10  
11 (Pr O. Bouchaud), Bordeaux (Pr M. Dupon, Pr Longy-Boursier, Pr P. Morlat, Pr JM.  
12  
13 Ragnaud), Bourg-en-Bresse (Dr P. Granier), Brest (Pr M. Garré), Caen (Pr R. Verdon),  
14  
15 Compiègne (Dr D. Merrien), Corbeil Essonnes (Dr A. Devidas), Créteil (Pr A. Sobel), Dijon  
16  
17 (Pr L. Piroth), Garches (Pr C. Perronne), Lagny (Dr E. Froguel), Libourne (Dr J. Ceccaldi),  
18  
19 Lyon (Pr D. Peyramond), Meaux (Dr C. Allard), Montpellier (Pr J. Reynes), Nancy (Pr T.  
20  
21 May), Nantes (Pr F. Raffi), Nice (Pr JG Fuzibet, Pr P. Dellamonica), Orléans (Dr P. Arsac),  
22  
23 Paris (Pr E. Bouvet, Pr F. Bricaire, Pr P. Bergmann, Pr J. Cabane, Dr J. Monsonogo, Pr PM.  
24  
25 Girard, Pr L. Guillevin, Pr S. Herson, Pr C. Leport, Pr MC. Meyohas, Pr JM. Molina, Pr G.  
26  
27 Pialoux, Pr D. Salmon), Poitiers (Pr P. Roblot), Reims (Pr R. Jaussaud), Rennes (Pr C.  
28  
29 Michelet), Saint-Etienne (Pr F. Lucht), Saint-Mandé (Pr T. Debord), Strasbourg (Dr D. Rey),  
30  
31 Toulon (Dr JP. De Jaureguiberry), Toulouse (Pr B. Marchou), Tours (Pr L. Bernard).  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Kaplan RC, Kingsley LA, Gange SJ *et al.* Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. *Aids* 2008;**22**(13):1615-24.
2. Henry K, Melroe H, Huebsch J *et al.* Severe premature coronary artery disease with protease inhibitors. *Lancet* 1998;**351**(9112):1328.
3. Lai S, Fishman EK, Lai H *et al.* Long-Term Cocaine Use and Antiretroviral Therapy Are Associated with Silent Coronary Artery Disease in African Americans with HIV Infection Who Have No Cardiovascular Symptoms. *Clin Infect Dis* 2008;**46**:600-610.
4. Mary-Krause M, Cotte L, Simon A *et al.* Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. *Aids* 2003;**17**(17):2479-86.
5. Friis-Moller N, Reiss P, Sabin CA *et al.* Class of antiretroviral drugs and the risk of myocardial infarction. *N Engl J Med* 2007;**356**(17):1723-35.
6. Butt AA, Chang CC, Kuller L *et al.* Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. *Arch Intern Med* 2011;**171**(8):737-43.
7. Lichtenstein KA, Armon C, Buchacz K *et al.* Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. *Clin Infect Dis* 2010;**51**(4):435-47.
8. Mondy KE, de las Fuentes L, Waggoner A *et al.* Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy. *Aids* 2008;**22**(7):849-56.
9. Sax PE. Strategies for management and treatment of dyslipidemia in HIV/AIDS. *AIDS Care* 2006;**18**(2):149-57.
10. Smith CJ, Levy I, Sabin CA *et al.* Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population. *HIV Med* 2004;**5**(2):88-92.
11. Guaraldi G, Squillace N, Stentarelli C *et al.* Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. *Clin Infect Dis* 2008;**47**(2):250-7.
12. Michel L, Carrieri MP, Fugon L *et al.* Harmful alcohol consumption and patterns of substance use in HIV-infected patients receiving antiretrovirals (ANRS-EN12-VESPA Study): relevance for clinical management and intervention. *AIDS Care* 2010;**22**(9):1136-45.
13. Stein M, Herman DS, Trisvan E *et al.* Alcohol use and sexual risk behavior among human immunodeficiency virus-positive persons. *Alcohol Clin Exp Res* 2005;**29**(5):837-43.
14. Braithwaite RS, Conigliaro J, McGinnis KA *et al.* Adjusting alcohol quantity for mean consumption and intoxication threshold improves prediction of nonadherence in HIV patients and HIV-negative controls. *Alcohol Clin Exp Res* 2008;**32**(9):1645-51.
15. Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. *J Acquir Immune Defic Syndr* 2006;**43**(4):411-7.
16. Spire B, Duran S, Souville M *et al.* Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. *Soc Sci Med* 2002;**54**(10):1481-96.
17. Conen A, Fehr J, Glass TR *et al.* Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. *Antivir Ther* 2009;**14**(3):349-57.
18. Braithwaite RS, Conigliaro J, Roberts MS *et al.* Estimating the impact of alcohol consumption on survival for HIV+ individuals. *AIDS Care* 2007;**19**(4):459-66.
19. Galai N, Vlahov D, Baretta JC *et al.* Prognostic factors for survival differ according to CD4+ cell count among HIV-infected injection drug users: pre-HAART and HAART eras. *J Acquir Immune Defic Syndr* 2005;**38**(1):74-81.
20. Hooshyar D, Hanson DL, Wolfe M *et al.* Trends in perimortal conditions and mortality rates among HIV-infected patients. *Aids* 2007;**21**(15):2093-100.
21. Samet JH, Cheng DM, Libman H *et al.* Alcohol consumption and HIV disease progression. *J Acquir Immune Defic Syndr* 2007;**46**(2):194-9.

22. Salmon-Ceron D, Lewden C, Morlat P *et al*. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. *J Hepatol* 2005;**42**(6):799-805.
23. Di Martino V, Rufat P, Boyer N *et al*. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. *Hepatology* 2001;**34**(6):1193-9.
24. Puoti M, Spinetti A, Ghezzi A *et al*. Mortality for liver disease in patients with HIV infection: a cohort study. *J Acquir Immune Defic Syndr* 2000;**24**(3):211-7.
25. Rosenthal E, Pialoux G, Bernard N *et al*. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). *J Viral Hepat* 2007;**14**(3):183-8.
26. Freiberg MS, McGinnis KA, Kraemer K *et al*. The association between alcohol consumption and prevalent cardiovascular diseases among HIV-infected and HIV-uninfected men. *J Acquir Immune Defic Syndr* 2010;**53**(2):247-53.
27. Freiberg MS, Cheng DM, Kraemer KL *et al*. The association between hepatitis C infection and prevalent cardiovascular disease among HIV-infected individuals. *Aids* 2007;**21**(2):193-7.
28. Mukamal KJ, Chen CM, Rao SR *et al*. Alcohol consumption and cardiovascular mortality among U.S. adults, 1987 to 2002. *J Am Coll Cardiol* 2010;**55**(13):1328-35.
29. Mukamal KJ, Conigrave KM, Mittleman MA *et al*. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. *N Engl J Med* 2003;**348**(2):109-18.
30. Saves M, Chene G, Ducimetiere P *et al*. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. *Clin Infect Dis* 2003;**37**(2):292-8.
31. CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992 Dec 18;**41**(RR-17):1-19.
32. Radloff L. The CES-D scale: a self-report depression scale for research in the general population. *Applied Psychology Measurement* 1977;**3**:385-491.
33. Justice AC, Holmes W, Gifford AL *et al*. Development and validation of a self-completed HIV symptom index. *J Clin Epidemiol* 2001;**54** Suppl 1:S77-90.
34. Carrieri MP, Villes V, Raffi F *et al*. Self-reported side-effects of anti-retroviral treatment among IDUs: a 7-year longitudinal study (APROCO-COPILOTE COHORT ANRS CO-8). *Int J Drug Policy* 2007;**18**(4):288-95.
35. Chesney MA, Ickovics JR, Chambers DB *et al*. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). *AIDS Care* 2000;**12**(3):255-66.
36. Sugiura N. Further analysis of the data by Akaike's information criterion and the finite corrections. *Communications in Statistics: Theory and Methods* 1978;**A7**:13-26.
37. Ueshima H, Choudhury SR, Okayama A *et al*. Cigarette smoking as a risk factor for stroke death in Japan: NIPPON DATA80. *Stroke* 2004;**35**(8):1836-41.
38. Bissell D, Paton A, Ritson B. ABC of alcohol. Help: referral. *Br Med J (Clin Res Ed)* 1982;**284**(6314):495-7.
39. Carrieri P, Cailleton V, Le Moing V *et al*. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. *J Acquir Immune Defic Syndr* 2001;**28**(3):232-9.
40. Fuhrer R, Rouillon F. La version française de l'échelle CES-D. Description and translation of the autoevaluation scale (in French). *Psychiatrie et Psychobiologie* 1989;**4**:163-166.
41. Schwartz G. Estimating the dimension of a model. *Annals of Statistics* 1978;**6**:461-464.
42. Therneau TM, Grambsch PM. *Modeling Survival Data: Extending the Cox Model* Springer, 2000.
43. Baker JV, Neuhaus J, Duprez D *et al*. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. *J Acquir Immune Defic Syndr* 2011;**56**(1):36-43.

- 1
- 2
- 3 44. Islam F, Wu J, Jansson J *et al.* Relative risk of cardiovascular disease among people living with HIV:  
4 a systematic review and meta-analysis. *HIV Med* 2012([Epub ahead of print]).
- 5 45. Friis-Moller N, Thiebaut R, Reiss P *et al.* Predicting the risk of cardiovascular disease in HIV-  
6 infected patients: the data collection on adverse effects of anti-HIV drugs study. *Eur J*  
7 *Cardiovasc Prev Rehabil* 2010;**17**(5):491-501.
- 8 46. Mukamal KJ, Chung H, Jenny NS *et al.* Alcohol use and risk of ischemic stroke among older adults:  
9 the cardiovascular health study. *Stroke* 2005;**36**(9):1830-4.
- 10 47. Waskiewicz A, Sygnowska E, Drygas W. Relationship between alcohol consumption and  
11 cardiovascular mortality--the Warsaw Pol-MONICA Project. *Kardiol Pol* 2004;**60**(6):552-62;  
12 discussion 563.
- 13 48. Burger M, Mensink G, Bronstrup A *et al.* Alcohol consumption and its relation to cardiovascular  
14 risk factors in Germany. *Eur J Clin Nutr* 2004;**58**(4):605-14.
- 15 49. Murray RP, Connett JE, Tyas SL *et al.* Alcohol volume, drinking pattern, and cardiovascular disease  
16 morbidity and mortality: is there a U-shaped function? *Am J Epidemiol* 2002;**155**(3):242-8.
- 17 50. Beulens JW, Algra A, Soedamah-Muthu SS *et al.* Alcohol consumption and risk of recurrent  
18 cardiovascular events and mortality in patients with clinically manifest vascular disease and  
19 diabetes mellitus: the Second Manifestations of ARterial (SMART) disease study.  
20 *Atherosclerosis* 2010;**212**(1):281-6.
- 21 51. Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected  
22 individuals living in Southern Alberta, Canada from 1984 to 2003. *HIV Med* 2005;**6**(2):99-106.
- 23 52. Marques-Vidal P, Montaye M, Arveiler D *et al.* Alcohol consumption and cardiovascular disease:  
24 differential effects in France and Northern Ireland. The PRIME study. *Eur J Cardiovasc Prev*  
25 *Rehabil* 2004;**11**(4):336-43.
- 26 53. Foerster M, Marques-Vidal P, Gmel G *et al.* Alcohol drinking and cardiovascular risk in a  
27 population with high mean alcohol consumption. *Am J Cardiol* 2009;**103**(3):361-8.
- 28 54. Pandrea I, Happel KI, Amedee AM *et al.* Alcohol's Role in HIV Transmission and Disease  
29 Progression. *Alcohol Research & Health* 2010;**33**(3):203-218.
- 30 55. Mukamal KJ, Cushman M, Mittleman MA *et al.* Alcohol consumption and inflammatory markers in  
31 older adults: the Cardiovascular Health Study. *Atherosclerosis* 2004;**173**(1):79-87.
- 32 56. Grulich AE, Jin F, Poynten IM *et al.* HIV, cancer, and aging. *Sex Health* 2011;**8**(4):521-5.
- 33 57. Palella FJ, Jr., Phair JP. Cardiovascular disease in HIV infection. *Curr Opin HIV AIDS* 2011;**6**(4):266-  
34 71.
- 35 58. Niaura R, Shadel WG, Morrow K *et al.* Human immunodeficiency virus infection, AIDS, and  
36 smoking cessation: the time is now. *Clin Infect Dis* 2000;**31**(3):808-12.
- 37 59. Barth J, Critchley J, Bengel J. Efficacy of psychosocial interventions for smoking cessation in  
38 patients with coronary heart disease: a systematic review and meta-analysis. *Ann Behav Med*  
39 2006;**32**(1):10-20.
- 40 60. Currier JS, Havlir DV. Complications of HIV disease and antiretroviral therapy. *Top HIV Med*  
41 2009;**17**(2):57-67.
- 42 61. Lloyd-Richardson EE, Stanton CA, Papandonatos GD *et al.* Motivation and patch treatment for  
43 HIV+ smokers: a randomized controlled trial. *Addiction* 2009;**104**(11):1891-900.
- 44 62. Roux P, Cohen J, Lascoux-Combe C *et al.* Determinants of the underreporting of alcohol  
45 consumption by HIV/HCV co-infected patients during face-to-face medical interviews: the  
46 role of the physician. *Drug Alcohol Depend* 2011;**116**(1-3):228-32.
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

**Table 1. Association between alcohol consumption and living injury indicators, after adjustment for HCV status, among HIV-infected patients receiving ART (ANRS CO8 APROCO-COPILOTE cohort - random effects logistic models, all patients - n=1154, follow-up period M0-M132)**

	ALT>50 IU/l & AST/ALT>1		ALT>50 IU/l & AST/ALT>2	
	AOR [95%CI]	p-value	AOR [95%CI]	p-value
<b>Alcohol consumption*</b>				
-abstainers (ref.)	1		1	
-≤1 AU/day	0.7 [0.5-1.2]	0.228	2.8 [0.4-18.4]	0.292
->1 and ≤4(3) AU/day for men(women)	1.0 [0.6-1.8]	0.847	0.7 [0.0-10.1]	0.772
->4(3) AU/day for men(women)	4.9 [2.4-9.8]	<10 <sup>-3</sup>	29.0 [3.4-250]	0.002
<b>HCV infection at M0</b>	12.9 [7.6-21.8]	<10 <sup>-3</sup>	11.2 [2.7-46.4]	0.001

ART = antiretroviral therapy; ALT= alanine transaminase; AST= aspartate transaminase

AOR = Adjusted Odds-Ratios from a random effects logistic model; CI = confidence interval

\* Time-varying variable (the last available value before each visit)



**Table 2. Factors associated with the first occurrence of a major CADE among HIV-infected patients receiving ART (ANRS CO8 APROCO-COPILOTE cohort - univariate and multivariate Cox proportional hazard models, all patients - n=1154, follow-up period M0-M132)**

	% of patients or mean (SD)	% of miss. data	Univariate analyses		Multivariate analysis	
			HR [95% CI]	p-value	AHR [95% CI]	p-value
<b><i>Socio-demographic and psychosocial characteristics</i></b>						
Female gender	22.0	0	0.26 [0.08-0.84]	0.025	0.25 [0.08-0.83]	0.024
Age at M0° - years	37.7 (9.5)	0	1.06 [1.03-1.09]	<10 <sup>-3</sup>	1.07 [1.04-1.10]	<10 <sup>-3</sup>
Secondary-school certificate at M0°	31.3	7.3	0.51 [0.26-1.01]	0.054		
Alcohol consumption at M0°		0				
- abstainers (ref)	18.8		1			
- ≤4(3) AU/day for men(women)	75.3		0.47 [0.24-0.89]	0.021		
- >4(3) AU/day for men(women)	5.9		0.75 [0.21-2.63]	0.648		
Alcohol consumption*		0				
- abstainers (ref)	18.6		1		1	
- ≤4(3) AU/day for men(women)	77.2		0.44 [0.24-0.81]	0.009	0.38 [0.20-0.71]	0.002
- >4(3) AU/day for men(women)	4.1		1.04 [0.30-3.58]	0.953	0.46 [0.13-1.63]	0.229
Tobacco consumption >20 cig./day*	15.8	0.1	3.17 [1.73-5.83]	<10 <sup>-3</sup>	4.19 [2.17-8.11]	<10 <sup>-3</sup>
Depressive symptoms <sup>#*</sup>	32.0	1.8	1.22 [0.67-2.21]	0.512		
Number of self-reported symptoms (excluding lipodystrophy)*	4.8 (3.8)	0.1	1.01 [0.95-1.08]	0.694		
Number of self-reported lipodystrophy symptoms*	2.5 (2.6)	0.4	1.07 [0.96-1.18]	0.223		
ART adherence*	63.2	0.3	2.42 [1.17-5.02]	0.017		
<b><i>Clinical characteristics</i></b>						
HIV transmission category°		0				
- homosexual	40.6		0.99 [0.42-2.34]	0.988		



- injecting drug use	17.8		0.92 [0.50-1.70]	0.793		
- other (ref)	41.6		1			
CDC clinical stage A at M0 <sup>°</sup>	51.2	0	0.44 [0.23-0.85]	0.014		
HCV infection at M0 <sup>°</sup>	22.4	4.3	1.16 [0.59-2.29]	0.655		
Time since HIV diagnosis at M0- <i>years</i> <sup>°</sup>	4.7 (4.2)	0.9	1.01 [0.94-1.08]	0.822		
Duration of exposure to efavirenz - <i>years</i> * <sup>§</sup>	1.0 (2.2)	0	0.86 [0.71-1.03]	0.102		
Duration of exposure to nevirapine - <i>years</i> * <sup>§</sup>	0.9 (2.2)	0	0.91 [0.78-1.07]	0.279		
Duration of exposure to abacavir - <i>years</i> * <sup>§</sup>	1.0 (2.1)	0	0.98 [0.84-1.13]	0.748		
Duration of exposure to lopinavir - <i>years</i> * <sup>§</sup>	0.4 (1.5)	0	1.01 [0.85-1.20]	0.929		
Duration of exposure to PI-based regimen - <i>years</i> * <sup>§</sup>	3.2 (3.1)	0	1.03 [0.92-1.15]	0.615		
Antiretroviral naivety at M0 <sup>°</sup>	44.4	0	1.14 [0.64-2.02]	0.654		
CD4+ cell count < 200 <i>cells/mm</i> <sup>3</sup> at M0 <sup>°</sup>	35.9	0.1	0.99 [0.55-1.80]	0.978		
Detectable viral load at M0 <sup>°</sup>	94.0	0.3	0.81 [0.25-2.61]	0.725		
CD4+ cell count < 200 <i>cells/mm</i> <sup>3</sup> * Detectable viral load*	<u>13.7</u> <u>43.4</u>	<u>0.02</u> <u>0.7</u>	2.48 [1.15-5.33] 0.99 [0.53-1.84]	0.020 0.980	2.52 [1.15-5.48]	0.020

CADE = coronary or other arterial disease event; ART = antiretroviral therapy; CHD = coronary heart disease

SD = standard deviation; (A)HR = (adjusted) hazard ratio; CI = confidence interval

<sup>°</sup> Fixed variable (measured at M0 or M1); \* Time-varying variable (the last available value before each visit);

percentages and averages were computed on all follow-up visits for time-varying variables

<sup>§</sup> Percentages and averages are computed at the end of the follow-up (last available visit for each patient)

<sup>#</sup> Depressive symptoms: the Centre for Epidemiologic Studies Depression Scale (CES-D) scores is >17 for men and >23 for women

**Table 3. Factors associated with the first occurrence of a major CADE among HIV-infected patients receiving ART (ANRS CO8 APROCO-COPILOTE cohort - univariate and multivariate Cox proportional hazard models, patients with available metabolic data - n=675, follow-up period M12-M132)**

	% of patients or mean (SD)	% of miss. data	Univariate analyses HR [95% CI]	p-value	Multivariate analysis AHR [95% CI]	p-value
<b><i>Socio-demographic and psychosocial characteristics</i></b>						
Female gender	19.0	0	0.33 [0.08-1.40]	0.134		
Age at M0 – years <sup>o</sup>	38.4 (9.5)	0	1.04 [1.01-1.07]	0.013	1.05 [1.02-1.09]	0.003
Secondary-school certificate at M0 <sup>o</sup>	35.4	6.7	0.34 [0.14-0.84]	0.019		
Alcohol consumption at M0 <sup>o</sup>		0				
- abstainers (ref)	15.1		1			
- ≤4(3) AU/day for men(women)	78.4		0.44 [0.18-1.03]	0.059		
- >4(3) AU/day for men(women)	6.5		1.04 [0.26-4.05]	0.959		
Alcohol consumption*		0				
- abstainers (ref)	16.5		1		1	
- ≤4(3) AU/day for men(women)	79.1		0.27 [0.13-0.58]	0.001	0.23 [0.11-0.49]	<10 <sup>-3</sup>
- >4(3) AU/day for men(women)	4.4		1.19 [0.33-4.23]	0.792	0.55 [0.14-2.14]	0.390
Tobacco consumption >20 cig./day*	15.7	0.1	3.58 [1.70-7.54]	0.001	5.59 [2.43-12.8]	<10 <sup>-3</sup>
Depressive symptoms <sup>#*</sup>	31.9	1.50	1.83 [0.90-3.73]	0.094		
Number of self-reported symptoms (excluding lipodystrophy)*	4.8 (3.8)	0.02	1.03 [0.95-1.12]	0.463		
Number of self-reported lipodystrophy symptoms*	2.6 (2.7)	0.16	1.10 [0.98-1.24]	0.111		
ARV adherence*	63.6	0.2	1.63 [0.70-3.81]	0.260		
<b><i>Clinical characteristics</i></b>						

HIV transmission category <sup>o</sup>		0				
- homosexual (ref)	44.0		1			
- injecting drug use	15.0		2.08 [0.75-5.73]	0.156		
- other	41.0		1.32 [0.59-2.93]	0.499		
CDC clinical stage A at M0 <sup>o</sup>	50.8	0	0.43 [0.19-0.97]	0.041		
HCV infection at M0 <sup>o</sup>	19.8	3.8	2.05 [0.94-4.47]	0.071		
Duration since HIV diagnosis at M0- years <sup>o</sup>	4.7 (4.2)	1.2	1.04 [0.96-1.13]	0.311		
Duration of exposure to efavirenz - years* <sup>§</sup>	1.4 (2.5)	0	0.89 [0.73-1.08]	0.236		
Duration of exposure to nevirapine - years* <sup>§</sup>	1.0 (2.3)	0	0.83 [0.66-1.06]	0.147		
Duration of exposure to abacavir - years* <sup>§</sup>	1.2 (2.3)	0	0.99 [0.85-1.17]	0.971		
Duration of exposure to lopinavir - years* <sup>§</sup>	0.5 (1.5)	0	1.07 [0.88-1.30]	0.505		
Duration of exposure to PI-based regimen - years* <sup>§</sup>	3.9 (3.1)	0	1.03 [0.89-1.18]	0.714		
Antiretroviral naivety at M0 <sup>o</sup>	41.5	0	0.86 [0.41-1.79]	0.683		
CD4+ cell count < 200 cells/mm <sup>3</sup> at M0 <sup>o</sup>	33.9	0	0.88 [0.41-1.88]	0.749		
Detectable viral load at M0 <sup>o</sup>	94.8	0.1	0.70 [0.17-2.94]	0.627		
CD4+ cell count < 200 cells/mm <sup>3</sup> *	<u>11.8</u>	<u>0</u>	2.58 [0.99-6.75]	0.052	4.02 [1.45-11.1]	0.007
Detectable viral load*	<u>40.2</u>	<u>0.03</u>	1.24 [0.59-2.59]	0.574		

### Metabolic characteristics

BMI categories <sup>o@</sup>		1.6				
- underweight: <18.5 (ref)	5.8		1			
- normal weight: 18.5–24.9	72.8		0.65 [0.15-2.76]	0.556		
- overweight or obese: >25	19.8		0.57 [0.11-2.87]	0.498		
Hypertriglyceridemia <sup>o@</sup>	8.4	0	2.06 [0.79-5.37]	0.141	2.98 [1.11-8.01]	0.030

Hypercholesterolemia <sup>°@</sup>	6.5	0.1	0.95 [0.22-3.97]	0.939		
Personal history of CHD <sup>°@</sup>	1.2	0	9.39 [2.22-39.8]	0.002		
Family history of CHD <sup>°@</sup>	28.0	0	1.82 [0.89-3.71]	0.102	2.25 [1.08-4.71]	0.031
Personal history of hypertension <sup>°@</sup>	6.1	0	2.73 [1.05-7.13]	0.040		

CADE = coronary or other arterial disease event; ART = antiretroviral therapy; CHD = coronary heart disease

SD = standard deviation; (A)HR = (adjusted) hazard ratio; CI = confidence interval

<sup>°</sup> Fixed variable (measured at M0, M1 or M12); \* Time-varying variable (the last available value before each visit); percentages and averages are computed on all follow-up visits for time-varying variables

@ At M12; § Percentages and averages are computed at the end of the follow-up (last available visit for each patient)

# Depressive symptoms: the Centre for Epidemiologic Studies Depression Scale (CES-D) scores is >17 for men and >23 for women

1  
2  
3 **Impact of Immunodepression and Moderate Alcohol Consumption on Coronary and**  
4 **other Arterial Disease Events in an 11-year Cohort of HIV-infected Patients on**  
5 **Antiretroviral Therapy**  
6  
7  
8

9  
10  
11  
12  
13 **Maria Patrizia Carrieri<sup>1,2,3\*</sup>, Camelia Protopopescu<sup>1,2,3\*§</sup>, Vincent Le Moing<sup>4</sup>, Philippe**  
14 **Reboud<sup>5</sup>, François Raffi<sup>6</sup>, Sophie Mahy<sup>7</sup>, Perrine Roux<sup>1,8</sup>, Lise Cuzin<sup>9</sup>, Bruno Spire<sup>1,2,3</sup>,**  
15 **Catherine Leport<sup>10,11</sup> and the ANRS CO8 APROCO-COPILOTE Study Group**  
16  
17  
18  
19

20  
21 \* Equal contribution  
22  
23  
24  
25  
26

27 <sup>1</sup> *INSERM, U912 (SESSTIM), Marseille, France*  
28

29 <sup>2</sup> *Aix Marseille Univ, IRD, UMR-S912, Marseille, France*  
30

31 <sup>3</sup> *ORS PACA, Observatoire Régional de la Santé Provence Alpes Côte d'Azur, Marseille,*  
32 *France*  
33

34 <sup>4</sup> *Service de Maladies Infectieuses et Tropicales, CHU de Montpellier, UMI 233 TransVIHMI,*  
35 *IRD, Université Montpellier 1, Montpellier, France*  
36  
37

38 <sup>5</sup> *INSERM, U897; Université Bordeaux Segalen, ISPED, Bordeaux, France*  
39

40 <sup>6</sup> *CHU Hôtel-Dieu, Nantes, France*  
41

42 <sup>7</sup> *CHU de Dijon, Université de Bourgogne, Dijon, France*  
43  
44

45 <sup>8</sup> *Substance Use Research Center, NYSPI, Columbia University, New York, USA*  
46  
47

48 <sup>9</sup> *Service de Maladies Infectieuses et Tropicales, CHU Purpan, Toulouse, France*  
49

50 <sup>10</sup> *Université Paris Diderot, Sorbonne Paris Cité, UMR 738, Paris, France*  
51

52 <sup>11</sup> *INSERM, UMR 738, Paris, France*  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 § Corresponding author address: INSERM U912 – ORS PACA, 23 rue Stanislas Torrents,  
4  
5 13006 Marseille, France

6  
7 ☎: +33 4 96 10 28 80      ☎: + 33 4 96 10 28 99      @: camelia.protopopescu@inserm.fr  
8  
9

10  
11  
12 *Abstract word count: 285 words*

13  
14  
15 *Text word count: 4548 words*  
16  
17

18  
19  
20 **Funding sources:** The ANRS CO8 (APROCO/COPILOTE) cohort is funded by ANRS  
21  
22 (Agence Nationale de Recherches sur le Sida et les hépatites virales) and CMIT (Collège des  
23  
24 Universitaires de Maladies Infectieuses et Tropicales), which received research grants from  
25  
26 Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences,  
27  
28 Pfizer and Roche.  
29

30  
31  
32 The funders were responsible for initiating, managing and financing the cohort, but did not  
33  
34 interfere with data analysis and interpretation and dissemination of the scientific results.  
35  
36

37  
38 **Competing interests:** All authors have completed the Unified Competing Interest form at  
39  
40 [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) <[http://www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf)> (available on  
41  
42 request from the corresponding author) and declare that (1) they have no support from any  
43  
44 company for the submitted work; (2) they have no relationships with any company that might  
45  
46 have an interest in the submitted work in the previous 3 years; (3) their spouses, partners, or  
47  
48 children have no financial relationships that may be relevant to the submitted work; and (4)  
49  
50 they have no non-financial interests that may be relevant to the submitted work.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Exclusive licence:** The Corresponding Author has the right to grant on behalf of all authors  
4 and does grant on behalf of all authors, an exclusive licence (or non exclusive for government  
5 employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to  
6 permit this article (if accepted) to be published in BMJ editions and any other BMJ PGL  
7 products and sublicences to exploit all subsidiary rights, as set out in our licence  
8 (<http://resources.bmj.com/bmj/authors/checklists-forms/licence-for-publication>).  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

19 **Data sharing:** There is no additional data available.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Summary

### Article Focus

- Major coronary or other arterial disease events (CADE) are frequent in HIV-infected individuals receiving antiretroviral therapy.
- While some antiretroviral classes can increase the risk of CADE, it is still controversial to what extent immune reconstitution and other factors like moderate alcohol consumption can reduce the risk of CADE in this population.

### Key Messages

- Moderate alcohol consumption and absence of immunodepression can be beneficial to reduce the risk of CADE in HIV-infected patients.
- Reduced immunological response to antiretroviral treatment (ART) over a long follow-up may have a more important impact on CADE than exposure to a specific antiretroviral drug.

### Strengths and Limitations

- This paper suggests the importance of combined risk reduction interventions including adherence counselling for assuring long term immunological response and decrease the risk of CADE.

### Short title

**CD4+, Moderate Alcohol Consumption and Coronary Events in HIV-infected patients**

**Abstract**

**Objective:** To investigate the relationship between response to antiretroviral treatment (ART), alcohol use and occurrence of a major coronary or other arterial disease event (CADE) in HIV-infected individuals.

**Design:** Cohort study. A Cox model was used to identify correlates of a first occurrence of a major CADE.

**Setting:** The French ANRS CO8 APROCO-COPILOTE cohort was set up in 1997 to study clinical progression and patient-reported outcomes (PRO) after initiating protease inhibitor-containing ART. Clinical data were retrieved from medical records. Self-administered questionnaires collected data on PRO and behaviours, including alcohol use.

**Participants:** Metabolic data were only available for a subgroup (n=675) of the study group (n=1154).

**Main outcomes measures:** Major coronary or other arterial disease first event.

**Results:** Over the 11-year follow-up, 49 major CADE were observed, with an incidence rate [95%CI]=0.75[0.57 to 0.99] per 100 person-years. Immunodepression (CD4+ cell count <200 cells/mm<sup>3</sup>) was associated with an increased risk of CADE (Adjusted Hazard Ratio AHR[95% CI]= 2.52[1.15 to 5.48]) after adjustment for female gender (0.25[0.08 to 0.83]), age (1.07[1.04 to 1.10]) and smoking>20 cigarettes/day (4.19[2.17 to 8.11]). Moreover, individuals with moderate alcohol consumption ( $\leq 4(3)$  AU/day for men(women)) had a lower risk of CADE (0.38[0.20 to 0.71]) than alcohol abstainers, while the risk for those drinking>4(3) AU/day for men(women) was not significantly different from this latter group. These associations remained valid after adjustment for metabolic disorders. No significant association with exposure to any specific antiretroviral was detected.

1  
2  
3 **Conclusions:** In the long term, absence of immunodepression and moderate alcohol  
4  
5 consumption remain associated with a lower risk of major CADE. Combined interventions to  
6  
7 reduce CADE risk-related behaviours including adherence counselling for assuring long term  
8  
9 immunological response to ART in HIV-infected individuals are now a clinical and public  
10  
11 health priority.  
12

13  
14  
15  
16  
17  
18 **Key words:** Coronary and other arterial disease events, Alcohol, CD4+ cell count, HIV,  
19  
20 ARV.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Cardiovascular disease risk factors (including for example hypertension and tobacco use), as well as immunological status[1] are major predictors of atherosclerosis in HIV-infected women and men. Although some antiretroviral (ARV) therapy drugs[2-5] have consistently been found to be associated with coronary arterial disease or myocardial infarction (MI) in these patients, more recently Butt and colleagues put into evidence the negative effect of HIV viral replication on heart failure[6]. In one study, patients having experienced a MI presented lower baseline and proximal CD4+ cell counts than those who did not, while no association was found between cardiovascular disease events and specific antiretroviral agents[7]. Moreover, known factors associated with cardiovascular risk[8] such as hyperlipidemia and insulin resistance[9-11] are becoming an increasingly major clinical concern in ARV-treated individuals.

Though excessive alcohol use may be frequent in HIV-infected individuals, its impact on the occurrence of cardiovascular disease in this population has been less investigated. Excessive alcohol consumption also plays a major role in HIV risk-taking behaviours, particularly in men who have sex with men and drug users[12, 13]. In HIV-infected individuals, excessive alcohol use is known to compromise patients' response to antiretroviral therapy (ART) through reduced adherence[14-17] and to predict HIV progression and increased mortality[18-21], mostly from liver diseases[22-25]. Some recent cross-sectional analyses in HIV-infected and uninfected men have found that heavy alcohol consumption is associated with a higher risk of cardiovascular disease[26, 27]. On the other hand, in uninfected adults, moderate alcohol consumption has been found to be associated with a reduced cardiovascular mortality[28], improved lipid profiles, increased insulin sensitivity and reduced risk of MI[29]. However, this association has not yet been studied in longitudinal studies involving HIV-infected populations including women. Moreover, there are as yet no consistent results

1  
2  
3 in the literature regarding the role that alcohol use plays in exacerbating cardiovascular risk in  
4  
5 ARV-treated patients and to what extent it can confound or boost the effect of immuno-  
6  
7 virological response to ART, ART-associated dyslipidemia and insulin resistance on the risk  
8  
9 of cardiovascular disease events.  
10

11  
12 We used data from the 11-year follow-up of the APROCO-COPILOTE cohort of patients  
13  
14 receiving ART since 1997 to investigate the relationship between viral load, CD4+ cell count,  
15  
16 alcohol consumption and the first occurrence of a major coronary or other arterial disease  
17  
18 event (CADE), after adjustment for known risk factors including metabolic disorders.  
19  
20

## 21 22 23 24 **Methods**

25  
26  
27 The French APROCO-COPILOTE cohort (ANRS CO8) was designed to study the clinical,  
28  
29 immunological, virological, and socio-behavioural course of HIV disease in HIV-1 positive  
30  
31 individuals who started the first generation of potent ART (treatment regimens including  
32  
33 protease inhibitors (PI)). The study was approved by the Ethics Committee of Cochin  
34  
35 Hospital (Paris) and informed consent was obtained from all participants.  
36  
37

### 38 39 *Setting*

40  
41  
42 Patients were enrolled in the cohort at their first PI-based ART prescription between May  
43  
44 1997 and June 1999 (n=1281) in 47 French centres, and clinically followed-up every 4  
45  
46 months thereafter, up to month 132 (M132).  
47

### 48 49 *Patients*

50  
51  
52 In the present study were included all patients who had either two alcohol assessment or one  
53  
54 alcohol assessment just preceding the CADE over the whole follow-up (n=1154).  
55  
56  
57  
58  
59  
60

### *Medical questionnaire*

The medical questionnaire at enrolment (M0) collected retrospective data about patient's HIV history including HIV transmission category, time since HIV diagnosis, previous exposure to antiretroviral treatment before enrolment, and co-infection with hepatitis C virus (HCV) defined as having positive HCV RNA and/or positive HCV antibodies. This information was complemented by medical questionnaires, completed by the HIV physicians at each follow-up visit, which collected clinical and laboratory data (plasma HIV RNA level, CD4+ cell count, HIV clinical stage, aspartate transaminase (AST) and alanine transaminase (ALT) levels), as well as data on the antiretroviral regimen prescribed. A third form, based on updated medical records, detailed all clinical severe events, including cardiovascular events, occurring during the study period. Information on metabolic disorders was available at M12 for a subset of cohorts' patients, who participated in a parallel cross-sectional survey, designed to study clinical and laboratory metabolic complications[30]. These "metabolic" data included height, weight, hypertriglyceridemia, hypercholesterolemia, personal history of coronary heart disease (CHD) and hypertension, and finally any family history of CHD.

At each follow-up visit, CD4+ cell count was measured by standardized flow cytometry, and plasma HIV RNA levels were measured using the assay routinely available in each participating centre. Immunodepression was defined by CD4+ cell count  $<200$  cells/mm<sup>3</sup>; viral load was classified as detectable if it was greater than the threshold value specific to each centre where the assay was performed and to each period. The detectability threshold of the viral load ranged from 20 to 500 copies/ml for the M0-M20 period and from 20 to 400 copies/ml for the rest of the follow-up. HIV clinical stage was defined using the 1993 Centres for Disease Control and Prevention (CDC) clinical classification system[31].

1  
2  
3 Serum triglyceride and cholesterol levels were measured after a 12-hour overnight fast.  
4  
5 Hypertriglyceridemia was defined as a triglyceride level  $\geq 2.2$  mmol/l, while  
6  
7 hypercholesterolemia was defined as a total cholesterol level  $\geq 5.5$  mmol/l.  
8  
9

### 10 *Outcome*

11  
12  
13 The details of all clinical severe events, including cardiovascular events, which occurred  
14 during follow-up, were obtained from medical records and validated by the cohort's  
15 validation committee[30]. The classification of clinical severe events was based on the 10th  
16  
17 Revision of the International Statistical Classification of Diseases and Related Health  
18  
19 Problems (ICD-10)<sup>i</sup>. An event was considered severe when it required medical intervention,  
20 hospitalization, when hospitalization was extended due to the event's occurrence, when it led  
21 to a life-threatening condition, or when it resulted in death. A group of cardiologists  
22 specifically validated the events selected as outcomes for this study. Among cardiovascular  
23 events, only major CADE were selected for this analysis as follows (listed in singular form):  
24 MI, stroke, coronary heart disease, peripheral arterial disease and cardiovascular surgery for  
25 coronary disease. We excluded the following from the definition of the outcome: heart failure,  
26 cardiac arrhythmia, phlebitis, pulmonary embolism, and peripheral venous diseases to keep  
27 only severe or life-threatening cardiovascular events in the analysis.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

### 43 *Self-administered questionnaire*

44  
45  
46 A self-administered questionnaire collected - at M0, M4, M12 and every 8 months thereafter  
47 during the first 5 years of follow-up, then yearly thereafter – data on socio-demographic  
48 characteristics including age, gender and educational level. Among other psycho-social and  
49 behavioural information, it also collected details on depressive symptoms, tobacco use,  
50 alcohol consumption, self-reported ART-related symptoms and adherence to ART.  
51  
52  
53  
54  
55  
56

57  
58 <sup>i</sup> <http://www.who.int/classifications/icd/en/>  
59  
60



1  
2  
3 Depression was measured using the validated French version of the Centre for Epidemiologic  
4  
5 Studies Depression Scale (CES-D), which is a 20-item scale commonly used in studies  
6  
7 involving HIV-infected patients[32].  
8  
9

10 Tobacco and alcohol consumption were evaluated during the previous 4 weeks. Alcohol  
11  
12 consumption was assessed using two questions about frequency of consumption and quantity  
13  
14 consumed daily, if applicable.  
15  
16

17  
18 A 13-item scale comprising the French version of the symptom index validated by Justice *et*  
19  
20 *al*[33] and described elsewhere[34] collected information about self-reported symptoms. Five  
21  
22 other questions gathered information about adherence to ART, according to the methodology  
23  
24 established by the AIDS Clinical Trial Group[35].  
25  
26

### 27 *Statistical analysis*

28  
29  
30 As the results of the analysis on the whole dataset (n=1154) could be affected by the lack of  
31  
32 important predictors of CADE like hypertriglyceridemia or hypercholesterolemia, we  
33  
34 conducted a secondary analysis on a subset of patients who had additional metabolic disorders  
35  
36 data. More specifically, two analyses on the following study populations were performed to  
37  
38 study predictors of major CADE:  
39  
40  
41

42 1) First analysis: the study population included all patients who had either two alcohol  
43  
44 assessment or one alcohol assessment just preceding the event over the whole follow-up  
45  
46 (n=1154). The follow-up period was M0-M132.  
47  
48

49  
50 2) Second analysis: the study population was restricted to the subset of patients with available  
51  
52 data on metabolic disorders, measured at M12 (n=675). Consequently, only events occurring  
53  
54 after M12 were considered in this second analysis.  
55  
56  
57  
58  
59  
60

1  
2  
3 The WHO body mass index (BMI) categories were used in the analysis: underweight and  
4  
5 overweight/obese patients were defined respectively as having a BMI lower than 18.5 and  
6  
7 greater than 25.  
8  
9

10 A time-varying cumulative measure of time exposure to specific ARV medications (abacavir,  
11  
12 efavirenz, nevirapine, lopinavir and protease inhibitors) was computed during which ART  
13  
14 included a specific drug from this list, from cohort enrolment to the date of each follow-up  
15  
16 visit.  
17  
18

19  
20 CD4+ cell count was tested either as a continuous variable or recoded in categories. The  
21  
22 dichotomous variable using the cut-off of 200 cells/mm<sup>3</sup> was found to be the most predictive  
23  
24 of the outcome (using Cox models and bias corrected Akaike's information criterion  
25  
26 AICc[36].  
27  
28

29  
30 Tobacco consumption was dichotomized in two categories: more than 20 cigarettes/day vs  
31  
32 other[37]. The average number of alcohol units (AU) consumed per day[38] was computed  
33  
34 using the two questions on alcohol consumption and then recoded in four categories  
35  
36 (abstainers;  $\leq 1$  AU/day;  $> 1$  and  $\leq 4(3)$  AU/day for men(women);  $> 4(3)$  AU/day for  
37  
38 men(women)), in order to test a gradient effect. We used information on AST and ALT liver  
39  
40 enzymes to test their correlation with alcohol consumption as a validation test of self-reported  
41  
42 alcohol consumption. As normal liver enzymes' reference ranges for each laboratory were not  
43  
44 available in our data set, we used a universal cut-off of ALT $> 50$  units per litre of serum as an  
45  
46 indicator of liver injury, and the AST/ALT ratio (in conjunction with ALT $> 50$  IU/l) as a  
47  
48 marker of possible cirrhosis and/or alcoholic liver disease (for AST/ALT $> 1$ ) and advanced  
49  
50 alcoholic liver disease (for AST/ALT $> 2$ ). We found a positive significant association between  
51  
52 excessive alcohol consumption and these two indicators of liver injury (after adjusting for  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 HCV status, see Table 1), which would suggest good accuracy of the self-reported data on  
4  
5 alcohol consumption.  
6

7  
8 Patients were classified as non-adherent if they reported taking less than 100% of prescribed  
9  
10 medications during the previous 4 weeks, using a validated algorithm[39]. A patient with a  
11  
12 CES-D score value above 17 (men) or 23 (women) was considered as presenting depressive  
13  
14 symptoms[40].  
15

16  
17 Incidence rate of major CADE was computed as the number of cases divided by the number  
18  
19 of person-years of follow-up. Follow-up duration was calculated as the difference in days  
20  
21 from enrolment to the date of the CADE, death or last visit, whichever occurred first. Follow-  
22  
23 up of patients experiencing major CADE was censored after the date of the first CADE. We  
24  
25 used a Cox proportional hazards model to identify characteristics associated with the first  
26  
27 occurrence of a major CADE. Psychosocial characteristics - depressive symptoms, tobacco  
28  
29 and alcohol consumption, self-reported symptoms, CD4+ cell count and viral load - were  
30  
31 evaluated at each visit and used as time-varying covariates in the statistical analysis. All the  
32  
33 other covariates were used as fixed variables (measured at M0, M1 or M12). For time-varying  
34  
35 factors, the last known value was carried forward in the case of missing data at a scheduled  
36  
37 visit. In the case of an event occurring between two consecutive follow-up visits, the values  
38  
39 for the time-varying variables measured at the visit preceding the event were used. Covariates  
40  
41 with a p-value<0.25 in univariate Cox analyses were considered eligible for the multivariate  
42  
43 Cox model. Three building strategies for the final model were compared: a backward stepwise  
44  
45 selection procedure based on the Wald test ( $p<0.05$ ), a selection procedure based on the  
46  
47 second-order or bias-corrected Akaike's information criterion AICc[36], and finally a  
48  
49 selection procedure based on the Schwartz Bayesian information criterion BIC[41]. All three  
50  
51 strategies selected the same final multivariate model. Interaction effects between the factors of  
52  
53 the multivariate final model were tested. The proportional-hazards assumption was verified  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 globally for the multivariate models and separately with respect to each covariate, using both  
4  
5 Kaplan-Meier estimates and tests based on Schoenfeld residuals[42]. A residual analysis for  
6  
7 outliers' detection was performed and the sensitivity of the model to influential outliers was  
8  
9 tested.

10  
11  
12 Several sensitivity analyses were performed. First, we excluded all patients with a history of  
13  
14 CHD and re-ran the model to verify whether the pattern of factors would remain unchanged.

15  
16  
17 Second, the patients who died due to alcoholic cirrhosis were excluded from the study. A third  
18  
19 analysis was performed separately on the subgroups of patients co-infected with HCV and  
20  
21 those not co-infected with HCV.  
22  
23

24  
25 All analyses were performed using Stata Intercooled software, version 12.1.  
26  
27  
28  
29  
30

## 31 **Results**

32  
33  
34 A total of 1154 patients were included in the present study, accounting for 9401 person-visits.  
35  
36 When comparing the study patients (n=1154) with those included in the cohort, but excluded  
37  
38 from the study due to missing alcohol data (n=127), no significant difference was found for  
39  
40 gender, age at enrolment, antiretroviral naivety, CDC clinical stage, baseline CD4+ cell  
41  
42 counts and HIV viral load at M0 (data not shown).  
43  
44  
45

46  
47 Median [interquartile range (IQR)] duration of follow-up of the selected patients, from their  
48  
49 first visit after the ART prescription (M1) until M132, was 5.9 [1.8-9.4] years. The loss to  
50  
51 follow-up of the cohort was 0.14% at M12, 0.31% at M36, 0.44% at M60 and 0.76% at  
52  
53 M120.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Over the 11-year follow-up of the cohort, a total of 85 severe cardiovascular events were  
4  
5 observed. These included 49 major CADE as follows: myocardial infarction (n=30), coronary  
6  
7 heart disease (n=4), stroke (n=7), peripheral arterial disease (n=7) and cardiovascular surgery  
8  
9 for coronary disease (n=1). The distribution of the other thirty six severe cardiovascular  
10  
11 events was as follows: phlebitis/pulmonary embolism (n=22), cardiomyopathy/congestive  
12  
13 heart failure (n=5), cardiac dysrhythmia (n=6), cerebral haemorrhage (n=2) and aortic  
14  
15 aneurysm (n=1).  
16  
17

18  
19 The incidence rate [95% CI] of all severe cardiovascular events was 1.3 [1.0 to 1.6] per 100  
20  
21 person-years, while for major CADE the incidence rate was 0.75 [0.57 to 0.99] per 100  
22  
23 person-years. Of the 49 major CADE, 40 occurred after M12. Furthermore, the major CADE  
24  
25 incidence over the period M12-M132 was 0.89 [0.66 to 1.22] per 100 person-years.  
26  
27

28  
29 The distribution of factors associated with major CADE, as well as the results of univariate  
30  
31 and multivariate Cox models, are reported in Table 2 for the entire study population (n=1154).  
32  
33 Table 3 focuses instead on the subset of patients with available data on metabolic disorders  
34  
35 (n=675).  
36  
37

38  
39 Women represented 22% of the study population (n=1154) (Table 2). Mean (SD) age at  
40  
41 baseline was 37.7 (9.5) years and approximately one third of the patients had a secondary  
42  
43 school certificate. Individuals HIV-infected through injecting drug use accounted for 18% of  
44  
45 the study patients. At baseline, 44% of all the patients were ARV naive, half were in CDC  
46  
47 stage A, more than three quarters (80%) had not experienced opportunistic infections and  
48  
49 22% were co-infected with HCV. The selected patients had a detectable viral load at 43% of  
50  
51 the follow-up visits, had a CD4+ cell count <200 cells/mm<sup>3</sup> at 14% and reported depressive  
52  
53 symptoms at 32% of them. The median [IQR] of CD4+ cell count was 442 [284-633]  
54  
55 cells/mm<sup>3</sup> during the follow-up. During ART, more than half of the patients (63%) were  
56  
57  
58  
59  
60

1  
2  
3 highly adherent, and after one year of ART the median [IQR] number of self-reported  
4 symptoms excluding lipodystrophy was 4 [2 to 7], while this value was 1 [0 to 5] for  
5 lipodystrophy symptoms. Only 16% of the patients declared smoking more than 20 cigarettes  
6 per day during cohort follow-up. Nearly 19% of the patients reported they were alcohol  
7 abstainers, three quarters reported moderate alcohol consumption (59% reporting less than 1  
8 AU/day and 18% between 1 and 4(3) AU/day for men(women)), while only a minority of  
9 patients (4%) reported elevated alcohol consumption. As the two intermediate categories ( $\leq 1$   
10 AU/day;  $>1$  and  $\leq 4(3)$  AU/day for men(women)) had similar estimated Adjusted Hazard  
11 Ratios (AHR) and p-values in both multivariate analyses, we decided to aggregate them for  
12 model parsimony.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

25  
26 In the subsample of patients with available metabolic data (Table 3), the majority (73%) had a  
27 normal BMI, 17% were classified in the overweight category and a minority was classified in  
28 each of the two more extreme categories (6% underweight and 3% obese). About 8% of the  
29 patients had hypertriglyceridemia and 6% had hypercholesterolemia at M12. One year after  
30 the enrolment in the cohort, 6% of the patients reported a personal history of hypertension.  
31  
32  
33  
34  
35  
36  
37 Only 1% and 28% respectively had a personal and family history of CHD.  
38  
39

40  
41 In the entire study group (n=1154), the following factors were found to be independent  
42 predictors of major CADE: older age at baseline (AHR[95% CI]=1.07[1.04 to 1.10]), tobacco  
43 consumption  $>20$  cigarettes/day (4.19[2.17 to 8.11]) and CD4+ cell count  $<200$  cells/mm<sup>3</sup> (  
44 2.52[1.15 to 5.48]) (see Table 2). In addition, a negative association was found between  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

In the entire study group (n=1154), the following factors were found to be independent predictors of major CADE: older age at baseline (AHR[95% CI]=1.07[1.04 to 1.10]), tobacco consumption  $>20$  cigarettes/day (4.19[2.17 to 8.11]) and CD4+ cell count  $<200$  cells/mm<sup>3</sup> (2.52[1.15 to 5.48]) (see Table 2). In addition, a negative association was found between female gender and major CADE (0.25[0.08 to 0.83]). After accounting for the effect of age, gender, tobacco consumption and CD4+ cell count  $<200$  cells/mm<sup>3</sup> in the multivariate Cox model, individuals with moderate alcohol consumption ( $\leq 4(3)$  AU/day for men(women)) were at lower risk of major CADE (0.38[0.20 to 0.71]), than alcohol abstainers, while those

1  
2  
3 drinking more than 4(3) AU/day for men(women) were not significantly different from  
4  
5 abstainers (p=0.229).  
6

7  
8 These results remained valid also when the analysis was restricted to the subgroup of patients  
9  
10 with available metabolic data and the follow-up period M12-M132. After adjusting for age,  
11  
12 tobacco consumption, hypertriglyceridemia and family history of CHD, we consistently found  
13  
14 a negative association between moderate alcohol use (0.23[0.11 to 0.49]), and a positive  
15  
16 association between CD4+ cell count <200 cells/mm<sup>3</sup> (4.02[1.45 to 11.1]) and major CADE  
17  
18 after one year after enrolment (Table 3).  
19  
20

21  
22 No significant association was found between time of exposure to different ARV drugs and  
23  
24 major CADE. No significant interaction was found between smoking habits and  
25  
26 hypertriglyceridemia or personal history of CHD. Furthermore, detectable viral load was not  
27  
28 associated with major CADE in univariate or multivariate analyses.  
29  
30

31  
32 For the Cox models fitted in this study, proportional-hazards assumption remained valid,  
33  
34 either globally and with respect to each covariate. The residual analysis did not alter the  
35  
36 results of the multivariate model.  
37  
38

39  
40 The sensitivity analyses performed by first excluding patients with a history of CHD (n=7),  
41  
42 and then patients who died due to alcoholic cirrhosis (n=6), confirmed the same pattern of risk  
43  
44 factors observed for the whole population. The other sensitivity analyses, performed  
45  
46 separately on the subgroups of patients with HCV co-infection and on those not co-infected  
47  
48 with HCV, revealed the same effect of alcohol consumption on CADE, although some  
49  
50 variables among the other factors were less significant for the co-infected patients (results not  
51  
52 shown, available on request).  
53  
54  
55  
56  
57  
58  
59  
60



## Discussion

This longitudinal study clearly confirms that in ARV-treated individuals, proximal CD4+ cell count lower than 200 cells/mm<sup>3</sup> remains a risk factor associated with major coronary and other arterial disease events. This result remains valid even after adjustment for metabolic disorders such as hypertriglyceridemia and family history of CHD, the strength of the association remaining unchanged.

The relationship between CADE and CD4+ cell count, in addition to the lack of association between CADE and specific ARV classes, confirms previous results[7] where the association between exposure to certain ARV and CADE was no longer evident after controlling for traditional risk factors and HIV disease markers. Indeed, the association between specific ARV drugs and major CADE, like myocardial infarctus, has been shown in very powerful studies[5], where adjustment for nadir CD4+ lymphocyte count or peak HIV-1 RNA level did not modify the results. However, in the study cited, no adjustment for proximal CD4+ cell count was performed, and the association with the class of ARV became weaker after adjustment for serum lipid levels[5]. Indeed, although ART may modify lipid levels and increase the risk of CADE, it may also reduce this risk by reducing HIV-associated inflammation following long-term suppression of HIV replication[43]. The lack of association with exposure to some specific ARV classes in the present study, factors usually associated with an increased risk of CADE[44, 45], suggests that reduced immunological response to ART over a long follow-up, as well as known CADE risk factors may have a more important impact than exposure to a specific antiretroviral drug.

It is also possible that patients with altered lipid profiles were switched to other classes of antiretroviral drugs during the follow-up. As a consequence, in the long term, CD4+ cell

1  
2  
3 count <200 cells/mm<sup>3</sup> remain a correlate of an increased risk of CADE, whatever the  
4  
5 antiretroviral received.  
6  
7

8 In our study, individuals reporting elevated alcohol consumption exhibited the same risk of  
9  
10 CADE as alcohol abstainers. In contrast, those reporting moderate alcohol consumptions had  
11  
12 a lower risk. This result was confirmed after adjustment for additional risk factors including  
13  
14 tobacco use, age, gender and CD4+ cell count. This relationship between alcohol  
15  
16 consumption and CADE remained significant and J-shaped, even after adjustment for data on  
17  
18 metabolic risk factors- such as having a history of CHD and hypertriglyceridemia -which was  
19  
20 available for a subset of patients. As highlighted in previous observations in the general  
21  
22 population[28, 46-49] and certain populations affected by other diseases[50], these results  
23  
24 confirmed that the increased risk of CADE in HIV-infected patients receiving ART is not  
25  
26 attributable to elevated alcohol use. Furthermore, we highlighted the apparent protective  
27  
28 effect of moderate alcohol consumption in ART treated HIV-infected patients.  
29  
30  
31  
32

33 It is important to note that after the introduction of ART in 1996, the sudden decrease  
34  
35 observed in HIV-related mortality was nonetheless accompanied by a relative increase of non-  
36  
37 HIV based mortality as a part of the total mortality of HIV-infected patients [51],  
38  
39 cardiovascular diseases becoming increasingly important. This increase can be explained  
40  
41 firstly by a reduction in the competing role of HIV-related mortality, which in the long term  
42  
43 was much more detrimental to health than other causes of deaths. Secondly, the high  
44  
45 prevalence in this population of other risk factors like tobacco use, together with ART-related  
46  
47 morbidity including altered lipid profiles and triglycerides, may contribute to an increased risk  
48  
49 of CADE.  
50  
51  
52

53 The association found in our study between moderate alcohol use and reduced CADE risk is  
54  
55 not consistent with all previous research in HIV-infected patients. Freiberg *et al*[26] pointed  
56  
57  
58  
59  
60

1  
2  
3 out that among HIV-infected men in the US, hazardous drinking and both alcohol abuse and  
4  
5 dependence were associated with a higher prevalence of cardiovascular disease compared  
6  
7 with infrequent and moderate drinking, even after adjusting for traditional risk factors,  
8  
9 antiretroviral therapy and CD4+ cell count. This difference in the results may be due to the  
10  
11 different design of the two studies (longitudinal for ours *vs* cross-sectional for Freiberg's), but  
12  
13 probably also to the different types of alcohol mainly consumed in the two populations, red  
14  
15 wine consumption being more widespread in France than in the US. This difference in the  
16  
17 pattern of alcohol use has already been highlighted in a comparative study on cardiovascular  
18  
19 disease in non HIV-infected Irish and French males, showing an increased protective effect of  
20  
21 drinking red wine in the latter population[52]. Increased wine consumption probably brings  
22  
23 about an increase in high-density lipoprotein cholesterol levels, which helps protect against  
24  
25 cardiovascular events. On the other hand, beer and spirits consumption are linked to increased  
26  
27 triglyceride levels[53]. We do not know to what extent moderate alcohol users are  
28  
29 representative of a population with better health status as alcohol use in France is relatively  
30  
31 frequent in the general population and this fact may increase the strength of the association  
32  
33 found.  
34  
35  
36  
37  
38

39 Another possible hypothesis is that excessive alcohol consumption can increase inflammatory  
40  
41 markers' levels[54], which in turn probably leads to a higher risk of CADE and premature  
42  
43 aging in HIV patients. However, this hypothesis was not demonstrated in a study conducted in  
44  
45 older adults without cardiovascular disease, where alcohol intake was found to be associated  
46  
47 with lower levels of inflammatory markers[55]. In the meantime it is important to remember  
48  
49 that individuals with immune suppression are at a greater risk of cancer, a disease whose  
50  
51 pattern of risk factors also include alcohol use, even when moderate[56].  
52  
53  
54

55 Tobacco smoking has consistently been found to be a major risk factor for cardiovascular  
56  
57 disease[57]. Smoking prevalence and dependence in HIV-infected patients is higher than in  
58  
59  
60

1  
2  
3 the general population[58]. Effective interventions for reducing and quitting smoking[59],  
4 especially for patients with several risk factors, are strongly recommended especially  
5 considering the increased cardiovascular risk which exists in HIV-infected smokers receiving  
6 ART[60]. However, results from studies reporting on the effectiveness of interventions for  
7 quitting smoking in HIV-infected individuals are inconsistent[61].  
8  
9

10  
11  
12  
13  
14 It is worth noting the lack of association between hypercholesterolemia and the risk of CADE  
15 in our study. This result suggests that HIV physicians need to be cautious about basing  
16 clinical decisions merely upon measured lipid levels in HIV-infected patients. Other risk  
17 factors, including behavioural ones, deserve greater consideration for clinical management.  
18  
19 Some limitations of this study need to be acknowledged. First, our definition of CADE  
20 includes different types of events which might not share the same pattern of risk factors.  
21  
22 However, an additional analysis performed on a restricted dataset and which adjusted for  
23 other potential risk factors (such as hypertriglyceridemia) confirmed the pattern found in the  
24 main analysis.  
25  
26

27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Second, information on alcohol use was mainly based on self-reports and these may tend to underestimate alcohol consumption. However, it has been reported that HIV-HCV co-infected patients tend to underreport alcohol use more to their hepatologist than to other physicians[62]. As our patients were all followed-up by HIV physicians, it is likely that the degree of underreporting did not greatly affect hazard ratios' estimates. Moreover, the association found between the excessive alcohol consumption and the biomarkers of alcoholic liver injury indicate a good accuracy of self-reported data on alcohol consumption.

Then, the fact that excessive alcohol users exhibit similar HRs to abstainers may be also attributable to the two following reasons. First, some individuals with excessive alcohol consumption may have died due to liver failure before experiencing a cardiovascular event

1  
2  
3 and this could have reduced the impact of excessive alcohol use on CADE. However, when  
4  
5 we performed a sensitivity analysis excluding patients who died due to alcoholic cirrhosis, the  
6  
7 results remained unchanged. Second, a proportion of abstainers may have been past (heavy)  
8  
9 alcohol users and may have had to stop drinking for health reasons. Unfortunately, we do not  
10  
11 have information about alcohol use before the beginning of the cohort, or about diagnosis of  
12  
13 alcoholism or reasons for quitting alcohol.  
14  
15

16  
17 Finally, it would have been interesting to compute the Framingham risk score[61] and use it  
18  
19 as a covariate in the multivariate model. Unfortunately, as our study was not initially designed  
20  
21 to thoroughly assess the impact of all possible CHD risk factors, some of the variables used in  
22  
23 the construction of this score (such as treated and untreated systolic blood pressure, as well as  
24  
25 total and high-density lipoprotein (HDL) cholesterol) were not available during the two first  
26  
27 years of our study. Moreover, our results showed a different pattern of factors than those  
28  
29 found in the Framingham study (some of the traditional risk factors, such as BMI and  
30  
31 hypercholesterolemia, were not significant), so using this score would have been less  
32  
33 informative than using all the factors separately.  
34  
35  
36

37  
38 It is surprising that the classical risk factor hypercholesterolemia was not found to be  
39  
40 associated with CADE risk in this study. This may be due to the fact that rather low-density  
41  
42 lipoprotein cholesterol and/or the total/HDL cholesterol quotient may be predictors of CADE  
43  
44 risk but not total cholesterol. Unfortunately, the complete data regarding cholesterol levels  
45  
46 were not available during the two first years of our study, and therefore these factors could not  
47  
48 be assessed in this analysis.  
49  
50

51  
52 This cohort is representative of the first generation of patients receiving potent ART. As  
53  
54 cardiovascular disease is a rising issue in all HIV-infected populations receiving ART, these  
55  
56  
57  
58  
59  
60

1  
2  
3 results can give important information about the pattern of risk and protective factors in all  
4  
5 treated HIV-infected populations.  
6  
7

8 In conclusion, in the long term, absence of immunodepression and moderate alcohol  
9  
10 consumption remain associated with a lower risk of major CADE. Combined interventions to  
11  
12 reduce CADE-risk-related behaviours including adherence counselling to assure long term  
13  
14 immunological response to ART in HIV-infected individuals are now a clinical and public  
15  
16 health priority.  
17  
18  
19  
20

### 21 **Acknowledgments**

22 The authors would like to thank all participating patients, nurses and physicians in clinical  
23  
24 sites.  
25

26 We would also like to thank Jude Sweeney for the English revision and editing of the  
27  
28 manuscript.  
29  
30

### 31 **Authors' contribution:**

32 Maria Patrizia Carrieri planned the data analyses and wrote the manuscript; Camelia  
33  
34 Protopopescu analyzed the data and wrote the manuscript; Vincent Le Moing contributed to  
35  
36 patients' recruitment and investigation and revised the manuscript; Philippe  
37  
38 Reboud contributed to patients' evaluation; François Raffi was responsible for cohort  
39  
40 initiation, contributed to patients' recruitment and investigation and revised the manuscript;  
41  
42 Sophie Mahy contributed to patients' recruitment and investigation; Perrine Roux contributed  
43  
44 to patients' evaluation and revised the manuscript; Lise Cuzin contributed to patients'  
45  
46 recruitment and investigation; Bruno Spire contributed to data analyses and revised the  
47  
48 manuscript; Catherine Leport was responsible for cohort initiation, contributed to patients'  
49  
50 recruitment and investigation and revised the manuscript. All authors approved the final  
51  
52 version of the manuscript.  
53  
54  
55  
56  
57  
58  
59  
60

**Authors' work position and postal address:**

1  
2  
3  
4  
5  
6  
7 Maria Patrizia Carrieri (PhD) is Senior Public Health Researcher in the “Environments,  
8  
9 Health Systems and Transmitted Diseases (ESSEM)” Team, National Institute of Health  
10  
11 (INSERM), U912 (SESSTIM), 23 rue Stanislas Torrents, 13006 Marseilles, France; Camelia  
12  
13 Protopopescu (PhD) is Senior Biostatistician in the “Environments, Health Systems and  
14  
15 Transmitted Diseases (ESSEM)” Team, National Institute of Health (INSERM), U912  
16  
17 (SESSTIM), 23 rue Stanislas Torrents, 13006 Marseilles, France; Pr Vincent Le Moing (MD,  
18  
19 PhD) is Professor of Infectious Diseases, Department of Infectious and Tropical Diseases,  
20  
21 University Hospital Montpellier, 80 avenue Augustin Fliche, 34295 Montpellier cedex 5,  
22  
23 France; Dr Philippe Reboud (MD) is Project Manager, National Institute of Health  
24  
25 (INSERM), U897, University Victor Segalen Bordeaux 2, 146, rue Léo Saignat – case 11,  
26  
27 33076 Bordeaux cedex, France; Pr François Raffi (MD, PhD) is Professor of Infectious  
28  
29 Diseases, Department of Infectious and Tropical Diseases, University Hospital Nantes – Hôtel  
30  
31 Dieu, Place Alexis Ricordeau, 44093 Nantes cedex 1, France; Dr Sophie Mahy (MD) is  
32  
33 Associate specialist, Department of Infectious and Tropical Diseases, University Hospital  
34  
35 Dijon, boulevard Maréchal-de-Lattre-de-Tassigny, 21000 Dijon, France; Perrine Roux (PhD)  
36  
37 is Senior Public Health Researcher in the “Environments, Health Systems and Transmitted  
38  
39 Diseases (ESSEM)” Team, National Institute of Health (INSERM), U912 (SESSTIM) and  
40  
41 Substance Use Research Center, NYSPI, Columbia University, New York, USA; Dr Lise  
42  
43 Cuzin (MD) is Associate specialist, Department of Infectious and Tropical Diseases,  
44  
45 University Hospital Purpan - COREVIH – Bat TURIAF - TSA 40031, 31059 Toulouse  
46  
47 Cedex, France; Dr Bruno Spire (MD, PhD) is Senior Public Health Researcher and leader of  
48  
49 the “Environments, Health Systems and Transmitted Diseases (ESSEM)” Team, National  
50  
51 Institute of Health (INSERM), U912 (SESSTIM), 23 rue Stanislas Torrents, 13006  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 Marseilles, France; Pr Catherine Leport (MD, PhD) is Professor of Infectious Diseases, LRPI-  
4  
5 UMR 738, UFR Médecine site Bichat, 16 rue Henri Huchard, 75018 Paris, France.  
6  
7  
8  
9

10  
11 **The ANRS CO8 APROCO-COPILOTE Study Group is composed of the following:**

12 **Scientific Committee:**

13  
14 • **Steering Committee:**

15  
16 Principal investigators: C. Leport, F. Raffi

17  
18 Methodology: G. Chêne, R. Salamon

19  
20 Social sciences: JP. Moatti, J. Pierret, B. Spire

21  
22 Virology: F. Brun-Vézinet, H. Fleury, B. Masquelier

23  
24 Pharmacology: G. Peytavin, R. Garraffo

25  
26 • **Other members:** D. Costagliola, P. Dellamonica, C. Katlama, L. Meyer, D. Salmon, A.  
27  
28 Sobel.  
29

30  
31  
32 **Events Validation Committee:** L. Cuzin, M. Dupon, X. Duval, V. Le Moing, B. Marchou,  
33  
34 T. May, P. Morlat, C. Rabaud, A. Waldner-Combernoux.  
35

36  
37 **Project coordination:** P. Reboud.  
38

39  
40 **ANRS representatives:** Sandrine Couffin-Cadiergues, Lucie Marchand.  
41

42 **Data monitoring and statistical analysis:** V. Bouteloup, AD. Bouhnik, C. Brunet-François,  
43  
44 V. Caron, MP. Carrieri, M. Courcoul, F. Couturier, L. Hardel, L. Iordache. P. Kurkdji, S.  
45  
46 Martiren, M. Préau, C. Protopopescu, J. Surzyn, A. Taieb, V. Villes.  
47

48 **Promotion:** Agence Nationale de Recherches sur le Sida et les hépatites virales (ANRS,  
49  
50 Action Coordonnée n°7).  
51

52  
53 **Other support:** Collège des Universitaires de Maladies Infectieuses et Tropicales (CMIT ex  
54  
55 APPIT), Sidaction Ensemble contre le Sida and associated pharmaceutical companies:  
56  
57  
58  
59  
60

1  
2  
3 Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences,  
4  
5 Pfizer and Roche.

6  
7 **Clinical Centres (investigators):** Amiens (Pr JL. Schmit), Angers (Dr JM. Chennebault),  
8  
9 Belfort (Dr JP. Faller), Besançon (Pr N. Mgy-Bertrand, Pr B. Hoen, Dr Drobachef), Bobigny  
10  
11 (Pr O. Bouchaud), Bordeaux (Pr M. Dupon, Pr Longy-Boursier, Pr P. Morlat, Pr JM.  
12  
13 Ragnaud), Bourg-en-Bresse (Dr P. Granier), Brest (Pr M. Garré), Caen (Pr R. Verdon),  
14  
15 Compiègne (Dr D. Merrien), Corbeil Essonnes (Dr A. Devidas), Créteil (Pr A. Sobel), Dijon  
16  
17 (Pr L. Piroth), Garches (Pr C. Perronne), Lagny (Dr E. Froguel), Libourne (Dr J. Ceccaldi),  
18  
19 Lyon (Pr D. Peyramond), Meaux (Dr C. Allard), Montpellier (Pr J. Reynes), Nancy (Pr T.  
20  
21 May), Nantes (Pr F. Raffi), Nice (Pr JG Fuzibet, Pr P. Dellamonica), Orléans (Dr P. Arsac),  
22  
23 Paris (Pr E. Bouvet, Pr F. Bricaire, Pr P. Bergmann, Pr J. Cabane, Dr J. Monsonogo, Pr PM.  
24  
25 Girard, Pr L. Guillevin, Pr S. Herson, Pr C. Leport, Pr MC. Meyohas, Pr JM. Molina, Pr G.  
26  
27 Pialoux, Pr D. Salmon), Poitiers (Pr P. Roblot), Reims (Pr R. Jaussaud), Rennes (Pr C.  
28  
29 Michelet), Saint-Etienne (Pr F. Lucht), Saint-Mandé (Pr T. Debord), Strasbourg (Dr D. Rey),  
30  
31  
32  
33  
34 Toulon (Dr JP. De Jaureguiberry), Toulouse (Pr B. Marchou), Tours (Pr L. Bernard).  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Kaplan RC, Kingsley LA, Gange SJ *et al.* Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. *Aids* 2008;**22**(13):1615-24.
2. Henry K, Melroe H, Huebsch J *et al.* Severe premature coronary artery disease with protease inhibitors. *Lancet* 1998;**351**(9112):1328.
3. Lai S, Fishman EK, Lai H *et al.* Long-Term Cocaine Use and Antiretroviral Therapy Are Associated with Silent Coronary Artery Disease in African Americans with HIV Infection Who Have No Cardiovascular Symptoms. *Clin Infect Dis* 2008;**46**:600-610.
4. Mary-Krause M, Cotte L, Simon A *et al.* Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. *Aids* 2003;**17**(17):2479-86.
5. Friis-Moller N, Reiss P, Sabin CA *et al.* Class of antiretroviral drugs and the risk of myocardial infarction. *N Engl J Med* 2007;**356**(17):1723-35.
6. Butt AA, Chang CC, Kuller L *et al.* Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. *Arch Intern Med* 2011;**171**(8):737-43.
7. Lichtenstein KA, Armon C, Buchacz K *et al.* Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. *Clin Infect Dis* 2010;**51**(4):435-47.
8. Mondy KE, de las Fuentes L, Waggoner A *et al.* Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy. *Aids* 2008;**22**(7):849-56.
9. Sax PE. Strategies for management and treatment of dyslipidemia in HIV/AIDS. *AIDS Care* 2006;**18**(2):149-57.
10. Smith CJ, Levy I, Sabin CA *et al.* Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population. *HIV Med* 2004;**5**(2):88-92.
11. Guaraldi G, Squillace N, Stentarelli C *et al.* Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. *Clin Infect Dis* 2008;**47**(2):250-7.
12. Michel L, Carrieri MP, Fugon L *et al.* Harmful alcohol consumption and patterns of substance use in HIV-infected patients receiving antiretrovirals (ANRS-EN12-VESPA Study): relevance for clinical management and intervention. *AIDS Care* 2010;**22**(9):1136-45.
13. Stein M, Herman DS, Trisvan E *et al.* Alcohol use and sexual risk behavior among human immunodeficiency virus-positive persons. *Alcohol Clin Exp Res* 2005;**29**(5):837-43.
14. Braithwaite RS, Conigliaro J, McGinnis KA *et al.* Adjusting alcohol quantity for mean consumption and intoxication threshold improves prediction of nonadherence in HIV patients and HIV-negative controls. *Alcohol Clin Exp Res* 2008;**32**(9):1645-51.
15. Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. *J Acquir Immune Defic Syndr* 2006;**43**(4):411-7.
16. Spire B, Duran S, Souville M *et al.* Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. *Soc Sci Med* 2002;**54**(10):1481-96.
17. Conen A, Fehr J, Glass TR *et al.* Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. *Antivir Ther* 2009;**14**(3):349-57.
18. Braithwaite RS, Conigliaro J, Roberts MS *et al.* Estimating the impact of alcohol consumption on survival for HIV+ individuals. *AIDS Care* 2007;**19**(4):459-66.
19. Galai N, Vlahov D, Baretta JC *et al.* Prognostic factors for survival differ according to CD4+ cell count among HIV-infected injection drug users: pre-HAART and HAART eras. *J Acquir Immune Defic Syndr* 2005;**38**(1):74-81.
20. Hooshyar D, Hanson DL, Wolfe M *et al.* Trends in perimortal conditions and mortality rates among HIV-infected patients. *Aids* 2007;**21**(15):2093-100.
21. Samet JH, Cheng DM, Libman H *et al.* Alcohol consumption and HIV disease progression. *J Acquir Immune Defic Syndr* 2007;**46**(2):194-9.

22. Salmon-Ceron D, Lewden C, Morlat P *et al*. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. *J Hepatol* 2005;**42**(6):799-805.
23. Di Martino V, Rufat P, Boyer N *et al*. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. *Hepatology* 2001;**34**(6):1193-9.
24. Puoti M, Spinetti A, Ghezzi A *et al*. Mortality for liver disease in patients with HIV infection: a cohort study. *J Acquir Immune Defic Syndr* 2000;**24**(3):211-7.
25. Rosenthal E, Pialoux G, Bernard N *et al*. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). *J Viral Hepat* 2007;**14**(3):183-8.
26. Freiberg MS, McGinnis KA, Kraemer K *et al*. The association between alcohol consumption and prevalent cardiovascular diseases among HIV-infected and HIV-uninfected men. *J Acquir Immune Defic Syndr* 2010;**53**(2):247-53.
27. Freiberg MS, Cheng DM, Kraemer KL *et al*. The association between hepatitis C infection and prevalent cardiovascular disease among HIV-infected individuals. *Aids* 2007;**21**(2):193-7.
28. Mukamal KJ, Chen CM, Rao SR *et al*. Alcohol consumption and cardiovascular mortality among U.S. adults, 1987 to 2002. *J Am Coll Cardiol* 2010;**55**(13):1328-35.
29. Mukamal KJ, Conigrave KM, Mittleman MA *et al*. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. *N Engl J Med* 2003;**348**(2):109-18.
30. Saves M, Chene G, Ducimetiere P *et al*. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. *Clin Infect Dis* 2003;**37**(2):292-8.
31. CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *MMWR Recomm Rep*. 1992 Dec 18;41(RR-17):1-19.
32. Radloff L. The CES-D scale: a self-report depression scale for research in the general population. *Applied Psychology Measurement* 1977;**3**:385-491.
33. Justice AC, Holmes W, Gifford AL *et al*. Development and validation of a self-completed HIV symptom index. *J Clin Epidemiol* 2001;**54** Suppl 1:S77-90.
34. Carrieri MP, Villes V, Raffi F *et al*. Self-reported side-effects of anti-retroviral treatment among IDUs: a 7-year longitudinal study (APROCO-COPILOTE COHORT ANRS CO-8). *Int J Drug Policy* 2007;**18**(4):288-95.
35. Chesney MA, Ickovics JR, Chambers DB *et al*. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). *AIDS Care* 2000;**12**(3):255-66.
36. Sugiura N. Further analysis of the data by Akaike's information criterion and the finite corrections. *Communications in Statistics: Theory and Methods* 1978;**A7**:13-26.
37. Ueshima H, Choudhury SR, Okayama A *et al*. Cigarette smoking as a risk factor for stroke death in Japan: NIPPON DATA80. *Stroke* 2004;**35**(8):1836-41.
38. Bissell D, Paton A, Ritson B. ABC of alcohol. Help: referral. *Br Med J (Clin Res Ed)* 1982;**284**(6314):495-7.
39. Carrieri P, Cailleton V, Le Moing V *et al*. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. *J Acquir Immune Defic Syndr* 2001;**28**(3):232-9.
40. Fuhrer R, Rouillon F. La version française de l'échelle CES-D. Description and translation of the autoevaluation scale (in French). *Psychiatrie et Psychobiologie* 1989;**4**:163-166.
41. Schwartz G. Estimating the dimension of a model. *Annals of Statistics* 1978;**6**:461-464.
42. Therneau TM, Grambsch PM. *Modeling Survival Data: Extending the Cox Model* Springer, 2000.
43. Baker JV, Neuhaus J, Duprez D *et al*. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. *J Acquir Immune Defic Syndr* 2011;**56**(1):36-43.

- 1
- 2
- 3 44. Islam F, Wu J, Jansson J *et al*. Relative risk of cardiovascular disease among people living with HIV:  
4 a systematic review and meta-analysis. *HIV Med* 2012([Epub ahead of print]).
- 5 45. Friis-Moller N, Thiebaut R, Reiss P *et al*. Predicting the risk of cardiovascular disease in HIV-  
6 infected patients: the data collection on adverse effects of anti-HIV drugs study. *Eur J*  
7 *Cardiovasc Prev Rehabil* 2010;**17**(5):491-501.
- 8 46. Mukamal KJ, Chung H, Jenny NS *et al*. Alcohol use and risk of ischemic stroke among older adults:  
9 the cardiovascular health study. *Stroke* 2005;**36**(9):1830-4.
- 10 47. Waskiewicz A, Sygnowska E, Drygas W. Relationship between alcohol consumption and  
11 cardiovascular mortality--the Warsaw Pol-MONICA Project. *Kardiol Pol* 2004;**60**(6):552-62;  
12 discussion 563.
- 13 48. Burger M, Mensink G, Bronstrup A *et al*. Alcohol consumption and its relation to cardiovascular  
14 risk factors in Germany. *Eur J Clin Nutr* 2004;**58**(4):605-14.
- 15 49. Murray RP, Connett JE, Tyas SL *et al*. Alcohol volume, drinking pattern, and cardiovascular disease  
16 morbidity and mortality: is there a U-shaped function? *Am J Epidemiol* 2002;**155**(3):242-8.
- 17 50. Beulens JW, Algra A, Soedamah-Muthu SS *et al*. Alcohol consumption and risk of recurrent  
18 cardiovascular events and mortality in patients with clinically manifest vascular disease and  
19 diabetes mellitus: the Second Manifestations of ARterial (SMART) disease study.  
20 *Atherosclerosis* 2010;**212**(1):281-6.
- 21 51. Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected  
22 individuals living in Southern Alberta, Canada from 1984 to 2003. *HIV Med* 2005;**6**(2):99-106.
- 23 52. Marques-Vidal P, Montaye M, Arveiler D *et al*. Alcohol consumption and cardiovascular disease:  
24 differential effects in France and Northern Ireland. The PRIME study. *Eur J Cardiovasc Prev*  
25 *Rehabil* 2004;**11**(4):336-43.
- 26 53. Foerster M, Marques-Vidal P, Gmel G *et al*. Alcohol drinking and cardiovascular risk in a  
27 population with high mean alcohol consumption. *Am J Cardiol* 2009;**103**(3):361-8.
- 28 54. Pandrea I, Happel KI, Amedee AM *et al*. Alcohol's Role in HIV Transmission and Disease  
29 Progression. *Alcohol Research & Health* 2010;**33**(3):203-218.
- 30 55. Mukamal KJ, Cushman M, Mittleman MA *et al*. Alcohol consumption and inflammatory markers in  
31 older adults: the Cardiovascular Health Study. *Atherosclerosis* 2004;**173**(1):79-87.
- 32 56. Grulich AE, Jin F, Poynten IM *et al*. HIV, cancer, and aging. *Sex Health* 2011;**8**(4):521-5.
- 33 57. Palella FJ, Jr., Phair JP. Cardiovascular disease in HIV infection. *Curr Opin HIV AIDS* 2011;**6**(4):266-  
34 71.
- 35 58. Niaura R, Shadel WG, Morrow K *et al*. Human immunodeficiency virus infection, AIDS, and  
36 smoking cessation: the time is now. *Clin Infect Dis* 2000;**31**(3):808-12.
- 37 59. Barth J, Critchley J, Bengel J. Efficacy of psychosocial interventions for smoking cessation in  
38 patients with coronary heart disease: a systematic review and meta-analysis. *Ann Behav Med*  
39 2006;**32**(1):10-20.
- 40 60. Currier JS, Havlir DV. Complications of HIV disease and antiretroviral therapy. *Top HIV Med*  
41 2009;**17**(2):57-67.
- 42 61. Lloyd-Richardson EE, Stanton CA, Papandonatos GD *et al*. Motivation and patch treatment for  
43 HIV+ smokers: a randomized controlled trial. *Addiction* 2009;**104**(11):1891-900.
- 44 62. Roux P, Cohen J, Lascoux-Combe C *et al*. Determinants of the underreporting of alcohol  
45 consumption by HIV/HCV co-infected patients during face-to-face medical interviews: the  
46 role of the physician. *Drug Alcohol Depend* 2011;**116**(1-3):228-32.
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

**Table 1. Association between alcohol consumption and living injury indicators, after adjustment for HCV status, among HIV-infected patients receiving ART (ANRS CO8 APROCO-COPILOTE cohort - random effects logistic models, all patients - n=1154, follow-up period M0-M132)**

	ALT>50 IU/l & AST/ALT>1		ALT>50 IU/l & AST/ALT>2	
	AOR [95% CI]	p-value	AOR [95% CI]	p-value
<b>Alcohol consumption*</b>				
-abstainers (ref.)	1		1	
-≤1 AU/day	0.7 [0.5-1.2]	0.228	2.8 [0.4-18.4]	0.292
->1 and ≤4(3) AU/day for men(women)	1.0 [0.6-1.8]	0.847	0.7 [0.0-10.1]	0.772
->4(3) AU/day for men(women)	4.9 [2.4-9.8]	<10 <sup>-3</sup>	29.0 [3.4-250]	0.002
<b>HCV infection at M0</b>	12.9 [7.6-21.8]	<10 <sup>-3</sup>	11.2 [2.7-46.4]	0.001

ART = antiretroviral therapy; ALT= alanine transaminase; AST= aspartate transaminase

AOR = Adjusted Odds-Ratios from a random effects logistic model; CI = confidence interval

\* Time-varying variable (the last available value before each visit)



**Table 2. Factors associated with the first occurrence of a major CADE among HIV-infected patients receiving ART (ANRS CO8 APROCO-COPILOTE cohort - univariate and multivariate Cox proportional hazard models, all patients - n=1154, follow-up period M0-M132)**

	% of patients or mean (SD)	% of miss. data	Univariate analyses		Multivariate analysis	
			HR [95% CI]	p-value	AHR [95% CI]	p-value
<b><i>Socio-demographic and psychosocial characteristics</i></b>						
Female gender	22.0	0	0.26 [0.08-0.84]	0.025	0.25 [0.08-0.83]	0.024
Age at M0° - years	37.7 (9.5)	0	1.06 [1.03-1.09]	<10 <sup>-3</sup>	1.07 [1.04-1.10]	<10 <sup>-3</sup>
Secondary-school certificate at M0°	31.3	7.3	0.51 [0.26-1.01]	0.054		
Alcohol consumption at M0°		0				
- abstainers (ref)	18.8		1			
- ≤4(3) AU/day for men(women)	75.3		0.47 [0.24-0.89]	0.021		
- >4(3) AU/day for men(women)	5.9		0.75 [0.21-2.63]	0.648		
Alcohol consumption*		0				
- abstainers (ref)	18.6		1		1	
- ≤4(3) AU/day for men(women)	77.2		0.44 [0.24-0.81]	0.009	0.38 [0.20-0.71]	0.002
- >4(3) AU/day for men(women)	4.1		1.04 [0.30-3.58]	0.953	0.46 [0.13-1.63]	0.229
Tobacco consumption >20 cig./day*	15.8	0.1	3.17 [1.73-5.83]	<10 <sup>-3</sup>	4.19 [2.17-8.11]	<10 <sup>-3</sup>
Depressive symptoms <sup>#*</sup>	32.0	1.8	1.22 [0.67-2.21]	0.512		
Number of self-reported symptoms (excluding lipodystrophy)*	4.8 (3.8)	0.1	1.01 [0.95-1.08]	0.694		
Number of self-reported lipodystrophy symptoms*	2.5 (2.6)	0.4	1.07 [0.96-1.18]	0.223		
ART adherence*	63.2	0.3	2.42 [1.17-5.02]	0.017		
<b><i>Clinical characteristics</i></b>						
HIV transmission category°		0				
- homosexual	40.6		0.99 [0.42-2.34]	0.988		



- injecting drug use	17.8		0.92 [0.50-1.70]	0.793		
- other (ref)	41.6		1			
CDC clinical stage A at M0 <sup>°</sup>	51.2	0	0.44 [0.23-0.85]	0.014		
HCV infection at M0 <sup>°</sup>	22.4	4.3	1.16 [0.59-2.29]	0.655		
Time since HIV diagnosis at M0- years <sup>°</sup>	4.7 (4.2)	0.9	1.01 [0.94-1.08]	0.822		
Duration of exposure to efavirenz - years* <sup>§</sup>	1.0 (2.2)	0	0.86 [0.71-1.03]	0.102		
Duration of exposure to nevirapine - years* <sup>§</sup>	0.9 (2.2)	0	0.91 [0.78-1.07]	0.279		
Duration of exposure to abacavir - years* <sup>§</sup>	1.0 (2.1)	0	0.98 [0.84-1.13]	0.748		
Duration of exposure to lopinavir - years* <sup>§</sup>	0.4 (1.5)	0	1.01 [0.85-1.20]	0.929		
Duration of exposure to PI-based regimen - years* <sup>§</sup>	3.2 (3.1)	0	1.03 [0.92-1.15]	0.615		
Antiretroviral naivety at M0 <sup>°</sup>	44.4	0	1.14 [0.64-2.02]	0.654		
CD4+ cell count < 200 cells/mm <sup>3</sup> at M0 <sup>°</sup>	35.9	0.1	0.99 [0.55-1.80]	0.978		
Detectable viral load at M0 <sup>°</sup>	94.0	0.3	0.81 [0.25-2.61]	0.725		
CD4+ cell count < 200 cells/mm <sup>3</sup> * Detectable viral load*	13.7	0.02	2.48 [1.15-5.33]	0.020	2.52 [1.15-5.48]	0.020
	43.4	0.7	0.99 [0.53-1.84]	0.980		

CADE = coronary or other arterial disease event; ART = antiretroviral therapy; CHD = coronary heart disease

SD = standard deviation; (A)HR = (adjusted) hazard ratio; CI = confidence interval

<sup>°</sup> Fixed variable (measured at M0 or M1); \* Time-varying variable (the last available value before each visit);

percentages and averages were computed on all follow-up visits for time-varying variables

<sup>§</sup> Percentages and averages are computed at the end of the follow-up (last available visit for each patient)

<sup>#</sup> Depressive symptoms: the Centre for Epidemiologic Studies Depression Scale (CES-D) scores is >17 for men and >23 for women

**Table 3. Factors associated with the first occurrence of a major CADE among HIV-infected patients receiving ART (ANRS CO8 APROCO-COPILOTE cohort - univariate and multivariate Cox proportional hazard models, patients with available metabolic data - n=675, follow-up period M12-M132)**

	% of patients or mean (SD)	% of miss. data	Univariate analyses HR [95% CI]	p-value	Multivariate analysis AHR [95% CI]	p-value
<b><i>Socio-demographic and psychosocial characteristics</i></b>						
Female gender	19.0	0	0.33 [0.08-1.40]	0.134		
Age at M0 – years <sup>o</sup>	38.4 (9.5)	0	1.04 [1.01-1.07]	0.013	1.05 [1.02-1.09]	0.003
Secondary-school certificate at M0 <sup>o</sup>	35.4	6.7	0.34 [0.14-0.84]	0.019		
Alcohol consumption at M0 <sup>o</sup>		0				
- abstainers (ref)	15.1		1			
- ≤4(3) AU/day for men(women)	78.4		0.44 [0.18-1.03]	0.059		
- >4(3) AU/day for men(women)	6.5		1.04 [0.26-4.05]	0.959		
Alcohol consumption*		0				
- abstainers (ref)	16.5		1		1	
- ≤4(3) AU/day for men(women)	79.1		0.27 [0.13-0.58]	0.001	0.23 [0.11-0.49]	<10 <sup>-3</sup>
- >4(3) AU/day for men(women)	4.4		1.19 [0.33-4.23]	0.792	0.55 [0.14-2.14]	0.390
Tobacco consumption >20 cig./day*	15.7	0.1	3.58 [1.70-7.54]	0.001	5.59 [2.43-12.8]	<10 <sup>-3</sup>
Depressive symptoms <sup>#*</sup>	31.9	1.50	1.83 [0.90-3.73]	0.094		
Number of self-reported symptoms (excluding lipodystrophy)*	4.8 (3.8)	0.02	1.03 [0.95-1.12]	0.463		
Number of self-reported lipodystrophy symptoms*	2.6 (2.7)	0.16	1.10 [0.98-1.24]	0.111		
ARV adherence*	63.6	0.2	1.63 [0.70-3.81]	0.260		
<b><i>Clinical characteristics</i></b>						

HIV transmission category <sup>o</sup>		0				
- homosexual (ref)	44.0		1			
- injecting drug use	15.0		2.08 [0.75-5.73]	0.156		
- other	41.0		1.32 [0.59-2.93]	0.499		
CDC clinical stage A at M0 <sup>o</sup>	50.8	0	0.43 [0.19-0.97]	0.041		
HCV infection at M0 <sup>o</sup>	19.8	3.8	2.05 [0.94-4.47]	0.071		
Duration since HIV diagnosis at M0- years <sup>o</sup>	4.7 (4.2)	1.2	1.04 [0.96-1.13]	0.311		
Duration of exposure to efavirenz - years* <sup>§</sup>	1.4 (2.5)	0	0.89 [0.73-1.08]	0.236		
Duration of exposure to nevirapine - years* <sup>§</sup>	1.0 (2.3)	0	0.83 [0.66-1.06]	0.147		
Duration of exposure to abacavir - years* <sup>§</sup>	1.2 (2.3)	0	0.99 [0.85-1.17]	0.971		
Duration of exposure to lopinavir - years* <sup>§</sup>	0.5 (1.5)	0	1.07 [0.88-1.30]	0.505		
Duration of exposure to PI-based regimen - years* <sup>§</sup>	3.9 (3.1)	0	1.03 [0.89-1.18]	0.714		
Antiretroviral naivety at M0 <sup>o</sup>	41.5	0	0.86 [0.41-1.79]	0.683		
CD4+ cell count < 200 cells/mm <sup>3</sup> at M0 <sup>o</sup>	33.9	0	0.88 [0.41-1.88]	0.749		
Detectable viral load at M0 <sup>o</sup>	94.8	0.1	0.70 [0.17-2.94]	0.627		
CD4+ cell count < 200 cells/mm <sup>3</sup> *	11.8	0	2.58 [0.99-6.75]	0.052	4.02 [1.45-11.1]	0.007
Detectable viral load*	40.2	0.03	1.24 [0.59-2.59]	0.574		

### Metabolic characteristics

BMI categories <sup>o@</sup>		1.6				
- underweight: <18.5 (ref)	5.8		1			
- normal weight: 18.5–24.9	72.8		0.65 [0.15-2.76]	0.556		
- overweight or obese: >25	19.8		0.57 [0.11-2.87]	0.498		
Hypertriglyceridemia <sup>o@</sup>	8.4	0	2.06 [0.79-5.37]	0.141	2.98 [1.11-8.01]	0.030

Hypercholesterolemia <sup>°</sup>	6.5	0.1	0.95 [0.22-3.97]	0.939		
Personal history of CHD <sup>°</sup>	1.2	0	9.39 [2.22-39.8]	0.002		
Family history of CHD <sup>°</sup>	28.0	0	1.82 [0.89-3.71]	0.102	2.25 [1.08-4.71]	0.031
Personal history of hypertension <sup>°</sup>	6.1	0	2.73 [1.05-7.13]	0.040		

CADE = coronary or other arterial disease event; ART = antiretroviral therapy; CHD = coronary heart disease

SD = standard deviation; (A)HR = (adjusted) hazard ratio; CI = confidence interval

<sup>°</sup> Fixed variable (measured at M0, M1 or M12); \* Time-varying variable (the last available value before each visit); percentages and averages are computed on all follow-up visits for time-varying variables

<sup>@</sup> At M12; <sup>§</sup> Percentages and averages are computed at the end of the follow-up (last available visit for each patient)

<sup>#</sup> Depressive symptoms: the Centre for Epidemiologic Studies Depression Scale (CES-D) scores is >17 for men and >23 for women